0000875320-16-000091.txt : 20160801 0000875320-16-000091.hdr.sgml : 20160801 20160801165111 ACCESSION NUMBER: 0000875320-16-000091 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 76 CONFORMED PERIOD OF REPORT: 20160630 FILED AS OF DATE: 20160801 DATE AS OF CHANGE: 20160801 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 161797957 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 10-Q 1 a2016q210-q.htm 10-Q Document

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________________________________________________
FORM 10-Q
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2016
or
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM              TO             
Commission file number 000-19319
____________________________________________
Vertex Pharmaceuticals Incorporated
(Exact name of registrant as specified in its charter)
Massachusetts
04-3039129
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
50 Northern Avenue, Boston, Massachusetts
02210
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code (617) 341-6100
____________________________________________

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes x No o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer x
Accelerated filer o
Non-accelerated filer o 
Smaller reporting company o
 
                                       (Do not check if a smaller reporting company)
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.
Common Stock, par value $0.01 per share
247,778,698
Class
Outstanding at July 22, 2016

 


VERTEX PHARMACEUTICALS INCORPORATED
FORM 10-Q
FOR THE QUARTER ENDED JUNE 30, 2016

TABLE OF CONTENTS
 
 
Page
 
 
 
Condensed Consolidated Statements of Operations - Three and Six Months Ended June 30, 2016 and 2015
 
Condensed Consolidated Statements of Comprehensive Loss - Three and Six Months Ended June 30, 2016 and 2015
 
Condensed Consolidated Balance Sheets - June 30, 2016 and December 31, 2015
 
Condensed Consolidated Statements of Shareholders' Equity and Noncontrolling Interest - Six Months Ended June 30, 2016 and 2015
 
Condensed Consolidated Statements of Cash Flows - Six Months Ended June 30, 2016 and 2015
 
 
 
“We,” “us,” “Vertex” and the “Company” as used in this Quarterly Report on Form 10-Q refer to Vertex Pharmaceuticals Incorporated, a Massachusetts corporation, and its subsidiaries.
“Vertex,” “KALYDECO®” and “ORKAMBI®” are registered trademarks of Vertex. Other brands, names and trademarks contained in this Quarterly Report on Form 10-Q are the property of their respective owners.



Part I. Financial Information
Item 1.    Financial Statements
VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Operations
(unaudited)
(in thousands, except per share amounts)
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2016
 
2015
 
2016
 
2015
Revenues:
 
 
 
 
 
 
 
Product revenues, net
$
425,651

 
$
160,388

 
$
820,061

 
$
291,263

Royalty revenues
5,282

 
5,077

 
8,878

 
11,869

Collaborative revenues
675

 
611

 
749

 
1,453

Total revenues
431,608

 
166,076

 
829,688

 
304,585

Costs and expenses:
 
 
 
 
 
 
 
Cost of product revenues
44,154

 
15,409

 
93,943

 
24,790

Royalty expenses
1,098

 
1,451

 
1,958

 
4,377

Research and development expenses
271,008

 
223,858

 
526,868

 
439,457

Sales, general and administrative expenses
111,652

 
94,394

 
216,866

 
180,254

Restructuring expenses (income), net
343

 
2,128

 
1,030

 
(1,144
)
Total costs and expenses
428,255

 
337,240

 
840,665

 
647,734

Income (loss) from operations
3,353

 
(171,164
)
 
(10,977
)
 
(343,149
)
Interest expense, net
(20,155
)
 
(21,111
)
 
(40,853
)
 
(42,418
)
Other (expenses) income, net
(1,219
)
 
1,414

 
3,192

 
(3,699
)
Loss before provision for income taxes
(18,021
)
 
(190,861
)
 
(48,638
)
 
(389,266
)
Provision for income taxes
18,130

 
30,131

 
23,615

 
30,430

Net loss
(36,151
)
 
(220,992
)
 
(72,253
)
 
(419,696
)
(Income) loss attributable to noncontrolling interest
(28,374
)
 
32,144

 
(33,903
)
 
32,242

Net loss attributable to Vertex
$
(64,525
)
 
$
(188,848
)
 
$
(106,156
)
 
$
(387,454
)
 
 
 
 
 
 
 
 
Amounts per share attributable to Vertex common shareholders:
 
 
 
 
 
 
 
Net loss:
 
 
 
 
 
 
 
Basic
$
(0.26
)
 
$
(0.78
)
 
$
(0.43
)
 
$
(1.61
)
Diluted
$
(0.26
)
 
$
(0.78
)
 
$
(0.43
)
 
$
(1.61
)
Shares used in per share calculations:
 
 
 
 
 
 
 
Basic
244,482

 
240,757

 
244,124

 
240,129

Diluted
244,482

 
240,757

 
244,124

 
240,129

The accompanying notes are an integral part of these condensed consolidated financial statements.


2

VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Comprehensive Loss
(unaudited)
(in thousands)
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2016
 
2015
 
2016
 
2015
Net loss
$
(36,151
)
 
$
(220,992
)
 
$
(72,253
)
 
$
(419,696
)
Changes in other comprehensive loss:
 
 
 
 
 
 
 
Unrealized holding gains (losses) on marketable securities
(29
)
 
(46
)
 
200

 
130

Unrealized gains (losses) on foreign currency forward contracts, net of tax
4,999

 
(4,280
)
 
(213
)
 
(3,974
)
Foreign currency translation adjustment
(3,461
)
 
1,828

 
(5,201
)
 
1,220

Total changes in other comprehensive loss
1,509

 
(2,498
)
 
(5,214
)
 
(2,624
)
Comprehensive loss
(34,642
)
 
(223,490
)
 
(77,467
)
 
(422,320
)
Comprehensive (income) loss attributable to noncontrolling interest
(28,374
)
 
32,144

 
(33,903
)
 
32,242

Comprehensive loss attributable to Vertex
$
(63,016
)
 
$
(191,346
)
 
$
(111,370
)
 
$
(390,078
)
The accompanying notes are an integral part of these condensed consolidated financial statements.


3

VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Balance Sheets
(unaudited)
(in thousands, except share and per share amounts)
 
June 30,
 
December 31,
 
2016
 
2015
Assets
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
605,866

 
$
714,768

Marketable securities, available for sale
465,570

 
327,694

Restricted cash and cash equivalents (VIE)
70,513

 
78,910

Accounts receivable, net
189,356

 
177,639

Inventories
66,589

 
57,207

Prepaid expenses and other current assets
56,256

 
50,935

Total current assets
1,454,150

 
1,407,153

Property and equipment, net
690,607

 
697,715

Intangible assets
284,340

 
284,340

Goodwill
50,384

 
50,384

Cost method investment in CRISPR
33,213

 
—

Notes receivable
—

 
30,000

Restricted cash
22,085

 
22,083

Other assets
14,203

 
6,912

Total assets
$
2,548,982

 
$
2,498,587

Liabilities and Shareholders’ Equity
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
51,302

 
$
74,942

Accrued expenses
275,165

 
305,820

Deferred revenues, current portion
11,468

 
16,296

Accrued restructuring expenses, current portion
7,683

 
7,894

Capital lease obligations, current portion
17,446

 
15,545

Senior secured term loan, current portion
221,576

 
71,296

Other liabilities, current portion
38,215

 
14,374

Total current liabilities
622,855

 
506,167

Deferred revenues, excluding current portion
7,411

 
9,714

Accrued restructuring expenses, excluding current portion
4,801

 
7,464

Capital lease obligations, excluding current portion
34,317

 
42,923

Deferred tax liability
132,810

 
110,439

Construction financing lease obligation, excluding current portion
472,374

 
472,611

Senior secured term loan, net of current portion and discount
74,921

 
223,863

Other liabilities, excluding current portion
30,648

 
31,778

Total liabilities
1,380,137

 
1,404,959

Commitments and contingencies


 


Shareholders’ equity:
 
 
 
Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding at June 30, 2016 and December 31, 2015
—

 
—

Common stock, $0.01 par value; 500,000,000 and 500,000,000 shares authorized at June 30, 2016 and December 31, 2015, respectively; 247,703,932 and 246,306,818 shares issued and outstanding at June 30, 2016 and December 31, 2015, respectively
2,440

 
2,427

Additional paid-in capital
6,350,244

 
6,197,500

Accumulated other comprehensive (loss) income
(3,390
)
 
1,824

Accumulated deficit
(5,367,940
)
 
(5,261,784
)
Total Vertex shareholders' equity
981,354

 
939,967

Noncontrolling interest
187,491

 
153,661

Total shareholders’ equity
1,168,845

 
1,093,628

Total liabilities and shareholders’ equity
$
2,548,982

 
$
2,498,587

The accompanying notes are an integral part of these condensed consolidated financial statements.


4

VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Shareholders’ Equity and Noncontrolling Interest
(unaudited)
(in thousands)
 
Common Stock
 
Additional
Paid-in Capital
 
Accumulated
Other
Comprehensive (Loss) Income
 
Accumulated Deficit
 
Total Vertex
Shareholders’ Equity
 
Noncontrolling
Interest
 
Total
Shareholders’ Equity
 
Shares
 
Amount
 
 
 
 
 
 
Balance at December 31, 2014
241,764

 
$
2,385

 
$
5,777,154

 
$
917

 
$
(4,705,450
)
 
$
1,075,006

 
$
21,177

 
$
1,096,183

Other comprehensive loss, net of tax
—

 
—

 
—

 
(2,624
)
 
—

 
(2,624
)
 
—

 
(2,624
)
Net loss
—

 
—

 
—

 
—

 
(387,454
)
 
(387,454
)
 
(32,242
)
 
(419,696
)
Issuance of common stock under benefit plans
2,578

 
21

 
87,333

 
—

 
—

 
87,354

 
—

 
87,354

Stock-based compensation expense
—

 
—

 
122,682

 
—

 
—

 
122,682

 
—

 
122,682

Noncontrolling interest upon consolidation
—

 
$
—

 
$
—

 
$
—

 
$
—

 
$
—

 
$
164,317

 
$
164,317

Balance at June 30, 2015
244,342

 
$
2,406

 
$
5,987,169

 
$
(1,707
)
 
$
(5,092,904
)
 
$
894,964

 
$
153,252

 
$
1,048,216

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance at December 31, 2015
246,307

 
$
2,427

 
$
6,197,500

 
$
1,824

 
$
(5,261,784
)
 
$
939,967

 
$
153,661

 
$
1,093,628

Other comprehensive loss, net of tax
—

 
—

 
—

 
(5,214
)
 
—

 
(5,214
)
 
—

 
(5,214
)
Net (loss) income
—

 
—

 
—

 
—

 
(106,156
)
 
(106,156
)
 
33,903

 
(72,253
)
Issuance of common stock under benefit plans
1,397

 
13

 
33,557

 
—

 
—

 
33,570

 
—

 
33,570

Stock-based compensation expense
—

 
—

 
119,187

 
—

 
—

 
119,187

 
(73
)
 
119,114

Balance at June 30, 2016
247,704

 
$
2,440

 
$
6,350,244

 
$
(3,390
)
 
$
(5,367,940
)
 
$
981,354

 
$
187,491

 
$
1,168,845

The accompanying notes are an integral part of these condensed consolidated financial statements.


5

VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Cash Flows
(unaudited)
(in thousands)
 
Six Months Ended June 30,
 
2016
 
2015
Cash flows from operating activities:
 
 
 
Net loss
$
(72,253
)
 
$
(419,696
)
Adjustments to reconcile net loss to net cash used in operating activities:
 
 
 
Stock-based compensation expense
117,414

 
120,645

Depreciation and amortization expense
31,378

 
30,428

Deferred income taxes
22,858

 
6,346

Other non-cash items, net
3,436

 
6,045

Changes in operating assets and liabilities:
 
 
 
Accounts receivable, net
(12,954
)
 
(21,197
)
Inventories
(7,779
)
 
(9,426
)
Prepaid expenses and other assets
(7,971
)
 
(15,397
)
Accounts payable
(23,821
)
 
(3,033
)
Accrued expenses and other liabilities
(14,562
)
 
8,098

Accrued restructuring expense
(2,892
)
 
(26,012
)
Deferred revenues
(7,131
)
 
(9,303
)
Net cash provided by (used in) operating activities
25,723

 
(332,502
)
Cash flows from investing activities:
 
 
 
Purchases of marketable securities
(470,077
)
 
(125,655
)
Maturities of marketable securities
332,316

 
741,725

Payment for acquisition of variable interest entity
—

 
(80,000
)
Expenditures for property and equipment
(27,892
)
 
(23,978
)
Increase in restricted cash and cash equivalents
—

 
(21,975
)
Investment in CRISPR Series B preferred stock
(3,075
)
 
—

Decrease in restricted cash and cash equivalents (VIE)
8,397

 
2,277

(Increase) decrease in other assets
(159
)
 
87

Net cash (used in) provided by investing activities
(160,490
)
 
492,481

Cash flows from financing activities:
 
 
 
Issuances of common stock under benefit plans
33,702

 
87,850

Payments on capital lease obligations
(7,538
)
 
(14,441
)
Proceeds from capital lease financing
—

 
13,386

Payments on construction financing lease obligation
(209
)
 
(184
)
Net cash provided by financing activities
25,955

 
86,611

Effect of changes in exchange rates on cash
(90
)
 
(1,306
)
Net (decrease) increase in cash and cash equivalents
(108,902
)
 
245,284

Cash and cash equivalents—beginning of period
714,768

 
625,259

Cash and cash equivalents—end of period
$
605,866

 
$
870,543

 
 
 
 
Supplemental disclosure of cash flow information:
 
 
 
Cash paid for interest
$
41,325

 
$
42,885

Cash paid for income taxes
$
1,237

 
$
1,022

Issuances of common stock exercises from employee benefit plans receivable
$
161

 
$
166

The Company has reclassified certain amounts in the period ending June 30, 2015 between operating, investing, and financing to correct improper classifications. 

The accompanying notes are an integral part of these condensed consolidated financial statements.

6
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)


A. Basis of Presentation and Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company") in accordance with accounting principles generally accepted in the United States of America ("GAAP").
The condensed consolidated financial statements reflect the operations of (i) the Company, (ii) its wholly-owned subsidiaries and (iii) consolidated variable interest entities (VIEs). All material intercompany balances and transactions have been eliminated. The Company operates in one segment, pharmaceuticals.

Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended June 30, 2016 and 2015.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2015, which are contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2015 that was filed with the Securities and Exchange Commission (the “SEC”) on February 16, 2016 (the "2015 Annual Report on Form 10-K").
Use of Estimates and Summary of Significant Accounting Policies
The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. Significant estimates in these condensed consolidated financial statements have been made in connection with the calculation of revenues, inventories, research and development expenses, stock-based compensation expense, restructuring expense, the fair value of intangible assets, goodwill, contingent consideration, noncontrolling interest, the consolidation of VIEs, leases, the fair value of cash flow hedges and the provision for or benefit from income taxes. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
The Company's significant accounting policies are described in Note A, "Nature of Business and Accounting Policies," in the 2015 Annual Report on Form 10-K.
Recent Accounting Pronouncements
In 2016, the Financial Accounting Standards Board (“FASB”) issued amended guidance applicable to leases that will be effective for the year ending December 31, 2019. Early adoption is permitted. This update requires an entity to recognize assets and liabilities for leases with lease terms of more than 12 months on the balance sheet. The Company is in the process of evaluating the new guidance and determining the expected effect on its consolidated financial statements.

In 2016, the FASB issued amended guidance applicable to share-based compensation to employees that will be effective for the year ending December 31, 2017. Early adoption is permitted. This update simplifies the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The Company is in the process of evaluating the new guidance and determining the expected effect on its consolidated financial statements.

For a discussion of other recent accounting pronouncements please refer to Note A, “Nature of Business and Accounting Policies—Recent Accounting Pronouncements,” in the 2015 Annual Report on Form 10-K. The Company did not adopt any


7
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

new accounting pronouncements during the six months ended June 30, 2016 that had a material effect on its condensed consolidated financial statements.
B.
Product Revenues, Net
The Company sells its products principally to a limited number of specialty pharmacy providers and selected regional wholesalers in North America as well as government-owned and supported customers in international markets (collectively, its “Customers”). The Company's Customers in North America subsequently resell the products to patients and health care providers. The Company recognizes net revenues from product sales upon delivery to the Customer as long as (i) there is persuasive evidence that an arrangement exists between the Company and the Customer, (ii) collectibility is reasonably assured and (iii) the price is fixed or determinable.
In order to conclude that the price is fixed or determinable, the Company must be able to (i) calculate its gross product revenues from sales to Customers and (ii) reasonably estimate its net product revenues upon delivery to its Customers' locations. The Company calculates gross product revenues based on the price that the Company charges its Customers. The Company estimates its net product revenues by deducting from its gross product revenues (a) trade allowances, such as invoice discounts for prompt payment and Customer fees, (b) estimated government and private payor rebates, chargebacks and discounts, (c) estimated reserves for expected product returns and (d) estimated costs of co-pay assistance programs for patients, as well as other incentives for certain indirect customers.
The Company makes significant estimates and judgments that materially affect the Company's recognition of net product revenues. In certain instances, the Company may be unable to reasonably conclude that the price is fixed or determinable at the time of delivery, in which case it defers the recognition of revenues. Once the Company is able to determine that the price is fixed or determinable, it recognizes the revenues associated with the units in which revenue recognition was deferred.
The following table summarizes activity in each of the product revenue allowance and reserve categories for the six months ended June 30, 2016:
 
Trade
Allowances
 
Rebates,
Chargebacks
and Discounts
 
Product
Returns
 
Other
Incentives
 
Total
 
(in thousands)
Balance at December 31, 2015
$
2,089

 
$
44,669

 
$
1,228

 
$
1,310

 
$
49,296

Provision related to current period sales
9,935

 
65,066

 
1,288

 
4,220

 
80,509

Adjustments related to prior period sales
(77
)
 
(1,712
)
 
(205
)
 
5

 
(1,989
)
Credits/payments made
(9,762
)
 
(44,113
)
 
(260
)
 
(4,638
)
 
(58,773
)
Balance at June 30, 2016
$
2,185

 
$
63,910

 
$
2,051

 
$
897

 
$
69,043

In the three and six months ended June 30, 2016, the Company sold ORKAMBI in France pursuant to early access programs. The Company has not recognized any product revenues based on these sales because the price is not fixed or determinable due to the ongoing negotiations regarding the reimbursement rate for ORKAMBI in France. If the negotiated reimbursement rate in France is lower than the price currently being paid by Customers in France under these programs, the Company would reimburse the difference between such prices to the Customers. The cash received from sales in France is included as a liability on the Company's condensed consolidated balance sheet, and the increase in "other liabilities, current portion" from December 31, 2015 to June 30, 2016 is primarily due to this liability.
C.
Collaborative Arrangements
Cystic Fibrosis Foundation Therapeutics Incorporated
In April 2011, the Company entered into an amendment (the “April 2011 Amendment”) to its existing collaboration agreement with Cystic Fibrosis Foundation Therapeutics Incorporated (“CFFT”) pursuant to which CFFT agreed to provide financial support for (i) development activities for VX-661, a compound that targets the processing and trafficking defect of the F508del CFTR proteins discovered under the collaboration, and (ii) additional research and development activities directed at discovering new compounds targeting the processing and trafficking defect of the F508del protein.


8
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

Under the April 2011 Amendment, CFFT agreed to provide the Company with up to $75.0 million in funding over approximately five years for corrector compound research and development activities. The Company retains the right to develop and commercialize KALYDECO (ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor), lumacaftor and VX-661. The Company recognized no collaborative revenues from this collaboration during the three and six months ended June 30, 2016 and 2015.
In the original agreement, as amended prior to the April 2011 Amendment, the Company agreed to pay CFFT tiered royalties calculated as a percentage, ranging from single digits to sub-teens, of annual net sales of any approved drugs first synthesized or tested during the research term that ended in 2008, including ivacaftor, lumacaftor and VX-661. The April 2011 Amendment provides for a tiered royalty in the same range on net sales of corrector compounds first synthesized or tested during the research term that ended in February 2014. In each of 2012 and 2013, CFFT earned a commercial milestone payment of $9.3 million from the Company upon achievement of certain sales levels for KALYDECO. In each of the fourth quarter of 2015 and first quarter of 2016, CFFT earned a commercial milestone payment of $13.9 million from the Company upon achievement of certain sales levels of lumacaftor. There are no additional commercial milestone payments payable by the Company to CFFT related to sales levels for KALYDECO or ORKAMBI.
The Company began marketing KALYDECO in the United States and certain countries in the European Union in 2012 and began marketing ORKAMBI in the United States in 2015. The Company received approval for ORKAMBI in the European Union in 2015 and in Canada and Australia in 2016. The Company has royalty obligations to CFFT for ivacaftor, lumacaftor and VX-661 until the expiration of patents covering that compound. The Company has patents in the United States and European Union covering the composition-of-matter of ivacaftor that expire in 2027 and 2025, respectively, subject to potential patent extensions. The Company has patents in the United States and European Union covering the composition-of-matter of lumacaftor that expire in 2030 and 2026, respectively, subject to potential extension. The Company has patents in the United States and European Union covering the composition-of-matter of VX-661 that expire in 2027 and 2028, respectively, subject to potential extension.
CRISPR Therapeutics AG
On October 26, 2015, the Company entered into a strategic collaboration, option and license agreement (the "CRISPR Agreement") with CRISPR Therapeutics AG and its affiliates ("CRISPR") to collaborate on the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene editing technology. The Company has the exclusive right to license up to six CRISPR-Cas9-based targets. In connection with the CRISPR Agreement, the Company made an upfront payment to CRISPR of $75.0 million and a $30.0 million investment in CRISPR pursuant to a convertible loan agreement that converted into preferred stock in January 2016. The Company expensed $75.0 million to research and development, and the $30.0 million investment was recorded at cost and is classified as a long-term asset on the Company’s condensed consolidated balance sheet. In the second quarter of 2016, the Company made an additional preferred stock investment in CRISPR of approximately $3.1 million.
The Company will fund all of the discovery activities conducted pursuant to the CRISPR Agreement. For potential hemoglobinapathy treatments, including treatments for sickle cell disease, the Company and CRISPR will share equally all research and development costs and worldwide revenues. For other targets that the Company elects to license, the Company would lead all development and global commercialization activities. For each of up to six targets that the Company elects to license, other than hemoglobinapathy targets, CRISPR has the potential to receive up to $420.0 million in development, regulatory and commercial milestones and royalties on net product sales.
The Company may terminate the CRISPR Agreement upon 90 days’ notice to CRISPR prior to any product receiving marketing approval or upon 270 days’ notice after a product has received marketing approval. The CRISPR Agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, the CRISPR Agreement will continue in effect until the expiration of the Company's payment obligations under the CRISPR Agreement.
Variable Interest Entities
The Company has entered into several agreements pursuant to which it has licensed rights to certain drug candidates from third-party collaborators, which has resulted in the consolidation of the third parties' financial statements into the


9
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

Company's condensed consolidated financial statements as VIEs. In order to account for the fair value of the contingent milestone and royalty payments related to these collaborations under GAAP, the Company uses present-value models based on assumptions regarding the probability of achieving the relevant milestones, estimates regarding the timing of achieving the milestones, estimates of future product sales and the appropriate discount rates. The Company bases its estimate of the probability of achieving the relevant milestones on industry data for similar assets and its own experience. The discount rates used in the valuation model represent a measure of credit risk and market risk associated with settling the liabilities. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period. Changes in these assumptions could have a material effect on the fair value of the contingent milestone and royalty payments. The following collaborations are reflected in the Company's financial statements as consolidated VIEs:
Parion Sciences, Inc.
License and Collaboration Agreement

On June 4, 2015, the Company entered into a strategic collaboration and license agreement (the "Parion Agreement") with Parion Sciences, Inc. (“Parion”).  Pursuant to the agreement, the Company is collaborating with Parion to develop investigational epithelial sodium channel (“ENaC”) inhibitors, including VX-371 (formerly P-1037) and VX-551 (formerly P-1055), for the potential treatment of cystic fibrosis, or CF, and other pulmonary diseases.  The Company is leading development activities for VX-371 and VX-551 and is responsible for all costs, subject to certain exceptions, related to development and commercialization of the compounds.

Pursuant to the Parion Agreement, the Company has worldwide development and commercial rights to Parion’s lead investigational ENaC inhibitors, VX-371 and VX-551, for the potential treatment of CF and all other pulmonary diseases and has the option to select additional compounds discovered in Parion’s research program.  Parion received an $80.0 million up-front payment and has the potential to receive up to an additional (i) $490.0 million in development and regulatory milestone payments for development of ENaC inhibitors in CF, including $360.0 million related to global filing and approval milestones, (ii) $370.0 million in development and regulatory milestones for VX-371 and VX-551 in non-CF pulmonary indications and (iii) $230.0 million in development and regulatory milestones should the Company elect to develop an additional ENaC inhibitor from Parion’s research program. The Company has agreed to pay Parion tiered royalties that range from the low double digits to mid-teens as a percentage of potential sales of licensed products.

The Company may terminate the Parion Agreement upon 90 days’ notice to Parion prior to any licensed product receiving marketing approval or upon 180 days’ notice after a licensed product has received marketing approval. If the Company experiences a change of control prior to the initiation of the first Phase 3 clinical trial for a licensed product, Parion may terminate the Parion Agreement upon 30 days’ notice, subject to the Company's right to receive specified royalties on any subsequent commercialization of licensed products. The Parion Agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, the Parion Agreement will continue in effect until the expiration of the Company's royalty obligations, which expire on a country-by-country basis on the later of (i) the date the last-to-expire patent covering a licensed product expires or (ii) ten years after the first commercial sale in the country.

The Company determined that Parion is a VIE based on, among other factors, the significance to Parion of the ENaC inhibitors licensed to the Company pursuant to the Parion Agreement and on the Company's power to direct the activities that most significantly affect the economic performance of Parion.  Accordingly, the Company consolidated Parion's financial statements beginning on June 4, 2015. However, the Company's interests in Parion are limited to those accorded to the Company in the Parion Agreement.

The Company recorded $255.3 million of intangible assets on the Company's condensed consolidated balance sheet for Parion's in-process research and development assets. These in-process research and development assets relate to Parion's pulmonary ENaC platform, including the intellectual property related to VX-371 and VX-551, that are licensed by Parion to the Company. The difference between the fair value of the consideration and the fair value of Parion's assets (including the fair value of intangible assets) and liabilities was allocated to goodwill. The measurement period for purchase accounting was closed during the quarter. There were no purchase accounting adjustments recorded during the measurement period.


10
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

BioAxone Biosciences, Inc.
In October 2014, the Company entered into a license and collaboration agreement (the “BioAxone Agreement”) with BioAxone Biosciences, Inc. (“BioAxone”), a privately-held biotechnology company, which resulted in the consolidation of BioAxone as a VIE beginning on October 1, 2014. The Company paid BioAxone initial payments of $10.0 million in the fourth quarter of 2014.
BioAxone has the potential to receive up to $90.0 million in milestones and fees, including development, regulatory and milestone payments and a license continuation fee. In addition, BioAxone would receive royalties and commercial milestones on future net product sales of VX-210, if any. The Company recorded an in-process research and development intangible asset of $29.0 million for VX-210 and a corresponding deferred tax liability of $11.3 million attributable to BioAxone. The Company holds an option to purchase BioAxone at a predetermined price. The option expires on the earliest of (a) the day the FDA accepts the Biologics License Application submission for VX-210, (b) the day the Company elects to continue the license instead of exercising the option to purchase BioAxone and (c) March 15, 2018, subject to the Company’s option to extend this date by one year.
Aggregate VIE Financial Information

An aggregate summary of net loss attributable to noncontrolling interest related to the Company's VIEs for the three and six months ended June 30, 2016 and 2015 is as follows:
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2016
 
2015
 
2016
 
2015
 
(in thousands)
Loss attributable to noncontrolling interest before provision for income taxes
$
2,835

 
$
1,293

 
$
3,674

 
$
1,579

Provision for income taxes
17,511

 
29,653

 
20,573

 
29,590

(Increase) decrease in fair value of contingent milestone and royalty payments
(48,720
)
 
1,198

 
(58,150
)
 
1,073

Net (income) loss attributable to noncontrolling interest
$
(28,374
)
 
$
32,144

 
$
(33,903
)
 
$
32,242


The increases in the fair value of the contingent milestone and royalty payments in the three and six months ended June 30, 2016 were primarily due to a Phase 2 clinical trial of VX-371, a compound being developed pursuant to the Parion Agreement, achieving its primary safety endpoint in the second quarter of 2016. The fair value of the contingent milestone and royalty payments also reflects changes in market interest rates and the time value of money. During the three and six months ended June 30, 2016 and 2015, the increase (decrease) in the fair value of the contingent milestone and royalty payments related to the Company's VIEs was as follows:
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2016
 
2015
 
2016
 
2015
 
(in thousands)
Parion
$
48,400

 
$
(1,621
)
 
$
57,400

 
$
(1,621
)
BioAxone
320

 
423

 
750

 
548


As of June 30, 2016, the fair value of the contingent milestone and royalty payments related to the Parion Agreement and the BioAxone Agreement was $231.4 million and $28.7 million, respectively. As of December 31, 2015, the fair value of the contingent milestone and royalty payments related to the Parion collaboration and the BioAxone collaboration was $179.0 million and $28.0 million, respectively.

The following table summarizes items related to the Company's VIEs included in the Company's condensed consolidated balance sheets as of the dates set forth in the table:


11
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

 
June 30, 2016
 
December 31, 2015
 
(in thousands)
Restricted cash and cash equivalents (VIE)
$
70,513

 
$
78,910

Prepaid expenses and other current assets
3,001

 
3,138

Intangible assets
284,340

 
284,340

Goodwill
19,391

 
19,391

Other assets
383

 
455

Accounts payable
1,129

 
676

Taxes payable
11,723

 
24,554

Other current liabilities
7,059

 
7,100

Deferred tax liability, net
132,810

 
110,438

Other liabilities
310

 
300

Noncontrolling interest
187,491

 
153,661


The Company has recorded the VIEs' cash and cash equivalents as restricted cash and cash equivalents (VIE) because (i) the Company does not have any interest in or control over the VIEs' cash and cash equivalents and (ii) the Company's agreements with each VIE do not provide for the VIEs' cash and cash equivalents to be used for the development of the assets that the Company licensed from the applicable VIE. Assets recorded as a result of consolidating the Company's VIEs' financial condition into the Company's balance sheet do not represent additional assets that could be used to satisfy claims against the Company's general assets.
Outlicense Arrangements
In the ordinary course of the Company's business, the Company has entered into various agreements pursuant to which it has outlicensed rights to certain drug candidates to third-party collaborators. Although the Company does not consider any of these outlicense arrangements to be material, the most notable of these outlicense arrangements is described below. Pursuant to these outlicense arrangements, our collaborators are responsible for all costs related to the continued development of such drug candidates. Depending on the terms of the arrangements, the Company's collaborators may be required to make upfront payments, milestone payments upon the achievement of certain product research and development objectives and/or pay royalties on future sales, if any, of commercial products resulting from the collaboration.

Janssen Pharmaceuticals, Inc.
In June 2014, the Company entered into an agreement (the “Janssen Influenza Agreement”) with Janssen Pharmaceuticals, Inc. (“Janssen Inc.”), which was amended in October 2014 to clarify certain roles and responsibilities of the parties.

Pursuant to the Janssen Influenza Agreement, Janssen Inc. has an exclusive worldwide license to develop and commercialize certain drug candidates for the treatment of influenza, including VX-787. The Company received non-refundable payments of $35.0 million from Janssen Inc. in 2014, which were recorded as collaborative revenue. The Company has the potential to receive development, regulatory and commercial milestone payments as well as royalties on future product sales, if any. Janssen Inc. may terminate the Janssen Influenza Agreement, subject to certain exceptions, upon six months' notice.
Janssen Inc. is responsible for costs related to the development and commercialization of the compounds. During the three and six months ended June 30, 2016, the Company recorded reimbursement for these development activities of $4.3 million and $7.8 million, respectively. During the three and six months ended June 30, 2015, the Company recorded reimbursement for these development activities of $7.1 million and $14.7 million, respectively. The reimbursements are recorded as a reduction to development expense in the Company's condensed consolidated statements of operations primarily due to the fact that Janssen Inc. directs the activities and selects the suppliers associated with these activities.


12
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

Subsequent Event
Moderna Therapeutics, Inc.
In July 2016, the Company entered into a strategic collaboration and licensing agreement (the "Moderna Agreement") with Moderna Therapeutics, Inc. ("Moderna") pursuant to which the parties are seeking to identify and develop messenger Ribonucleic Acid ("mRNA") Therapeutics™ for the treatment of CF. In connection with the Moderna Agreement in the third quarter of 2016, the Company made an upfront payment to Moderna of $20.0 million and made a $20.0 million investment in Moderna pursuant to a convertible promissory note. Moderna has the potential to receive future development and regulatory milestones of up to $275.0 million, including $220.0 million in approval and reimbursement milestones, as well as tiered royalty payments on future sales.
Under the terms of the collaboration, Moderna will lead discovery efforts and the Company will lead all preclinical, development and commercialization activities associated with the advancement of mRNA Therapeutics that result from this collaboration and will fund all expenses related to the collaboration.
The Company may terminate the Moderna Agreement by providing advanced notice to Moderna, with the required length of notice dependent on whether any product developed under the Moderna Agreement has received marketing approval. The Moderna Agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, the Moderna Agreement will continue in effect until the expiration of the Company's payment obligations under the Moderna Agreement.
D.
Earnings Per Share
Basic net loss per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period, excluding restricted stock and restricted stock units that have been issued but are not yet vested. Diluted net loss per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period when the effect is dilutive.
The Company did not include the securities in the following table in the computation of the net loss per share attributable to Vertex common shareholders calculations because the effect would have been anti-dilutive during each period:
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2016
 
2015
 
2016
 
2015
 
(in thousands)
Stock options
12,231

 
11,933

 
12,231

 
11,933

Unvested restricted stock and restricted stock units
3,506

 
3,355

 
3,506

 
3,355

E.
Fair Value Measurements
The fair value of the Company’s financial assets and liabilities reflects the Company’s estimate of amounts that it would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company’s assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:


13
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

Level 1:
Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2:
Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
Level 3:
Unobservable inputs based on the Company’s assessment of the assumptions that market participants would use in pricing the asset or liability.
The Company’s investment strategy is focused on capital preservation. The Company invests in instruments that meet the credit quality standards outlined in the Company’s investment policy. This policy also limits the amount of credit exposure to any one issue or type of instrument. As of June 30, 2016, the Company’s investments were in money market funds, short-term government-sponsored enterprise securities, U.S. Treasury securities, corporate debt securities and commercial paper.
As of June 30, 2016, all of the Company’s financial assets that were subject to fair value measurements were valued using observable inputs. The Company’s financial assets valued based on Level 1 inputs consisted of money market funds, short-term government-sponsored enterprise securities and U.S. Treasury securities. The Company’s financial assets valued based on Level 2 inputs consisted of corporate debt securities and commercial paper, which consisted of investments in highly-rated investment-grade corporations.
The following table sets forth the Company’s financial assets (excluding VIE cash and cash equivalents) and liabilities subject to fair value measurements:
 
Fair Value Measurements as
of June 30, 2016
 
 
 
Fair Value Hierarchy
 
Total
 
Level 1
 
Level 2
 
Level 3
 
(in thousands)
Financial assets carried at fair value:
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
110,696

 
$
110,696

 
$
—

 
$
—

Marketable securities:
 
 
 
 
 
 
 
U.S. Treasury securities
33,142

 
33,142

 
—

 
—

Government-sponsored enterprise securities
131,900

 
131,900

 
—

 
—

Corporate debt securities
135,675

 
—

 
135,675

 
—

Commercial paper
164,853

 
—

 
164,853

 
—

Prepaid and other current assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
9,966

 
—

 
9,966

 
—

Other assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
1,604

 
—

 
1,604

 
—

Total financial assets
$
587,836


$
275,738

 
$
312,098

 
$
—

Financial liabilities carried at fair value:
 
 
 
 
 
 
 
Other liabilities, current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
$
(7,317
)
 
$
—

 
$
(7,317
)
 
$
—

Other liabilities, excluding current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
(88
)
 
—

 
(88
)
 
—

Total financial liabilities
$
(7,405
)
 
$
—

 
$
(7,405
)
 
$
—



14
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

 
Fair Value Measurements as
of December 31, 2015
 
 
 
Fair Value Hierarchy
 
Total
 
Level 1
 
Level 2
 
Level 3
 
(in thousands)
Financial instruments carried at fair value (asset position):
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
199,507

 
$
199,507

 
$
—

 
$
—

Government-sponsored enterprise securities
85,994

 
85,994

 
—

 
—

Commercial paper
34,889

 
—

 
34,889

 
—

Corporate debt securities
11,533

 
—

 
11,533

 
—

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities
87,162

 
87,162

 
—

 
—

Commercial paper
99,123

 
—

 
99,123

 
—

Corporate debt securities
141,409

 
—

 
141,409

 
—

Prepaid and other current assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
5,161

 
—

 
5,161

 
—

Other assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
605

 
$
—

 
605

 
$
—

Total financial assets
$
665,383

 
$
372,663

 
$
292,720

 
$
—

Financial instruments carried at fair value (liability position):
 
 
 
 
 
 
 
Other liabilities, current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
$
(769
)
 
$
—

 
$
(769
)
 
$
—

Other liabilities, excluding current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
(132
)
 
—

 
(132
)
 
—

Total financial liabilities
$
(901
)
 
$
—

 
$
(901
)
 
$
—

The Company's VIEs invested in cash equivalents consisting of money market funds of $70.2 million as of June 30, 2016, which are valued based on Level 1 inputs. These cash equivalents are not included in the table above. The Company’s noncontrolling interest related to VIEs includes the fair value of the contingent milestone and royalty payments, which are valued based on Level 3 inputs. Please refer to Note C, “Collaborative Arrangements,” for further information.
As of June 30, 2016, the fair value and carrying value of the Company's Term Loan was $296.5 million. The fair value of the Company's Term Loan was estimated based on Level 3 inputs computed using the effective interest rate of the Term Loan. The effective interest rate considers the timing and amount of estimated future interest payments as well as current market rates. Please refer to Note K, "Long-term Obligations" for further information regarding the Company's Term Loan.


15
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

F.
Marketable Securities
A summary of the Company’s cash, cash equivalents and marketable securities is shown below:
 
Amortized Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Fair Value
 
(in thousands)
As of June 30, 2016
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
Cash and money market funds
$
605,866

 
$
—

 
$
—

 
$
605,866

Total cash and cash equivalents
$
605,866

 
$
—

 
$
—

 
$
605,866

Marketable securities:
 
 
 
 
 
 
 
U.S. Treasury securities (due within 1 year)
$
33,138

 
$
4

 
$
—

 
$
33,142

Government-sponsored enterprise securities (due within 1 year)
131,868

 
35

 
(3
)
 
131,900

Commercial paper (due within 1 year)
164,575

 
278

 
—

 
164,853

Corporate debt securities (due within 1 year)
135,663

 
34

 
(22
)
 
135,675

Total marketable securities
$
465,244

 
$
351

 
$
(25
)
 
$
465,570

Total cash, cash equivalents and marketable securities
$
1,071,110

 
$
351

 
$
(25
)
 
$
1,071,436

 
 
 
 
 
 
 
 
As of December 31, 2015
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
Cash and money market funds
$
582,352

 
$
—

 
$
—

 
$
582,352

Government-sponsored enterprise securities
85,994

 
—

 
—

 
85,994

Commercial paper
34,889

 
—

 
—

 
34,889

Corporate debt securities
11,533

 
—

 
—

 
11,533

Total cash and cash equivalents
$
714,768

 
$
—

 
$
—

 
$
714,768

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities (due within 1 year)
$
87,176

 
$
—

 
$
(14
)
 
$
87,162

Commercial paper (due within 1 year)
98,877

 
246

 
—

 
99,123

Corporate debt securities (due within 1 year)
141,515

 
—

 
(106
)
 
141,409

Total marketable securities
$
327,568

 
$
246

 
$
(120
)
 
$
327,694

Total cash, cash equivalents and marketable securities
$
1,042,336

 
$
246

 
$
(120
)
 
$
1,042,462

The Company has a limited number of marketable securities in insignificant loss positions as of June 30, 2016, which the Company does not intend to sell and has concluded it will not be required to sell before recovery of the amortized costs for the investment at maturity. There were no charges recorded for other-than-temporary declines in fair value of marketable securities nor gross realized gains or losses recognized in the three and six months ended June 30, 2016 and 2015.


16
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

G.
Accumulated Other Comprehensive (Loss) Income
A summary of the Company's changes in accumulated other comprehensive (loss) income by component is shown below:
 
Foreign Currency Translation Adjustment
 
Unrealized Holding Gains (Losses) on Marketable Securities
 
Unrealized Gains on Foreign Currency Forward Contracts, net of tax
 
Total
 
(in thousands)
Balance at December 31, 2015
$
(2,080
)
 
$
126

 
$
3,778

 
$
1,824

Other comprehensive (loss) income before reclassifications
(5,201
)
 
200

 
1,847

 
(3,154
)
Amounts reclassified from accumulated other comprehensive loss
—

 
—

 
(2,060
)
 
(2,060
)
Net current period other comprehensive (loss) income
$
(5,201
)
 
$
200

 
$
(213
)
 
$
(5,214
)
Balance at June 30, 2016
$
(7,281
)
 
$
326

 
$
3,565

 
$
(3,390
)
 
Foreign Currency Translation Adjustment
 
Unrealized Holding (Losses) Gains on Marketable Securities
 
Unrealized Gains (Losses) on Foreign Currency Forward Contracts
 
Total
 
(in thousands)
Balance at December 31, 2014
$
(971
)
 
$
(123
)
 
$
2,011

 
$
917

Other comprehensive (loss) income before reclassifications
1,220

 
130

 
(1,370
)
 
(20
)
Amounts reclassified from accumulated other comprehensive loss
—

 
—

 
(2,604
)
 
(2,604
)
Net current period other comprehensive (loss) income
$
1,220

 
$
130

 
$
(3,974
)
 
$
(2,624
)
Balance at June 30, 2015
$
249

 
$
7

 
$
(1,963
)
 
$
(1,707
)
H.
Hedging
The Company maintains a hedging program intended to mitigate the effect of changes in foreign exchange rates for a portion of the Company’s forecasted product revenues denominated in certain foreign currencies. The program includes foreign currency forward contracts that are designated as cash flow hedges under GAAP having contractual durations from one to eighteen months.
The Company formally documents the relationship between foreign currency forward contracts (hedging instruments) and forecasted product revenues (hedged items), as well as the Company's risk management objective and strategy for undertaking various hedging activities, which includes matching all foreign currency forward contracts that are designated as cash flow hedges to forecasted transactions. The Company also formally assesses, both at the hedge’s inception and on an ongoing basis, whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If the Company determines that a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, the Company would discontinue hedge accounting treatment prospectively. The Company measures effectiveness based on the change in fair value of the forward contracts and the fair value of the hypothetical foreign currency forward contracts with terms that match the critical terms of the risk being hedged. As of June 30, 2016, all hedges were determined to be highly effective and the Company had not recorded any ineffectiveness related to the hedging program.
The following table summarizes the notional amount of the Company’s outstanding foreign currency forward contracts designated as cash flow hedges:


17
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

 
As of June 30, 2016
 
As of December 31, 2015
Foreign Currency
(in thousands)
Euro
$
193,542

 
$
103,362

British pound sterling
79,845

 
78,756

Australian dollar
28,318

 
27,167

Total foreign currency forward contracts
$
301,705

 
$
209,285

The following table summarizes the fair value of the Company's outstanding foreign currency forward contracts designated as cash flow hedges under GAAP included on the Company's condensed consolidated balance sheets:
As of June 30, 2016
Assets
 
Liabilities
Classification
 
Fair Value
 
Classification
 
Fair Value
(in thousands)
Prepaid and other current assets
 
$
9,966

 
Other liabilities, current portion
 
$
(7,317
)
Other assets
 
1,604

 
Other liabilities, excluding current portion
 
(88
)
Total assets
 
$
11,570

 
Total liabilities
 
$
(7,405
)
As of December 31, 2015
Assets
 
Liabilities
Classification
 
Fair Value
 
Classification
 
Fair Value
(in thousands)
Prepaid and other current assets
 
$
5,161

 
Other liabilities, current portion
 
$
(769
)
Other assets
 
605

 
Other liabilities, excluding current portion
 
(132
)
Total assets
 
$
5,766

 
Total liabilities
 
$
(901
)
The following table summarizes the potential effect of offsetting derivatives by type of financial instrument on the Company's condensed consolidated balance sheets:
 
As of June 30, 2016
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amounts Presented
 
Gross Amounts Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
11,570

 
$
—

 
$
11,570

 
$
(7,405
)
 
$
4,165

Total liabilities
$
(7,405
)
 
$
—

 
$
(7,405
)
 
$
7,405

 
$
—

 
As of December 31, 2015
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amounts Presented
 
Gross Amounts Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
5,766

 
$
—

 
$
5,766

 
$
(901
)
 
$
4,865

Total liabilities
$
(901
)
 
$
—

 
$
(901
)
 
$
901

 
$
—



18
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

I. Inventories
Inventories consisted of the following:
 
As of June 30, 2016
 
As of December 31, 2015
 
(in thousands)
Raw materials
$
5,408

 
$
8,696

Work-in-process
45,807

 
40,695

Finished goods
15,374

 
7,816

Total
$
66,589

 
$
57,207

J. Intangible Assets and Goodwill
Intangible Assets
As of June 30, 2016 and December 31, 2015, in-process research and development intangible assets of $284.3 million were recorded on the Company's condensed consolidated balance sheet.
In June 2015, in connection with entering into the Parion Agreement, the Company recorded an in-process research and development intangible asset of $255.3 million based on the Company’s estimate of the fair value of Parion’s lead investigational ENaC inhibitors, including VX-371 and VX-551, that were licensed by the Company from Parion. The Company aggregated the fair value of the ENaC inhibitors into a single intangible asset because the phase, nature and risks of development as well as the amount and timing of benefits associated with the assets were similar. In October 2014, the Company recorded an in-process research and development intangible asset of $29.0 million based on the Company’s estimate of the fair value of VX-210, a drug candidate for patients with spinal cord injuries that was licensed by the Company from BioAxone. The Company used discount rates of 7.1% and 7.5% in the present-value models to estimate the fair values of the ENaC inhibitors and VX-210 intangible assets, respectively.
Goodwill
As of June 30, 2016 and December 31, 2015, goodwill of $50.4 million was recorded on the Company's condensed consolidated balance sheet.
K. Long-term Obligations
Fan Pier Leases
In 2011, the Company entered into two lease agreements, pursuant to which the Company leases approximately 1.1 million square feet of office and laboratory space in two buildings (the “Buildings”) at Fan Pier in Boston, Massachusetts (the “Fan Pier Leases”). The Company commenced lease payments in December 2013, and will make lease payments pursuant to the Fan Pier Leases through December 2028. The Company has an option to extend the term of the Fan Pier Leases for an additional ten years.
Because the Company was involved in the construction project, the Company was deemed for accounting purposes to be the owner of the Buildings during the construction period and recorded project construction costs incurred by the landlord. Upon completion of the Buildings, the Company evaluated the Fan Pier Leases and determined that the Fan Pier Leases did not meet the criteria for “sale-leaseback” treatment. Accordingly, the Company began depreciating the asset and incurring interest expense related to the financing obligation in 2013. The Company bifurcates its lease payments pursuant to the Fan Pier Leases into (i) a portion that is allocated to the Buildings and (ii) a portion that is allocated to the land on which the Buildings were constructed. The portion of the lease obligations allocated to the land is treated as an operating lease that commenced in 2011.
Property and equipment, net, included $495.7 million and $502.3 million as of June 30, 2016 and December 31, 2015, respectively, related to construction costs for the Buildings. The carrying value of the Company's lease agreement liability for the Buildings was $472.8 million and $473.0 million as of June 30, 2016 and December 31, 2015, respectively.


19
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

San Diego Lease
On December 2, 2015, the Company entered into a lease agreement for 3215 Merryfield Row, San Diego, California with ARE-SD Region No. 23, LLC. Pursuant to this agreement, the Company agreed to lease approximately 170,000 square feet of office and laboratory space in a building to be built in San Diego, California. The lease will commence upon completion of the building, scheduled for the second half of 2017, and will extend for 16 years from the commencement date. Pursuant to the lease agreement, during the initial 16-year term, the Company will pay an average of approximately $10.2 million per year in aggregate rent, exclusive of operating expenses. The Company has the option to extend the lease term for up to two additional five-year terms.

Term Loan
In July 2014, the Company entered into a credit agreement with the lenders party thereto, and Macquarie US Trading LLC ("Macquarie"), as administrative agent. The credit agreement provides for a $300.0 million senior secured term loan ("Term Loan"). The credit agreement also provides that, subject to satisfaction of certain conditions, the Company may request that the lenders establish an incremental senior secured term loan facility in an aggregate amount not to exceed $200.0 million.
The Term Loan initially bore interest at a rate of 7.2% per annum, which was reduced to 6.2% per annum based on the FDA's approval of ORKAMBI. The Term Loan bears interest at a rate of LIBOR plus 5.0% per annum during the third year of the term.
The maturity date of all loans under the facilities is July 9, 2017. Interest is payable quarterly and on the maturity date. In October 2015, the Company amended the terms of the credit agreement to provide for, among other things, a modification to the repayment schedule of the loan. As amended, the Company is required to repay principal on the Term Loan in quarterly installments of $75 million from October 1, 2016 through the maturity date.
The Company may prepay the Term Loan, in whole or in part, at any time; provided that prepayments prior to the July 9, 2016 are subject to a make-whole premium to ensure Macquarie receives approximately the present value of two years of interest payments over the life of the loan. The Company accounted for the amendment as a debt modification, as opposed to an extinguishment of debt, based on an insignificant change to the present value of the future cash flows relating to the credit agreement.
The Company's obligations under the Term Loan are unconditionally guaranteed by certain of its domestic subsidiaries. All obligations under the Term Loan, and the guarantees of those obligations, are secured, subject to certain exceptions, by substantially all of the Company's assets and the assets of all guarantors, including the pledge of all or a portion of the equity interests of certain of its subsidiaries.
The credit agreement requires that the Company maintain, on a quarterly basis, a minimum level of KALYDECO net revenues. Further, the credit agreement includes negative covenants, subject to exceptions, restricting or limiting the Company's ability and the ability of its subsidiaries to, among other things, incur additional indebtedness, grant liens, engage in certain investment, acquisition and disposition transactions, pay dividends, repurchase capital stock and enter into transactions with affiliates. The credit agreement also contains customary representations and warranties, affirmative covenants and events of default, including payment defaults, breach of representations and warranties, covenant defaults and cross defaults. If an event of default occurs, the administrative agent would be entitled to take various actions, including the acceleration of amounts due under outstanding loans. There have been no events of default as of or during the period ended June 30, 2016.
Based on the Company's evaluation of the Term Loan, the Company determined that the Term Loan contains several embedded derivatives. These embedded derivatives are clearly and closely related to the host instrument because they relate to the Company's credit risk; therefore, they do not require bifurcation from the host instrument, the Term Loan.
The Company incurred $5.3 million in fees paid to Macquarie that were recorded as a discount on the Term Loan and are being recorded as interest expense using the effective interest method over the term of the loan in the Company’s condensed consolidated statements of operations. As of June 30, 2016 and December 31, 2015, the unamortized discount associated


20
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

with the Term Loan that was included in the senior secured term loan caption on the Company’s condensed consolidated balance sheet was $3.4 million and $4.6 million, respectively.
L. Stock-based Compensation Expense
During the three and six months ended June 30, 2016 and 2015, the Company recognized the following stock-based compensation expense:
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2016
 
2015
 
2016
 
2015
 
(in thousands)
Stock-based compensation expense by type of award:
 
 
 
 
 
 
 
Stock options
$
31,826

 
$
37,687

 
$
58,086

 
$
66,646

Restricted stock and restricted stock units
29,608

 
24,902

 
57,141

 
52,071

ESPP share issuances
1,436

 
1,825

 
3,960

 
3,965

Less stock-based compensation expense capitalized to inventories
(928
)
 
(1,153
)
 
(1,773
)
 
(2,037
)
Total stock-based compensation included in costs and expenses
$
61,942

 
$
63,261

 
$
117,414

 
$
120,645

 
 
 
 
 
 
 


Stock-based compensation expense by line item:
 
 
 
 
 
 
 
Research and development expenses
$
40,640

 
$
41,632

 
$
75,088

 
$
79,849

Sales, general and administrative expenses
21,302

 
21,629

 
42,326

 
40,796

Total stock-based compensation included in costs and expenses
$
61,942

 
$
63,261

 
$
117,414

 
$
120,645

The following table sets forth the Company's unrecognized stock-based compensation expense, net of estimated forfeitures, by type of award and the weighted-average period over which that expense is expected to be recognized:
 
As of June 30, 2016
 
Unrecognized Expense,
Net of
Estimated Forfeitures
 
Weighted-average
Recognition
Period
 
(in thousands)
 
(in years)
Type of award:
 
 
 
Stock options
$
176,251

 
2.66
Restricted stock and restricted stock units
$
201,858

 
2.57
ESPP share issuances
$
5,546

 
0.64


21
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

The following table summarizes information about stock options outstanding and exercisable at June 30, 2016:
 
 
Options Outstanding
 
Options Exercisable
Range of Exercise Prices
 
Number
Outstanding
 
Weighted-average
Remaining
Contractual Life
 
Weighted-average
Exercise Price
 
Number
Exercisable
 
Weighted-average
Exercise Price
 
 
(in thousands)
 
(in years)
 
(per share)
 
(in thousands)
 
(per share)
$18.93–$20.00
 
137

 
1.61
 
$
18.93

 
137

 
$
18.93

$20.01–$40.00
 
1,964

 
3.45
 
$
34.24

 
1,962

 
$
34.23

$40.01–$60.00
 
2,066

 
6.07
 
$
48.14

 
1,657

 
$
48.66

$60.01–$80.00
 
1,368

 
7.62
 
$
75.90

 
734

 
$
75.39

$80.01–$100.00
 
3,555

 
8.60
 
$
90.68

 
1,080

 
$
88.91

$100.01–$120.00
 
1,644

 
8.57
 
$
109.32

 
500

 
$
109.27

$120.01–$134.69
 
1,497

 
9.05
 
$
130.61

 
420

 
$
129.84

Total
 
12,231

 
7.21
 
$
79.37

 
6,490

 
$
63.32

M. Other Arrangements
Sale of HIV Protease Inhibitor Royalty Stream
In 2008, the Company sold to a third party its rights to receive royalty payments from GlaxoSmithKline plc, net of royalty amounts to be earned by and due to a third party, for a one-time cash payment of $160.0 million. These royalty payments relate to net sales of HIV protease inhibitors, which had been developed pursuant to a collaboration agreement between the Company and GlaxoSmithKline plc. As of June 30, 2016, the Company had $18.9 million in deferred revenues related to the one-time cash payment, which it is recognizing over the life of the collaboration agreement with GlaxoSmithKline plc based on the units-of-revenue method. In addition, the Company continues to recognize royalty revenues equal to the amount of the third-party subroyalty and an offsetting royalty expense for the third-party subroyalty payment.
N. Income Taxes
The Company is subject to United States federal, state, and foreign income taxes. For the three and six months ended June 30, 2016, the Company recorded a provision for income taxes of $18.1 million and $23.6 million, respectively. The provision for income taxes recorded in the three and six months ended June 30, 2016 included $17.5 million and $20.6 million, respectively, related to the Company's VIEs' income tax provision. The Company has no liability for taxes payable by the Company's VIEs and the income tax provision and related liability have been allocated to noncontrolling interest (VIE). For the three and six months ended June 30, 2015, the Company recorded a provision for income taxes of $30.1 million and $30.4 million, respectively, primarily related to the Company's VIEs' income tax provision.
As of June 30, 2016 and December 31, 2015, the Company had unrecognized tax benefits of $0.4 million. The Company recognizes interest and penalties related to income taxes as a component of income tax expense. As of June 30, 2016, no interest and penalties have been accrued. The Company does not expect that its unrecognized tax benefits will materially increase within the next twelve months. The Company did not recognize any material interest or penalties related to uncertain tax positions as of June 30, 2016 and December 31, 2015. In 2016, it is reasonably possible that the Company will reduce the balance of its unrecognized tax benefits by approximately $0.4 million due to the application of statute of limitations and settlements with taxing authorities, all of which would reduce the Company’s effective tax rate.
The Company continues to maintain a valuation allowance against certain deferred tax assets where it is more likely than not that the deferred tax asset will not be realized because of its extended history of annual losses.
The Company files United States federal income tax returns and income tax returns in various state, local and foreign jurisdictions. The Company is no longer subject to any tax assessment from an income tax examination in the United States


22
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

before 2011 or any other major taxing jurisdiction for years before 2009, except where the Company has net operating losses or tax credit carryforwards that originated before 2009. The Company currently is under examination by the Internal Revenue Service for the year ended December 31, 2011 and in Delaware, Canada and Quebec for varying periods including the years ended December 31, 2011 through 2014. No adjustments have been reported. The Company is not under examination by any other jurisdictions for any tax year. The Company concluded audits with Pennsylvania and Texas during 2016 and Massachusetts and New York during 2015 with no material adjustments.
The Company currently intends to reinvest the total amount of its unremitted earnings. At June 30, 2016, foreign earnings, which were not significant, have been retained indefinitely by foreign subsidiary companies for reinvestment; therefore, no provision has been made for income taxes that would be payable upon the distribution of such earnings, and it would not be practicable to determine the amount of the related unrecognized deferred income tax liability. Upon repatriation of those earnings, in the form of dividends or otherwise, the Company would be subject to United States federal income taxes (subject to an adjustment for foreign tax credits) and withholding taxes payable to the various foreign countries.
O. Restructuring Liabilities
2003 Kendall Restructuring
In 2003, the Company adopted a plan to restructure its operations to coincide with its increasing internal emphasis on advancing drug candidates through clinical development to commercialization. The restructuring liability relates to specialized laboratory and office space that is leased to the Company pursuant to a 15-year lease that terminates in 2018. The Company has not used more than 50% of this space since it adopted the plan to restructure its operations in 2003. This unused laboratory and office space currently is subleased to third parties.
The activities related to the restructuring liability for the three and six months ended June 30, 2016 and 2015 were as follows:
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2016
 
2015
 
2016
 
2015
 
(in thousands)
 
 
 
 
Liability, beginning of the period
$
7,224

 
$
9,506

 
$
7,944

 
$
11,596

Cash payments
(3,833
)
 
(2,584
)
 
(7,764
)
 
(6,569
)
Cash received from subleases
3,008

 
2,799

 
6,016

 
5,275

Restructuring expense (income)
(11
)
 
203

 
192

 
(378
)
Liability, end of the period
$
6,388

 
$
9,924

 
$
6,388

 
$
9,924


Fan Pier Move Restructuring
In connection with the relocation of its Massachusetts operations to Fan Pier in Boston, Massachusetts, which commenced in 2013, the Company is incurring restructuring charges related to its remaining lease obligations at its facilities in Cambridge, Massachusetts. The majority of these restructuring charges were recorded in the third quarter of 2014 upon decommissioning three facilities in Cambridge. During the first quarter of 2015, the Company terminated two of these lease agreements resulting in a credit to restructuring expense equal to the difference between the Company’s estimated future cash flows related to its lease obligations for these facilities and the termination payment paid to the Company’s landlord on the effective date of the termination. The third major facility included in this restructuring activity is 120,000 square feet of the Kendall Square Facility that the Company continued to use for its operations following its 2003 Kendall Restructuring. The rentable square footage in this portion of the Kendall Square Facility was subleased to a third party in February 2015. The Company will continue to incur charges through April 2018 related to the difference between the Company’s estimated future cash flows related to this portion of the Kendall Square Facility, which include an estimate for sublease income to be received from the Company's sublessee and its actual cash flows. The Company discounted the estimated cash flows related to this restructuring activity at a discount rate of 9%.


23
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

The activities related to the restructuring liability for the three and six months ended June 30, 2016 and 2015 were as follows:
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2016
 
2015
 
2016
 
2015
 
(in thousands)
 
 
 
 
Liability, beginning of the period
$
5,449

 
$
11,137

 
$
5,964

 
$
33,390

Cash payments
(3,096
)
 
(3,095
)
 
(6,252
)
 
(22,351
)
Cash received from subleases
2,361

 
—

 
4,769

 
—

Restructuring expense (income)
149

 
975

 
382

 
(2,022
)
Liability, end of the period
$
4,863

 
$
9,017

 
$
4,863

 
$
9,017

Other Restructuring Activities
The Company has engaged in several other restructuring activities that are unrelated to its 2003 Kendall Restructuring and the Fan Pier Move Restructuring. The most significant activity commenced in October 2013 when the Company adopted a restructuring plan that included (i) a workforce reduction primarily related to the commercial support of INCIVEK following the continued and rapid decline in the number of patients being treated with INCIVEK as new medicines for the treatment of HCV infection neared approval and (ii) the write-off of certain assets. This action resulted from the Company's decision to focus its investment on future opportunities in CF and other research and development programs.
The activities related to the Company's other restructuring liabilities for the three and six months ended June 30, 2016 and 2015 were as follows:
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2016
 
2015
 
2016
 
2015
 
(in thousands)
 
 
 
 
Liability, beginning of the period
$
1,262

 
$
845

 
$
1,450

 
$
869

Cash payments
(234
)
 
(893
)
 
(673
)
 
(1,223
)
Restructuring expense
205

 
950

 
456

 
1,256

Liability, end of the period
$
1,233

 
$
902

 
$
1,233

 
$
902

P. Commitments and Contingencies
Financing Arrangements
As of June 30, 2016, the Company had irrevocable stand-by letters of credit outstanding that were issued in connection with property leases and other similar agreements totaling $21.9 million that are cash collateralized. The cash used to support these letters of credit is included in restricted cash, as of June 30, 2016, on the Company's condensed consolidated balance sheet.
Litigation
On May 28, 2014, a purported shareholder class action Local No. 8 IBEW Retirement Plan & Trust v. Vertex Pharmaceuticals Incorporated, et al. was filed in the United States District Court for the District of Massachusetts, naming the Company and certain of the Company's current and former officers and directors as defendants. The lawsuit alleged that the Company made material misrepresentations and/or omissions of material fact in the Company's disclosures during the period from May 7, 2012 through May 29, 2012, all in violation of Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. The purported class consists of all persons (excluding defendants) who purchased the Company’s common stock between May 7, 2012 and May 29, 2012. The plaintiffs seek unspecified monetary damages, costs and attorneys’ fees as well as disgorgement of the proceeds from certain individual defendants’ sales of the Company’s stock. On October 8, 2014, the Court approved Local No. 8 IBEW Retirement Fund as lead plaintiff, and Scott


24
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

and Scott LLP as lead counsel for the plaintiff and the putative class. On February 23, 2015, the Company filed a reply to the plaintiffs’ opposition to its motion to dismiss.  The court heard oral argument on the motion to dismiss on March 6, 2015 and took the motion under advisement. On September 30, 2015, the court granted the Company's motion to dismiss. On October 15, 2015, the plaintiff filed a notice of appeal. The First Circuit Court of Appeals issued a scheduling order on December 24, 2015. On February 2, 2016, the Plaintiff filed their opening brief and the Company filed its opposition brief on March 7, 2016. On March 24, 2016, the plaintiff filed their reply brief. Oral argument on the appeal took place on July 26, 2016. The Company believes the claims to be without merit and intend to vigorously defend the litigation. As of June 30, 2016, the Company has not recorded any reserves for this purported class action.
Guaranties and Indemnifications
As permitted under Massachusetts law, the Company’s Articles of Organization and By-laws provide that the Company will indemnify certain of its officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that the Company could be required to make under these indemnification provisions is unlimited. However, the Company has purchased directors’ and officers’ liability insurance policies that could reduce its monetary exposure and enable it to recover a portion of any future amounts paid. No indemnification claims currently are outstanding, and the Company believes the estimated fair value of these indemnification arrangements is minimal.
The Company customarily agrees in the ordinary course of its business to indemnification provisions in agreements with clinical trial investigators and sites in its drug development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for the Company and its real estate leases. The Company also customarily agrees to certain indemnification provisions in its drug discovery, development and commercialization collaboration agreements. With respect to the Company’s clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator’s institution relating to personal injury or property damage, violations of law or certain breaches of the Company’s contractual obligations arising out of the research or clinical testing of the Company’s compounds or drug candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by the Company, to violations of law by the Company or to certain breaches of the Company’s contractual obligations. The indemnification provisions appearing in the Company’s collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for its collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although the Company believes the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that the Company could be required to make under these provisions is generally unlimited. The Company has purchased insurance policies covering personal injury, property damage and general liability that reduce its exposure for indemnification and would enable it in many cases to recover all or a portion of any future amounts paid. The Company has never paid any material amounts to defend lawsuits or settle claims related to these indemnification provisions. Accordingly, the Company believes the estimated fair value of these indemnification arrangements is minimal.
Other Contingencies
The Company has certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a reserve for contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. There were no material contingent liabilities accrued as of June 30, 2016 or December 31, 2015.


25

Item 2.     Management's Discussion and Analysis of Financial Condition and Results of Operations
OVERVIEW
We are in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. We use precision medicine approaches with the goal of creating transformative medicines for patients in specialty markets. Our business is focused on developing and commercializing therapies for the treatment of cystic fibrosis, or CF, and advancing our research and development programs in other indications, while maintaining our financial strength. Our two marketed products are ORKAMBI and KALYDECO.
Cystic Fibrosis
ORKAMBI
ORKAMBI (lumacaftor in combination with ivacaftor) was approved by the United States Food and Drug Administration, or FDA, in July 2015 and by the European Commission in November 2015, for the treatment of patients with CF twelve years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator, or CFTR, gene. ORKAMBI was approved for this patient population in Canada and Australia in the first quarter of 2016. Our future ORKAMBI net product revenues in the United States will reflect the number of patients for whom treatment with ORKAMBI is initiated, the proportion of initiated patients who remain on treatment, patient compliance with the recommended treatment regimen and the level of rebates, chargebacks, discounts and other adjustments to our ORKAMBI gross product revenues. We believe that there currently are approximately 8,500 patients in the United States who are eligible for treatment with ORKAMBI. We have begun the country-by-country reimbursement approval process in ex-U.S. markets. We believe that there are approximately 12,000 patients with CF twelve years of age and older who are homozygous for the F508del mutation in Europe and approximately an aggregate of 2,500 patients with CF twelve years of age and older who are homozygous for the F508del mutation in Canada and Australia.
In May 2016, the FDA accepted our supplemental New Drug Application, or sNDA, for ORKAMBI for the treatment of patients with CF six to eleven years of age who are homozygous for the F508del mutation in their CFTR gene. The FDA granted our request for priority review and set the target review date of September 30, 2016. The sNDA was based upon the results of a Phase 3 clinical trial evaluating lumacaftor in combination with ivacaftor in 58 patients with CF six to eleven years of age who are homozygous for the F508del mutation in their CFTR gene. We have completed enrollment in a second Phase 3 clinical trial evaluating lumacaftor in combination with ivacaftor in approximately 200 patients in this same patient population. If this clinical trial is successful, we expect to submit a Marketing Authorization Application to the European Medicines Agency seeking approval of ORKAMBI in this patient population in the European Union in the first half of 2017.
We recently initiated a Phase 3 clinical trial for lumacaftor in combination with ivacaftor in patients with CF two to five years of age who are homozygous for the F508del mutation in their CFTR gene. The first part of the two-part clinical trial is evaluating safety and pharmacokinetics to inform dose selection for the second part of the clinical trial. The primary endpoint of the second part of the clinical trial is safety and tolerability, with multiple efficacy measurements as secondary endpoints.
KALYDECO
KALYDECO (ivacaftor) was approved in 2012 in the United States and European Union as a treatment for patients with CF six years of age and older who have the G551D mutation in their CFTR gene. Since 2012, we have increased the number of patients who are being treated with KALYDECO in the United States and ex-U.S. markets by expanding the label for KALYDECO to include patients with CF who have additional mutations in their CFTR gene and to include patients in additional age demographics. We believe that there are approximately 4,000 patients in North America, Europe and Australia who are currently eligible for treatment with KALYDECO.
We have initiated a Phase 3 clinical trial for ivacaftor in patients with CF less than two years of age to evaluate the effect of ivacaftor on markers of CF disease in young children. The clinical trial utilizes a weight-based dose of ivacaftor granules that can be mixed in soft foods or liquids. The clinical trial is enrolling patients with one of the ten CFTR gene mutations for which KALYDECO is currently approved.
VX-661
VX-661 is an orally-administered CFTR corrector drug candidate that we are evaluating in a Phase 3 development program in combination with ivacaftor in multiple CF patient populations who have at least one copy of the F508del mutation in their CFTR gene. Details of the patient population and status of each of these clinical trials is as follows:



26

•
Two copies of the F508del in their CFTR gene: We plan to complete enrollment in this clinical trial in August 2016 and expect data from this clinical trial to be available in the first half of 2017.
•
One copy of the F508del mutation in their CFTR gene and a second mutation in their CFTR gene that results in a gating defect in the CFTR protein: We plan to complete enrollment in this clinical trial in late 2016 or early 2017.
•
One copy of the F508del mutation in their CFTR gene and a second mutation in their CFTR gene that results in residual CFTR function: We expect to complete enrollment in this clinical trial in the second half of 2016.
•
One copy of the F508del mutation in their CFTR gene and a second mutation that results in minimal CFTR function: Enrollment is complete in the first part of this clinical trial and we expect an interim futility analysis of efficacy data to be completed in the third quarter of 2016.
If supported by data from the Phase 3 clinical program, Vertex plans to submit an NDA to the FDA for VX-661 in combination with ivacaftor in the second half of 2017.

In addition to evaluating the efficacy of the combination regimen, these Phase 3 clinical trials will provide safety data on the combination of VX-661 and ivacaftor to support the planned development of a triple combination regimen that includes a next-generation corrector in combination with VX-661 and ivacaftor.

ENaC Inhibition
VX-371 is an investigational epithelial sodium channel, or ENaC, inhibitor, we are evaluating in a Phase 2 development program in collaboration with Parion Sciences, Inc., or Parion. Parion completed a Phase 2 clinical trial in approximately 142 patients with CF with no restriction on the mutations in their CFTR gene. The primary endpoint of the clinical trial was safety as compared to patients on placebo. Secondary endpoints evaluated the effect on mean absolute forced expiratory volume in one second, or FEV1 and patient-reported respiratory symptoms as reported in the CF questionnaire-revised, or CFQ-R. The clinical trial met its primary safety endpoint and data from the clinical trial showed that VX-371 was generally well tolerated. There were no statistically significant changes in FEV1 or CFQ-R for patients who received VX-371.

In the first quarter of 2016, we initiated a Phase 2a clinical trial evaluating VX-371 in approximately 150 patients on ORKAMBI, both with and without the addition of hypertonic saline, who have two copies of the F508del mutation in their CFTR gene. The primary endpoints of this clinical trial are safety and mean absolute change from baseline in FEV1 at day 28 as compared to patients on placebo.
In vitro, VX-371 showed a meaningful change in cilia beat frequency when VX-371 was used in combination with ORKAMBI in human bronchial epithelial cells with two copies of the F508del mutation, but did not show a meaningful change in cilia beat frequency when VX-371 was used alone.

Next-generation CFTR Corrector Compounds
We are developing two next-generation CFTR corrector compounds, VX-152 and VX-440, that we plan to evaluate as part of triple combination treatment regimens. We initiated Phase 1 clinical trials in healthy volunteers of each of VX-152 and VX-440, alone and as part of a triple combination with VX-661 and ivacaftor, in the fourth quarter of 2015. If these clinical trials are successful, we plan to initiate Phase 2 clinical development in patients with CF to evaluate one or both of VX-152 and VX-440 in triple combinations with VX-661 and ivacaftor in the second half of 2016.

Moderna Collaboration
In July 2016, we entered into a strategic collaboration and licensing agreement with Moderna Therapeutics, Inc., pursuant to which we are seeking to identify and develop messenger Ribonucleic Acid Therapeutics™ for the treatment of CF.
Research and Development
We are engaged in a number of other research and mid- and early-stage development programs, including in the areas of oncology, pain and neurology.
Oncology
We are conducting two Phase 1/2 clinical trials of VX-970, a protein kinase inhibitor of ataxia telangiectasia and Rad3-related, or ATR, in combination with commonly used DNA-damaging chemotherapies across a range of solid tumor types, including triple-negative breast cancer and non-small cell lung cancer. We also are in Phase 1 development of VX-803, a


27

second ATR inhibitor, alone and in combination with chemotherapy. We have initiated Phase 1 clinical development of VX-984, a third oncology drug candidate, alone and in combination with pegylated liposomal doxorubicin.
Pain
We are developing VX-150 and VX-241, two drug candidates for the treatment of pain. We have initiated a six-week cross-over Phase 2 proof-of-concept clinical trial to evaluate VX-150 in approximately 100 patients with symptomatic osteoarthritis of the knee. We recently completed enrollment of this clinical trial.
Acute Spinal Cord Injury
We are developing VX-210, a drug candidate for the treatment of acute spinal cord injury, that we exclusively licensed from BioAxone BioSciences, Inc. VX-210 is designed to inhibit a protein known as Rho that blocks neural regeneration after injury. We have initiated a Phase 2b/3 clinical trial to evaluate the efficacy and safety of VX-210 in patients with certain acute cervical spinal cord injuries.
Research
We plan to continue investing in our research programs and fostering scientific innovation in order to identify and develop transformative medicines. We believe that pursuing research in diverse areas allows us to balance the risks inherent in drug development and may provide drug candidates that will form our pipeline in future years.
Drug Discovery and Development
Discovery and development of a new pharmaceutical product is a difficult and lengthy process that requires significant financial resources along with extensive technical and regulatory expertise and can take 10 to 15 years or more. Potential drug candidates are subjected to rigorous evaluations, driven in part by stringent regulatory considerations, designed to generate information concerning efficacy, side-effects, proper dosage levels and a variety of other physical and chemical characteristics that are important in determining whether a drug candidate should be approved for marketing as a pharmaceutical product. Most chemical compounds that are investigated as potential drug candidates never progress into development, and most drug candidates that do advance into development never receive marketing approval. Because our investments in drug candidates are subject to considerable risks, we closely monitor the results of our discovery, research, clinical trials and nonclinical studies and frequently evaluate our drug development programs in light of new data and scientific, business and commercial insights, with the objective of balancing risk and potential. This process can result in abrupt changes in focus and priorities as new information becomes available and as we gain additional understanding of our ongoing programs and potential new programs, as well as those of our competitors.
If we believe that data from a completed registration program support approval of a drug candidate, we submit an NDA to the FDA requesting approval to market the drug candidate in the United States and seek analogous approvals from comparable regulatory authorities in foreign jurisdictions. To obtain approval, we must, among other things, demonstrate with evidence gathered in nonclinical studies and well-controlled clinical trials that the drug candidate is safe and effective for the disease it is intended to treat and that the manufacturing facilities, processes and controls for the manufacture of the drug candidate are adequate. The FDA and foreign regulatory authorities have substantial discretion in deciding whether or not a drug candidate should be granted approval based on the benefits and risks of the drug candidate in the treatment of a particular disease, and could delay, limit or deny regulatory approval. If regulatory delays are significant or regulatory approval is limited or denied altogether, our financial results and the commercial prospects for the drug candidate involved will be harmed.
Regulatory Compliance
Our marketing of pharmaceutical products is subject to extensive and complex laws and regulations. We have a corporate compliance program designed to actively identify, prevent and mitigate risk through the implementation of compliance policies and systems, and through the promotion of a culture of compliance. Among other laws, regulations and standards, we are subject to various United States federal and state laws, and comparable foreign laws pertaining to health care fraud and abuse, including anti-kickback and false claims statutes, and laws prohibiting the promotion of drugs for unapproved or off-label uses. Anti-kickback laws make it illegal for a prescription drug manufacturer to solicit, offer, receive or pay any remuneration to induce the referral of business, including the purchase or prescription of a particular drug. False claims laws prohibit anyone from presenting for payment to third-party payors, including Medicare and Medicaid, claims for reimbursed drugs or services that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services. We expect to continue to devote substantial resources to maintain, administer and expand these compliance programs globally.
Reimbursement


28

Sales of our products depend, to a large degree, on the extent to which our products are covered by third-party payors, such as government health programs, commercial insurance and managed health care organizations. We dedicate substantial management and other resources in order to obtain and maintain appropriate levels of reimbursement for our products from third-party payors, including governmental organizations in the United States and ex-U.S. markets. In the United States, we continue to engage in discussions with numerous commercial insurers and managed health care organizations, along with government health programs that are typically managed by authorities in the individual states. Following the European Commission’s November 2015 approval of ORKAMBI in Europe, we are working to obtain government reimbursement for ORKAMBI on a country-by-country basis, because in many foreign countries patients are unable to access prescription pharmaceutical products that are not reimbursed by their governments. Consistent with our experience with KALYDECO when it was first approved, we expect reimbursement discussions in ex-U.S. markets may take a significant period of time.


29

RESULTS OF OPERATIONS
 
Three Months Ended June 30,
 
Increase/(Decrease)
 
Six Months Ended June 30,
 
Increase/(Decrease)
 
2016
 
2015
 
$
 
%
 
2016
 
2015
 
$
 
%
 
(in thousands)
 
 
 
(in thousands)
 
 
Revenues
$
431,608

 
$
166,076

 
$
265,532

 
160
 %
 
$
829,688

 
$
304,585

 
$
525,103

 
172
 %
Operating costs and expenses
428,255

 
337,240

 
91,015

 
27
 %
 
840,665

 
647,734

 
192,931

 
30
 %
Other items, net
(67,878
)
 
(17,684
)
 
(50,194
)
 
(284
)%
 
(95,179
)
 
(44,305
)
 
$
(50,874
)
 
(115
)%
Net loss attributable to Vertex
$
(64,525
)
 
$
(188,848
)
 
$
(124,323
)
 
(66
)%
 
$
(106,156
)
 
$
(387,454
)
 
$
(281,298
)
 
(73
)%
Net Loss Attributable to Vertex
Net loss attributable to Vertex was $(64.5) million in the second quarter of 2016 as compared to a net loss attributable to Vertex of $(188.8) million in the second quarter of 2015. Our revenues increased significantly in the second quarter of 2016 as compared to the second quarter of 2015 due to net product revenues from ORKAMBI, which was approved by the FDA in July 2015, and increased KALYDECO net product revenues. Our operating costs and expenses increased in the second quarter of 2016 as compared to the second quarter of 2015 primarily due to increases in research and development expenses, sales, general and administrative expenses and cost of product revenues. Other items, net in the second quarter of 2016 included an aggregate of $48.4 million in charges related to the increase in the fair value of the contingent milestone payments and royalties payable by us to Parion. In the near term, we expect net loss (income) attributable to Vertex will be dependent on expected increases in ORKAMBI net product revenues.
Net loss attributable to Vertex was $(106.2) million in the first half of 2016 as compared to a net loss attributable to Vertex of $(387.5) million in the first half of 2015. Our revenues increased significantly in the first half of 2016 as compared to the first half of 2015 due to net product revenues from ORKAMBI and increased KALYDECO net product revenues. Our operating costs and expenses increased in the first half of 2016 as compared to the first half of 2015 primarily due to increases in research and development expenses, sales, general and administrative expenses and cost of product revenues. Other items, net in the first half of 2016 included an aggregate of $57.4 million in charges related to the increase in the fair value of the contingent milestone payments and royalties payable by us to Parion.
Diluted Net Loss Per Share Attributable to Vertex Common Shareholders
Diluted net loss per share attributable to Vertex common shareholders was $(0.26) in the second quarter of 2016 as compared to a diluted net loss per share attributable to Vertex common shareholders of $(0.78) in the second quarter of 2015. Diluted net loss per share attributable to Vertex common shareholders was $(0.43) in the first half of 2016 as compared to a diluted net loss per share attributable to Vertex common shareholders of $(1.61) in the first half of 2015.
Revenues
 
Three Months Ended June 30,
 
Increase/(Decrease)
 
Six Months Ended June 30,
 
Increase/(Decrease)
 
2016
 
2015
 
$
 
%
 
2016
 
2015
 
$
 
%
 
(in thousands)
 
 
 
(in thousands)
 
 
Product revenues, net
$
425,651

 
$
160,388

 
$
265,263

 
165
%
 
$
820,061

 
$
291,263

 
$
528,798

 
182
 %
Royalty revenues
5,282

 
5,077

 
205

 
4
%
 
8,878

 
11,869

 
(2,991
)
 
(25
)%
Collaborative revenues
675

 
611

 
64

 
10
%
 
749

 
1,453

 
(704
)
 
(48
)%
Total revenues
$
431,608

 
$
166,076

 
$
265,532

 
160
%
 
$
829,688

 
$
304,585

 
$
525,103

 
172
 %
Product Revenues, Net
 
Three Months Ended June 30,
 
Increase/(Decrease)
 
Six Months Ended June 30,
 
Increase/(Decrease)
 
2016
 
2015
 
$
 
%
 
2016
 
2015
 
$
 
%
 
(in thousands)
 
 
 
(in thousands)
 
 
ORKAMBI
$
245,496

 
$
—

 
N/A

 
N/A

 
$
468,624

 
$
—

 
N/A

 
N/A

KALYDECO
180,235

 
154,888

 
25,347

 
16
%
 
$
350,744

 
$
285,062

 
$
65,682

 
23
 %
INCIVEK
(80
)
 
5,500

 
N/A

 
N/A

 
693

 
6,201

 
(5,508
)
 
(89
)%
Total product revenues, net
$
425,651

 
$
160,388

 
$
265,263

 
165
%
 
$
820,061

 
$
291,263

 
$
528,798

 
182
 %


30

Our total net product revenues increased in the second quarter and the first half of 2016 as compared to the second quarter and the first half of 2015 due to net product revenues from ORKAMBI, which was approved by the FDA in July 2015, and increased KALYDECO net product revenues. The FDA has set a target review date of September 30, 2016 for our sNDA for ORKAMBI for the treatment of patients with CF six to eleven years of age who are homozygous for the F508del mutation in their CFTR gene.
We believe that the level of our ORKAMBI revenues for the remainder of 2016 will be dependent on:
•the number of additional patients who begin treatment with ORKAMBI;
•the rate at which additional patients initiate treatment;
•the proportion of initiated patients who remain on treatment; and
•the compliance rate for patients who remain on treatment.
In the first half of 2016, revenues from additional patients who began treatment with ORKAMBI in the United States were partially offset by discontinuations by patients who had previously initiated treatment with ORKAMBI. We expect ORKAMBI net product revenues to continue to increase during the remainder of 2016. In the short term, we expect that our ex-U.S. ORKAMBI net product revenues will be primarily from Germany due to the time it will take to complete the reimbursement discussions in other European countries. In the second quarter and first half of 2016, we recognized approximately $15.9 million and $24.7 million, respectively, in ex-U.S. ORKAMBI net product revenues, which were mainly from Germany. We are also selling ORKAMBI in France pursuant to an early access program, but are not recognizing any revenues because the price is not determinable.
The increase in KALYDECO net product revenues in the second quarter and first half of 2016, as compared to the second quarter and first half of 2015, was primarily due to additional patients being treated with KALYDECO as we completed reimbursement discussions in various jurisdictions and increased the number of patients eligible to receive KALYDECO through multiple label expansions. In the second quarter and first half of 2016, we recognized approximately $76.9 million and $152.5 million, respectively, in ex-U.S. KALYDECO net product revenues.
We have withdrawn INCIVEK from the market in the United States. We may continue to have small adjustments to INCIVEK revenues over the next several quarters as we adjust our INCIVEK reserves for rebates, chargebacks and discounts.
Royalty Revenues
Our royalty revenues were $5.3 million and $8.9 million in the second quarter and the first half of 2016, respectively, as compared to $5.1 million and $11.9 million in the second quarter and the first half of 2015, respectively. Our royalty revenues consist of (i) revenues related to a cash payment we received in 2008 when we sold our rights to certain HIV royalties and (ii) revenues related to certain third-party royalties payable by our collaborators on sales of HIV and HCV drugs that also result in corresponding royalty expenses.
Collaborative Revenues
Our collaborative revenues were $0.7 million and $0.7 million in the second quarter and the first half of 2016, respectively, as compared to $0.6 million and $1.5 million in the second quarter and the first half of 2015, respectively. Our collaborative revenues have historically fluctuated significantly from one period to another and may continue to fluctuate in the future.


31

Operating Costs and Expenses
 
Three Months Ended June 30,
 
Increase/(Decrease)
 
Six Months Ended June 30,
 
Increase/(Decrease)
 
2016
 
2015
 
$
 
%
 
2016
 
2015
 
$
 
%
 
(in thousands)
 
 
 
(in thousands)
 
 
Cost of product revenues
$
44,154

 
$
15,409

 
$
28,745

 
187
 %
 
$
93,943

 
$
24,790

 
$
69,153

 
279
 %
Royalty expenses
1,098

 
1,451

 
(353
)
 
(24
)%
 
1,958

 
4,377

 
(2,419
)
 
(55
)%
Research and development expenses
271,008

 
223,858

 
47,150

 
21
 %
 
526,868

 
439,457

 
87,411

 
20
 %
Sales, general and administrative expenses
111,652

 
94,394

 
17,258

 
18
 %
 
216,866

 
180,254

 
36,612

 
20
 %
Restructuring expenses (income), net
343

 
2,128

 
(1,785
)
 
(84
)%
 
1,030

 
(1,144
)
 
N/A

 
N/A

Total costs and expenses
$
428,255

 
$
337,240

 
$
91,015

 
27
 %
 
$
840,665

 
$
647,734

 
$
192,931

 
30
 %
Cost of Product Revenues
Our cost of product revenues includes the cost of producing inventories that correspond to product revenues for the reporting period, plus the third-party royalties payable on our net sales of our products. Pursuant to our agreement with Cystic Fibrosis Foundation Therapeutics Incorporated, or CFFT, our tiered third-party royalties on sales of KALYDECO and ORKAMBI, calculated as a percentage of net sales, range from the single digits to the sub-teens. Our cost of product revenues increased in the second quarter and first half of 2016 as compared to the second quarter and first half of 2015, primarily due to increased net product revenues. The increase in cost of product revenues in the first half of 2016 as compared to the first half of 2015 also reflected the second and final $13.9 million commercial milestone that was earned by CFFT in the first quarter of 2016 related to sales of ORKAMBI and that was included in cost of product revenues in the first quarter of 2016. In future periods, our cost of product revenues will not be affected by commercial milestones on ORKAMBI, with our cost of product revenues generally tracking our net product revenues.
Royalty Expenses
Royalty expenses include third-party royalties payable upon net sales of telaprevir by our collaborators in their territories and expenses related to a subroyalty payable to a third party on net sales of an HIV protease inhibitor sold by GlaxoSmithKline. Royalty expenses do not include royalties we pay to CFFT on sales of KALYDECO and ORKAMBI, which instead are included in cost of product revenues. Royalty expenses in the second quarter and the first half of 2016 decreased by $0.4 million and $2.4 million, respectively, as compared to the second quarter and the first half of 2015, primarily as a result of decreased INCIVO (telaprevir) sales by our collaborator Janssen NV.
Research and Development Expenses
 
Three Months Ended June 30,
 
Increase/(Decrease)
 
Six Months Ended June 30,
 
Increase/(Decrease)
 
2016
 
2015
 
$
 
%
 
2016
 
2015
 
$
 
%
 
(in thousands)
 
 
 
(in thousands)
 
 
Research expenses
$
79,886

 
$
65,195

 
$
14,691

 
23
%
 
$
142,896

 
$
130,757

 
$
12,139

 
9
%
Development expenses
191,122

 
158,663

 
32,459

 
20
%
 
383,972

 
308,700

 
75,272

 
24
%
Total research and development expenses
$
271,008

 
$
223,858

 
$
47,150

 
21
%
 
$
526,868

 
$
439,457

 
$
87,411

 
20
%
Our research and development expenses include internal and external costs incurred for research and development of our drugs and drug candidates. We do not assign our internal costs, such as salary and benefits, stock-based compensation expense, laboratory supplies and other direct expenses and infrastructure costs, to individual drugs or drug candidates, because the employees within our research and development groups typically are deployed across multiple research and development programs. These internal costs are significantly greater than our external costs, such as the costs of services provided to us by clinical research organizations and other outsourced research, which we allocate by individual program. All research and development costs for our drugs and drug candidates are expensed as incurred.
Since January 1, 2013, we have incurred $3.3 billion in research and development expenses associated with drug discovery and development. The successful development of our drug candidates is highly uncertain and subject to a number of risks. In addition, the duration of clinical trials may vary substantially according to the type, complexity and novelty of the drug candidate and the disease indication being targeted. The FDA and comparable agencies in foreign countries impose


32

substantial requirements on the introduction of therapeutic pharmaceutical products, typically requiring lengthy and detailed laboratory and clinical testing procedures, sampling activities and other costly and time-consuming procedures. Data obtained from nonclinical and clinical activities at any step in the testing process may be adverse and lead to discontinuation or redirection of development activities. Data obtained from these activities also are susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The duration and cost of discovery, nonclinical studies and clinical trials may vary significantly over the life of a project and are difficult to predict. Therefore, accurate and meaningful estimates of the ultimate costs to bring our drug candidates to market are not available.
In 2015 and the first half of 2016, costs related to our CF programs represented the largest portion of our development costs. Any estimates regarding development and regulatory timelines for our drug candidates are highly subjective and subject to change. We cannot make a meaningful estimate when, if ever, our clinical development programs will generate revenues and cash flows.
Research Expenses
 
Three Months Ended June 30,
 
Increase/(Decrease)
 
Six Months Ended June 30,
 
Increase/(Decrease)
 
2016
 
2015
 
$
 
%
 
2016
 
2015
 
$
 
%
 
(in thousands)
 
 
 
(in thousands)
 
 
Research Expenses:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Salary and benefits
$
19,268

 
$
19,798

 
$
(530
)
 
(3
)%
 
$
39,978

 
$
40,254

 
$
(276
)
 
(1
)%
Stock-based compensation expense
13,409

 
13,081

 
328

 
3
 %
 
24,065

 
26,857

 
(2,792
)
 
(10
)%
Laboratory supplies and other direct expenses
11,810

 
10,416

 
1,394

 
13
 %
 
21,684

 
19,584

 
2,100

 
11
 %
Outsourced services and acquired research assets
17,534

 
4,947

 
12,587

 
254
 %
 
21,695

 
9,505

 
12,190

 
128
 %
Infrastructure costs
17,865

 
16,953

 
912

 
5
 %
 
35,474

 
34,557

 
917

 
3
 %
Total research expenses
$
79,886

 
$
65,195

 
$
14,691

 
23
 %
 
$
142,896

 
$
130,757

 
$
12,139

 
9
 %
We maintain a substantial investment in research activities. Our research expenses increased by 23% in the second quarter of 2016 as compared to the second quarter of 2015 and increased by 9% in the first half of 2016 as compared to the first half of 2015. Outsourced services and acquired research assets in the second quarter of 2016 and first half of 2016 included approximately $10.0 million in expenses related to the acquisition of early-stage research assets for which there were no comparable expenses in the second quarter of 2015. We expect to continue to invest in our research programs with a focus on identifying drug candidates with the goal of creating transformative medicines.
Development Expenses
 
Three Months Ended June 30,
 
Increase/(Decrease)
 
Six Months Ended June 30,
 
Increase/(Decrease)
 
2016
 
2015
 
$
 
%
 
2016
 
2015
 
$
 
%
 
(in thousands)
 
 
 
(in thousands)
 
 
Development Expenses:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Salary and benefits
$
45,062

 
$
39,427

 
$
5,635

 
14
 %
 
$
89,413

 
$
81,622

 
$
7,791

 
10
 %
Stock-based compensation expense
27,231

 
28,551

 
(1,320
)
 
(5
)%
 
51,023

 
52,992

 
(1,969
)
 
(4
)%
Laboratory supplies and other direct expenses
13,005

 
8,473

 
4,532

 
53
 %
 
21,255

 
15,417

 
5,838

 
38
 %
Outsourced services
71,555

 
56,303

 
15,252

 
27
 %
 
156,043

 
106,397

 
49,646

 
47
 %
Drug supply costs
4,204

 
2,702

 
1,502

 
56
 %
 
6,857

 
4,285

 
2,572

 
60
 %
Infrastructure costs
30,065

 
23,207

 
6,858

 
30
 %
 
59,381

 
47,987

 
11,394

 
24
 %
Total development expenses
$
191,122

 
$
158,663

 
$
32,459

 
20
 %
 
$
383,972

 
$
308,700

 
$
75,272

 
24
 %
Our development expenses increased by $32.5 million, or 20%, in the second quarter of 2016 as compared to the second quarter of 2015 and increased by $75.3 million, or 24%, in the first half of 2016 as compared to the first half of 2015, primarily due to an increase in outsourced services related to ongoing clinical trials, including our Phase 3 development program for VX-661 in combination with ivacaftor, and an increase in infrastructure costs.


33

Sales, General and Administrative Expenses
 
Three Months Ended June 30,
 
Increase/(Decrease)
 
Six Months Ended June 30,
 
Increase/(Decrease)
 
2016
 
2015
 
$
 
%
 
2016
 
2015
 
$
 
%
 
(in thousands)
 
 
 
(in thousands)
 
 
Sales, general and administrative expenses
$
111,652

 
$
94,394

 
$
17,258

 
18
%
 
$
216,866

 
$
180,254

 
$
36,612

 
20
%
Sales, general and administrative expenses increased by 18% in the second quarter of 2016 as compared to the second quarter of 2015 and increased by 20% in the first half of 2016 as compared to the first half of 2015, primarily due to increased investment in commercial support for ORKAMBI in ex-U.S. markets. We expect sales, general and administrative expenses during the remainder of 2016 will be similar to our sales, general and administrative expenses in the first half of 2016.
Restructuring Expense, Net
We recorded restructuring expenses of $0.3 million and $1.0 million in the second quarter and the first half of 2016, respectively, as compared to restructuring expenses of $2.1 million in the second quarter of 2015 and restructuring credits of $1.1 million in the first half of 2015. Our restructuring expenses in the second quarter and first half of 2016 primarily relate to adjustments to our restructuring liability in connection with the relocation of our corporate headquarters to Boston, Massachusetts for which we had accrued a restructuring liability in excess of the termination fee we ultimately paid.
Other Items
Interest Expense, Net
Interest expense, net was $20.2 million and $40.9 million in the second quarter and the first half of 2016, respectively as compared to $21.1 million and $42.4 million in the second quarter the first half of 2015, respectively. During the remainder of 2016, we expect to incur approximately $30 million of interest expense associated with the leases for our corporate headquarters and approximately $9 million of interest expense related to our credit agreement.
Other (Expense) Income, Net
Other (expense) income, net was an expense of $1.2 million and income of $3.2 million in the second quarter and the first half of 2016, respectively as compared to income of $1.4 million and expense of $3.7 million in the second quarter and the first half of 2015, respectively. Other (expense) income, net in each of the second quarter and first half of 2016 and the second quarter and the first half of 2015 was primarily due to foreign exchange gains and losses.
Income Taxes
We recorded a provision for income taxes of $18.1 million and $23.6 million in the second quarter and the first half of 2016, respectively as compared to $30.1 million and $30.4 million in the second quarter and the first half of 2015, respectively. The provision for income taxes in the second quarter and first half of 2016 and 2015 was due to income tax on our VIEs, as well as state and foreign tax in various jurisdictions.
Noncontrolling Interest (VIEs)
The net loss (income) attributable to noncontrolling interest (VIEs) recorded on our condensed consolidated statements of operations reflects Parion and BioAxone's net loss (income) for the reporting period, adjusted for any changes during the reporting period in the fair value of the contingent milestone and royalty payments payable by us to Parion and BioAxone.
In the second quarter and the first half of 2016, the net income attributable to noncontrolling interest (VIEs) was $28.4 million and $33.9 million, respectively. In the second quarter and the first half of 2015, the net loss attributable to noncontrolling interest (VIEs) was $32.1 million and $32.2 million, respectively.
LIQUIDITY AND CAPITAL RESOURCES
As of June 30, 2016, we had cash, cash equivalents and marketable securities of $1.07 billion, which represented an increase of $29 million from $1.04 billion as of December 31, 2015. In the first half of 2016, we largely maintained our cash, cash equivalents and marketable securities balance due to increased cash receipts in the first half of 2016 from product sales, offset by increased cash expenditures in the first half of 2016 related to, among other things, research and development expenses and sales, general and administrative expenses.
Our future cash flows will be substantially dependent on product sales of KALYDECO and ORKAMBI.
Sources of Liquidity
We intend to rely on our existing cash, cash equivalents and marketable securities together with cash flows from product sales as our primary source of liquidity. We are receiving cash flows from sales of ORKAMBI and KALYDECO from the United States and ex-U.S. markets. We expect ORKAMBI net product revenues to continue to increase during the remainder of 2016. In the short term, we expect that our ex-U.S. ORKAMBI net product revenues will be primarily from Germany due to the time it will take to complete the reimbursement discussions in other European countries.
We borrowed $300.0 million under a credit agreement that we entered into in July 2014 and, subject to certain conditions, we may request up to an additional $200.0 million pursuant to that credit agreement. In 2014 and 2015, we also received significant proceeds from the issuance of common stock under our employee benefit plans, but we have received limited proceeds from employee benefit plans in 2016 and the amount and timing of future proceeds from employee benefits


34

plans is uncertain. Other possible sources of liquidity include strategic collaborative agreements that include research and/or development funding, commercial debt, public and private offerings of our equity and debt securities, development milestones and royalties on sales of products, software and equipment leases, strategic sales of assets or businesses and financial transactions. Negative covenants in our credit agreement may prohibit or limit our ability to access these sources of liquidity.
Future Capital Requirements
We incur substantial operating expenses to conduct research and development activities and to operate our organization. Under the terms of our credit agreement, we are required to repay the principal amount on the $300.0 million we borrowed in July 2014 in installments of $75 million on each of October 1, 2016, January 1, 2017, April 1, 2017 and July 9, 2017. We also have substantial facility and capital lease obligations, including leases for two buildings in Boston, Massachusetts that continue through 2028. In addition, we have entered into certain collaboration agreements with third parties that include the funding of certain research, development and commercialization efforts with the potential for future milestone and royalty payments by us upon the achievement of pre-established developmental and regulatory targets.
We expect that cash flows from KALYDECO and ORKAMBI, together with our current cash, cash equivalents and marketable securities will be sufficient to fund our operations for at least the next twelve months. The adequacy of our available funds to meet our future operating and capital requirements will depend on many factors, including the amounts of future revenues generated by KALYDECO and ORKAMBI and the potential introduction of one or more of our other drug candidates to the market, the level of our business development activities and the number, breadth, cost and prospects of our research and development programs.
Financing Strategy
In July 2014, we borrowed $300.0 million pursuant to a credit agreement. In addition, subject to certain conditions, we may request that the lenders loan us up to an additional $200.0 million under the credit agreement. We may seek to refinance our credit agreement based on our current credit profile and prevailing market conditions. We may raise additional capital through public offerings or private placements of our securities or securing new collaborative agreements or other methods of financing. We will continue to manage our capital structure and will consider all financing opportunities, whenever they may occur, that could strengthen our long-term liquidity profile. There can be no assurance that any such financing opportunities will be available on acceptable terms, if at all.
CONTRACTUAL COMMITMENTS AND OBLIGATIONS
Our commitments and obligations were reported in our Annual Report on Form 10-K for the year ended December 31, 2015, which was filed with the Securities and Exchange Commission, or SEC, on February 16, 2016. There have been no material changes from the contractual commitments and obligations previously disclosed in that Annual Report on Form 10-K, except that on July 1, 2016, we entered into a collaboration agreement with Moderna Therapeutics, Inc., or Moderna, pursuant to which Moderna is eligible to receive development and regulatory milestones of up to $275 million, as well as tiered royalty payments on future sales.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
Our discussion and analysis of our financial condition and results of operations is based upon our condensed consolidated financial statements prepared in accordance with generally accepted accounting principles in the United States. The preparation of these financial statements requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reported periods. These items are monitored and analyzed by management for changes in facts and circumstances, and material changes in these estimates could occur in the future. Changes in estimates are reflected in reported results for the period in which the change occurs. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from our estimates if past experience or other assumptions do not turn out to be substantially accurate. During the six months ended June 30, 2016, there were no material changes to our critical accounting policies as reported in our Annual Report on Form 10-K for the year ended December 31, 2015, which was filed with the SEC on February 16, 2016.
RECENT ACCOUNTING PRONOUNCEMENTS
For a discussion of recent accounting pronouncements please refer to Note A, “Nature of Business and Accounting Policies—Recent Accounting Pronouncements,” in the 2015 Annual Report on Form 10-K. There were no new accounting pronouncements adopted during the six months ended June 30, 2016 that had a material effect on our financial statements.
Item 3.    Quantitative and Qualitative Disclosures About Market Risk
As part of our investment portfolio, we own financial instruments that are sensitive to market risks. The investment portfolio is used to preserve our capital until it is required to fund operations, including our research and development activities. None of these market risk-sensitive instruments are held for trading purposes.
Interest Rate Risk
As of June 30, 2016, we invest our cash in a variety of financial instruments, principally money market funds, short-term government-sponsored enterprise securities, U.S. Treasury securities, investment-grade corporate bonds and commercial paper. These investments are denominated in U.S. dollars. All of our interest-bearing securities are subject to interest rate risk and could decline in value if interest rates fluctuate. Substantially all of our investment portfolio consists of marketable securities with active secondary or resale markets to help ensure portfolio liquidity, and we have implemented guidelines limiting the term-to-maturity of our investment instruments. Due to the conservative nature of these instruments, we do not believe that we have a material exposure to interest rate risk.
Foreign Exchange Market Risk
As a result of our foreign operations, we face exposure to movements in foreign currency exchange rates, primarily the Euro, Swiss Franc, British Pound, Australian Dollar and Canadian Dollar against the U.S. dollar. The current exposures arise primarily from cash, accounts receivable, intercompany receivables, payables and inventories. Both positive and negative affects to our net revenues from international product sales from movements in foreign currency exchange rates are partially mitigated by the natural, opposite affect that foreign currency exchange rates have on our international operating costs and expenses.
We maintain a foreign currency management program with the objective of reducing the impact of exchange rate fluctuations on our operating results and forecasted revenues and expenses denominated in foreign currencies.
Item 4.    Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our chief executive officer and chief financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this Quarterly Report on Form 10-Q, have concluded that, based on such evaluation, as of June 30, 2016 our disclosure controls and procedures were effective and designed to provide reasonable assurance that the information required to be disclosed is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Changes in Internal Controls Over Financial Reporting
No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended) occurred during the three months ended June 30, 2016 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
PART II. Other Information
Item 1.     Legal Proceedings
Local No. 8 IBEW Retirement Plan & Trust v. Vertex Pharmaceuticals Incorporated, et al.
On May 28, 2014, a purported shareholder class action Local No. 8 IBEW Retirement Plan & Trust v. Vertex Pharmaceuticals Incorporated, et al. was filed in the United States District Court for the District of Massachusetts, naming us and certain of our current and former officers and directors as defendants. The lawsuit alleged that we made material misrepresentations and/or omissions of material fact in our disclosures during the period from May 7, 2012 through May 29, 2012, all in violation of Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. The purported class consists of all persons (excluding defendants) who purchased our common stock between May 7, 2012 and May 29, 2012. The plaintiffs seek unspecified monetary damages, costs and attorneys’ fees as well as disgorgement of the proceeds from certain individual defendants’ sales of our stock. On October 8, 2014, the Court approved Local No. 8 IBEW Retirement Fund as lead plaintiff, and Scott and Scott LLP as lead counsel for the plaintiff and the putative class. We filed a motion to dismiss the complaint on December 8, 2014 and the plaintiffs filed their opposition to our motion to dismiss on January 22, 2015. On February 23, 2015, we filed a reply to the plaintiffs’ opposition to our motion to dismiss.  The court heard oral argument on our motion to dismiss on March 6, 2015 and took the motion under advisement. On September 30, 2015, the court granted our motion to dismiss. On October 15, 2015, the plaintiff filed a notice of appeal. The First Circuit Court of Appeals issued a scheduling order on December 24, 2015. On February 2, 2016, the Plaintiff filed their opening brief and we filed our opposition brief on March 7, 2016. On March 24, 2016, the plaintiff filed their reply brief. Oral arguments on the appeal took place on July 26, 2016. We believe the claims to be without merit and intend to vigorously defend the litigation.
DOJ Subpoena
In the third quarter of 2015, we received a subpoena from the United States Department of Justice related to our marketed medicines. This subpoena requests documents relating primarily to our Good Laboratory Practices in a bioanalytical laboratory. We are in the process of responding to the subpoena and intend to continue to cooperate.
Item 1A. Risk Factors
Information regarding risk factors appears in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2015, which was filed with the SEC on February 16, 2016. There have been no material changes from the risk factors previously disclosed in that Annual Report on Form 10-K, except that:

Risk Relating to the Referendum of the United Kingdom’s Membership of the European Union.

On June 23, 2016, the United Kingdom, or the U.K., held a referendum in which voters approved an exit from the European Union, or the E.U., commonly referred to as “Brexit.” As a result of the referendum, it is expected that the British government will begin negotiating the terms of the U.K.’s withdrawal from the E.U. A withdrawal could, among other outcomes, disrupt the free movement of goods, services and people between the U.K. and the E.U., undermine bilateral cooperation in key policy areas and significantly disrupt trade between the U.K. and the E.U. In addition, Brexit could lead to legal uncertainty and potentially divergent national laws and regulations as the U.K. determines which E.U. laws to replace or replicate. Given the lack of comparable precedent, it is unclear what financial, trade, regulatory and legal implications the withdrawal of the U.K. from the E.U. would have and how such withdrawal would affect us.

The announcement of Brexit caused significant volatility in global stock markets and currency exchange rate fluctuations that resulted in the strengthening of the U.S. dollar against foreign currencies in which we conduct business. The announcement of Brexit and the withdrawal of the U.K. from the E.U. may also create global economic uncertainty, which may cause third-party payors, including governmental organizations, to closely monitor their costs and reduce their spending budgets. Any of these effects of Brexit, among others, could adversely affect our business, financial condition and operating results.



35

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q and, in particular, our Management’s Discussion and Analysis of Financial Condition and Results of Operations set forth in Part I-Item 2, contain or incorporate a number of forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding:
•
our expectations regarding the amount of, timing of and trends with respect to our revenues, costs and expenses and other gains and losses, including those related to net product revenues from KALYDECO and ORKAMBI;
•
our expectations regarding clinical trials, development timelines and regulatory authority filings and submissions for our drug candidates including, ivacaftor, lumacaftor, VX-661, VX-371 (formerly P-1037), VX-152, VX-440, VX-970, VX-803, VX-984, VX-150, VX-241 and VX-210, as well as the sNDA for ORKAMBI for the treatment of patients with CF six to eleven years of age who are homozygous for the F508del mutation in their CFTR gene and the NDA for VX-661 in combination with ivacaftor;
•
our expectations regarding planned clinical trials for next-generation correctors based upon pre-clinical data;
•
our ability to successfully market KALYDECO and ORKAMBI or any of our other drug candidates for which we obtain regulatory approval;
•
our expectations regarding the timing and structure of clinical trials of our drugs and drug candidates, including ivacaftor, lumacaftor, VX-661, VX-371 (formerly P-1037), VX-152, VX-440, VX-970, VX-803, VX-984, VX-150, VX-241 and VX-210, and the expected timing of our receipt of data from our ongoing and planned clinical trials;
•
the data that will be generated by ongoing and planned clinical trials and the ability to use that data to advance compounds, continue development or support regulatory filings;
•
our beliefs regarding the support provided by clinical trials and preclinical and nonclinical studies of our drug candidates for further investigation, clinical trials or potential use as a treatment;
•
our plan to continue investing in our research and development programs and our strategy to develop our drug candidates, alone or with third party-collaborators;
•
the establishment, development and maintenance of collaborative relationships;
•
potential business development activities;
•
potential fluctuations in foreign currency exchange rates;
•
our ability to use our research programs to identify and develop new drug candidates to address serious diseases and significant unmet medical needs; and
•
our liquidity and our expectations regarding the possibility of raising additional capital.
Any or all of our forward-looking statements in this Quarterly Report on Form 10-Q may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many factors mentioned in this Quarterly Report on Form 10-Q will be important in determining future results. Consequently, no forward-looking statement can be guaranteed. Actual future results may vary materially from expected results. We also provide a cautionary discussion of risks and uncertainties under “Risk Factors” in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2015, which was filed with the SEC on February 16, 2016. These are factors and uncertainties that we think could cause our actual results to differ materially from expected results. Other factors and uncertainties besides those listed there could also adversely affect us.
Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “intends,” “expects” and similar expressions are intended to identify forward-looking statements. There are a number of factors and uncertainties that could cause actual events or results to differ materially from those indicated by such forward-looking statements, many of which are beyond our control. In addition, the forward-looking statements contained herein represent our estimate only as of the date of this filing and should not be relied upon as representing our estimate as of any subsequent date. While we may elect to update these


36

forward-looking statements at some point in the future, we specifically disclaim any obligation to do so to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking statements.
Item 2.     Unregistered Sales of Equity Securities and Use of Proceeds
Issuer Repurchases of Equity Securities
The table set forth below shows all repurchases of securities by us during the three months ended June 30, 2016:
Period
 
Total Number
of Shares Purchased
Average Price
Paid per Share
Total Number of Shares
Purchased as Part of
Publicly Announced
Plans or Programs
Maximum Number of
Shares that May Yet
be Purchased Under
the Plans or Programs
April 1, 2016 to April 30, 2016
35,566
$0.01
—
—
May 1, 2016 to May 31, 2016
12,960
$0.01
—
—
June 1, 2016 to June 30, 2016
18,772
$0.01
—
—
The repurchases were made under the terms of our Amended and Restated 2006 Stock and Option Plan and our Amended and Restated 2013 Stock and Option Plan. Under these plans, we award shares of restricted stock to our employees that typically are subject to a lapsing right of repurchase by us. We may exercise this right of repurchase if a restricted stock recipient’s service to us is terminated. If we exercise this right, we are required to repay the purchase price paid by or on behalf of the recipient for the repurchased restricted shares, which typically is the par value per share of $0.01. Repurchased shares are returned and are available for future awards under the terms of our Amended and Restated 2013 Stock and Option Plan.
Item 6.    Exhibits
Exhibit Number
Exhibit Description
3.1
Amended and Restated By-Laws of Vertex Pharmaceuticals Incorporated, as subsequently amended on April 26, 2016. (1)
10.1
Vertex Pharmaceuticals Incorporated Employee Stock Purchase Plan, as amended and restated as of July 12, 2016*
31.1
Certification of the Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002.
31.2
Certification of the Chief Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002.
32.1
Certification of the Chief Executive Officer and the Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS
XBRL Instance
101.SCH
XBRL Taxonomy Extension Schema
101.CAL
XBRL Taxonomy Extension Calculation
101.LAB
XBRL Taxonomy Extension Labels
101.PRE
XBRL Taxonomy Extension Presentation
101.DEF
XBRL Taxonomy Extension Definition
(1) Incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K, filed with the Securities and Exchange Commission on April 27, 2016.
*    Management contract, compensatory plan or agreement.



37

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
Vertex Pharmaceuticals Incorporated
 
 
 
August 1, 2016
By:
/s/ Ian F. Smith
 
 
Ian F. Smith
 
 
Executive Vice President and Chief Financial Officer
(principal financial officer and
duly authorized officer)



38
 EX-10.1 2 a2016q210-q_exhibit101.htm EXHIBIT 10.1 Exhibit
EXHIBIT 10.1

VERTEX PHARMACEUTICALS INCORPORATED
EMPLOYEE STOCK PURCHASE PLAN
(as amended and restated as of July 12, 2016)

ARTICLE 1
PURPOSE AND DEFINITIONS

SECTION 1.1. PURPOSE. The purpose of the Vertex Pharmaceuticals Incorporated Employee Stock Purchase Plan is to provide eligible employees with an opportunity to purchase shares of Common Stock in the Company through payroll deductions, thereby encouraging employees to share in the economic growth and success of the Company through stock ownership.

SECTION 1.2. DEFINITIONS. Whenever used in the Plan, unless the context clearly indicates otherwise, the following terms shall have the following meanings:

(a)    "BOARD OF DIRECTORS" means the Board of Directors of the Company.

(b)    "CODE" means the Internal Revenue Code of 1986, as the same may be amended from time to time, and references thereto shall include the valid Treasury regulations issued thereunder.
 
(c)    "COMMITTEE" means the Management Development and Compensation Committee of the Board of Directors or such other committee of the Board of Directors designated by the Board of Directors to administer the Company’s equity compensation plans.

(d)    "COMMON STOCK" means shares of the $.01 par value common stock of the Company and any other stock or securities resulting from the adjustment thereof or substitution therefor as described in Section 3.4.

(e)    "COMPANY" means Vertex Pharmaceuticals Incorporated or any successor by merger, purchase, or otherwise.

(f)    "COMPENSATION" means the cash compensation received by an Employee for services, including pre-tax employee compensation made to the Company's 401(k) savings plan, but not including overtime or bonuses.

(g)    "EFFECTIVE DATE" means July 1, 1992.

(h)    "ELECTION" means an election by a Participant to terminate his or her participation in an Offering Period following the purchase of shares of Common Stock in accordance with Article V on the first Purchase Date of such Offering Period, which election shall be made within such Offering Period and on or prior to such first Purchase Date and shall be on a form furnished by the Company for such purpose and shall be made by having such Participant complete, sign and file such form with the Company in the manner prescribed by the Company; provided that if the Fair Market Value of the Common Stock on the first day of the applicable Offering Period is greater than the Fair Market Value of the Common Stock on the first Purchase Date of such Offering Period each Participant in such Offering Period shall automatically (i) be deemed to have completed, signed and filed an Election and (ii) be enrolled in the Offering Period commencing on the Offering Date immediately following such first Purchase Date, with the Participant’s payroll deductions for such Offering Period determined by reference to the last payroll deduction authorization properly submitted by the Participant to the Company in accordance with the Plan.

(i)    "EMPLOYEE" means any person who receives a regular stated compensation from the Company or a Subsidiary other than a pension, severance pay, retainer, or fee under contract.


233395v2

(j)    "FAIR MARKET VALUE" of a share of Common Stock on a particular date shall be the average of the highest and lowest quoted selling prices on such date (the "valuation date") on the securities market where the Common Stock of the Company is traded, or if there were no sales on the valuation date, on the immediately preceding date within a reasonable period (as determined in the sole discretion of the Committee) on which there were sales. In the event that there were no sales in such a market within a reasonable period, the fair market value shall be as determined in good faith by the Committee in its sole discretion. The Fair Market Value as determined in this paragraph shall be rounded down to the next lower whole cent if the foregoing calculation results in fractional cents.

(k)    "OFFERING" means the offering of shares of Common Stock to Participants pursuant to this Plan.

(l)    "OFFERING DATE" means each May 15 and November 15. If any such date shall fall other than on a business day, then the Offering Date shall be the next succeeding business day.

(m)    "OFFERING PERIOD" means either (i) the period from an Offering Date through the second Purchase Date following such Offering Date or (ii) if a Participant validly exercises (or is deemed to validly exercise) an Election, the period from an Offering Date through the first Purchase Date following such Offering Date.

(n)    "PARTICIPANT" means an Employee who has elected to participate in the Plan in accordance with and subject to the terms of the Plan and any procedures established by the Committee.

(o)    "PURCHASE DATE" means each May 14 and November 14.

(p)    "PLAN" means the Vertex Pharmaceuticals Incorporated Employee Stock Purchase Plan, an "employee stock purchase plan" within the meaning of Section 423(b) of the Code, together with any and all amendments thereto.

(q)    "STOCK PURCHASE ACCOUNT," with respect to a Participant, means the account established on the books and records of the Company or a Subsidiary for such Participant representing the payroll deductions credited to such account in accordance with the provisions of the Plan.

(r)    "SUBSIDIARY" means any corporation, fifty percent (50%) or more of the total combined voting power of all classes of stock of which is beneficially owned, directly or indirectly, by the Company.


ARTICLE II
PARTICIPATION

SECTION 2.1. PARTICIPATION REQUIREMENTS.

(a)    COMMENCEMENT OF PARTICIPATION. Subject to Section 2.2 and Section 3.2(b), each person who becomes an Employee after the Effective Date may elect to become a Participant in the Plan, in accordance with and subject to the terms of the Plan and any procedures established by the Committee, on any Offering Date following the date on which such person becomes an Employee.

(b)    ELIGIBILITY OF FORMER PARTICIPANTS. If a person terminates employment with the Company after becoming a Participant and subsequently resumes being an Employee of the Company, such person will again become eligible to participate on the Offering Date next following the date such person resumed being an Employee of the Company.

SECTION 2.2. EXCLUSIONS. Notwithstanding any provision of the Plan to the contrary, in no event shall the following persons be eligible to participate in the Plan:


- 2 -
233395v2

(a)    Any Employee whose customary employment is twenty (20) hours or less per week;

(b)    Any Employee whose customary employment is for not more than five (5) months in any calendar year; or

(c)    Any Employee who, immediately after the beginning of an Offering Period, owns (or under Section 423(b)(3) of the Code would be deemed to own) stock possessing five percent (5%) or more of the total combined voting power or value of all classes of stock of the Company or of any Subsidiary.

ARTICLE III
OFFERING OF COMMON STOCK

SECTION 3.1. RESERVATION OF COMMON STOCK. The Board of Directors shall reserve 1,748,660 shares of Common Stock for issuance under the Plan after March 17, 2004, subject to adjustment in accordance with Section 3.4, provided that no more than 248,660 of such shares shall be issued prior to May 15, 2004. On May 13, 2008, the Board of Directors shall reserve an additional 2,000,000 shares of Common Stock for issuance under the Plan. On May 16, 2012, the Board of Directors shall reserve an additional 2,500,000 shares of Common Stock for issuance under the Plan.

SECTION 3.2. OFFERING OF COMMON STOCK.

(a)    GENERAL. Subject to Sections 3.2(b) and 3.2(c), each Participant in the Plan on an Offering Date shall be entitled to purchase shares of Common Stock on each Purchase Date within the Offering Period that begins with such Offering Date with the amounts deducted from such Participant's Compensation during such Offering Period pursuant to Article IV, provided, however, that a Participant shall not participate in more than one Offering Period simultaneously. The purchase price for such shares of Common Stock shall be determined under Section 3.3.

(b)    LIMITATIONS. Notwithstanding Section 3.2(a), no Participant may purchase shares of Common Stock under the Plan and under all other Code Section 423 employee stock purchase plans of the Company and its Subsidiaries, if any, at a rate in excess of $25,000 in fair market value of such shares (measured as of the relevant Offering Date) for each calendar year during which rights to purchase shares of Common Stock under the Plan are outstanding at any time. This paragraph is intended to be consistent with the limitation of Code section 423(b)(8) and shall be interpreted accordingly.

(c)    MAXIMUM. Notwithstanding Section 3.2(a), and subject to adjustment pursuant to Section 3.4, the maximum aggregate number of shares of Common Stock that may be purchased by any Participant on any Purchase Date is 2,500 shares.

SECTION 3.3. DETERMINATION OF PURCHASE PRICE FOR OFFERED COMMON STOCK. The purchase price per share of the shares of Common Stock to be acquired by a Participant on a Purchase Date pursuant to an Offering shall be equal to eighty-five percent (85%) of the lesser of:

(a)    the Fair Market Value of a share of Common Stock on the Offering Date for such Offering Period; or

(b)    the Fair Market Value of a share of Common Stock on such Purchase Date;

provided, however, in no event shall the purchase price be less than the par value of a share of Common Stock.

SECTION 3.4. EFFECT OF CERTAIN TRANSACTIONS. The number of shares of Common Stock reserved for the Plan pursuant to Section 3.1, the maximum number of shares of Common Stock offered pursuant to Sections 3.2(b) and 3.2(c), and the determination under Section 3.3 of the purchase price per share of the shares of Common Stock offered to Participants pursuant to an Offering shall be appropriately adjusted to reflect any increase or decrease in the

- 3 -
233395v2

number of issued shares of Common Stock resulting from a stock split, a consolidation of shares, the payment of a stock dividend, or any other capital adjustment affecting the number of issued shares of Common Stock. In the event that the outstanding shares of Common Stock shall be changed into or exchanged for a different number or kind of shares of stock or other securities of the Company or another corporation, whether through reorganization, recapitalization, merger, consolidation, or otherwise, then there shall be substituted for each share of Common Stock reserved for issuance under the Plan but not yet purchased by Participants, the number and kind of shares of stock or other securities into which each outstanding share of Common Stock shall be so changed or for which each such share shall be exchanged.

ARTICLE IV
PAYROLL DEDUCTIONS

SECTION 4.1. PAYROLL DEDUCTION ELECTIONS. Any Employee eligible to participate in the Plan may become a Participant and elect to have the Company deduct from the Compensation payable to such Participant during each Offering Period any amount between one percent (1%) and fifteen percent (15%) of such Participant's Compensation, in whole multiples of one percent (1%). Such election shall be made during the thirty day period preceding the Offering Period to which it first relates. Such election shall become effective as of the first day of such Participant's first pay period that begins on or after the first day of such Offering Period and shall remain effective for each successive pay period and for each subsequent Offering until changed or terminated pursuant to this Article IV. The percentage deduction specified by the Participant will be deducted from each payment of Compensation made to the Participant.

SECTION 4.2. ELECTION TO INCREASE OR DECREASE PAYROLL DEDUCTIONS. Subject to Section 4.4, a Participant who has a payroll deduction election in effect under Section 4.1 may prospectively increase or decrease, during an Offering Period, the percentage amount of the deductions being made by the Company from such Participant's Compensation (including a decrease to zero) by delivering to the Company written direction to make such change. Such change shall become effective as soon as practicable after the Company's receipt of such written direction and shall remain in effect until changed or terminated pursuant to this Article IV. A Participant shall be permitted to increase or decrease the percentage amount of the deductions being made from such Participant's Compensation only once during each of the portions of an Offering Period that ends on a Purchase Date; provided, however, a Participant may terminate the deductions being made from such Participant's Compensation at any time during such Offering Period. If a Participant terminates deductions, such Participant cannot resume deductions during that Offering Period.
A Participant who makes a hardship withdrawal from a retirement savings plan sponsored or maintained by the Company or its Subsidiaries qualifying under Code section 401(k) (a “401(k) Plan”) shall be deemed to have terminated his or her payroll deduction election as of the date of such hardship withdrawal, shall cease to be a Participant as of such date, and the entire amount remaining to the credit of such Participant in such Participant's Stock Purchase Account shall be refunded to such Participant, without interest, as soon as administratively practicable thereafter. To the extent the Company relies on the safe harbor provided by Section 1.401(k)-1(d)(3)(iv)(E)(2) of the Treasury Regulations, a Participant who has made a hardship withdrawal from a 401(k) Plan shall not be permitted to participate in the Plan until the first Offering Period that begins at least six (6) months after the date of the hardship withdrawal.

SECTION 4.3. TERMINATION OF ELECTION UPON TERMINATION OF EMPLOYMENT. The termination of employment of a Participant for any reason shall automatically terminate the Participant’s participation in the Plan and the entire amount remaining to the credit of such Participant in such Participant's Stock Purchase Account shall be refunded to such Participant, without interest, as soon as administratively practicable thereafter.

SECTION 4.4. FORM OF ELECTIONS. Except as otherwise permitted by the Company, any election by a Participant regarding participation in or withdrawal from the Plan or deductions from Compensation pursuant to this Article IV shall be on a form furnished by the Company for such purpose and shall be made by having such Participant file such form with the Company in the time and manner prescribed from time to time by the Company.

SECTION 4.5. TAXES. Payroll deductions shall be made on an after-tax basis. The Company shall have the right, as a condition of exercise, to make such provision as it deems necessary to satisfy its obligations to withhold federal, state

- 4 -
233395v2

and local income or other taxes incurred by reason of the purchase or disposition of shares of Common Stock under the Plan. The Company in its discretion may, to the extent permitted by law, satisfy its withholding obligations by deduction from any payment of any kind due to the Participant or by withholding shares of Common Stock purchased under the Plan (but not in excess of the minimum statutory amounts or such greater amounts that, in the discretion of the Company, would not results in adverse accounting consequences to the Company). By electing to participate in the Plan, each Participant agrees to provide such information about any transfer of any shares of Common Stock acquired under the Plan as may be requested by the Company or any Subsidiary in order to assist it in complying with applicable tax laws.

ARTICLE V
STOCK PURCHASE ACCOUNTS AND PURCHASE OF COMMON STOCK

SECTION 5.1. STOCK PURCHASE ACCOUNTS. A Stock Purchase Account shall be established and maintained on the books and records of the Company for each Participant. Amounts deducted from a Participant's Compensation pursuant to Article IV shall be credited to such Participant's Stock Purchase Account. No interest or other increment shall accrue or be payable to any Participant with respect to any amounts credited to such Stock Purchase Accounts. All amounts credited to such Stock Purchase Accounts shall be withdrawn, paid, or applied toward the purchase of shares of Common Stock pursuant to the provisions of this Article V.

SECTION 5.2. PURCHASE OF COMMON STOCK.

(a)    GENERAL. As of each Purchase Date, the amount to the credit of a Participant in such Participant's Stock Purchase Account shall be used to purchase from the Company on such Participant's behalf the largest number of whole shares of Common Stock which can be purchased at the price determined under Section 3.3 with the amount then credited to such Participant's Stock Purchase Account, subject to the limitations set forth in Article III on the maximum number of shares of Common Stock such Participant may purchase. As of such date, such Participant's Stock Purchase Account shall be charged with the aggregate purchase price of the shares of Common Stock purchased on such Participant's behalf. No brokerage or other fees are to be charged upon a purchase. Stock transfer taxes, if any, shall be paid by the Company. The remaining balance attributable to any fractional shares, if any, credited to such Participant's Stock Purchase Account shall be carried forward and used to purchase shares of Common Stock on the next succeeding Purchase Date; provided that any excess balance remaining in a Participant's Stock Purchase Account after the application of the limitations or maximums in Section 3.2 shall be refunded to the Participant without interest as soon as is administratively practicable.

(b)    ISSUANCE OF COMMON STOCK. The shares of Common Stock purchased for a Participant as of a Purchase Date shall be deemed to have been issued by the Company for all purposes as of the close of business on such date. Prior to such date, none of the rights and privileges of a stockholder of the Company shall exist with respect to such shares of Common Stock. As soon as practical, the Company shall deliver to the Participant’s account maintained by the broker engaged by the Company to administer the Company equity program, the number of shares of Common Stock purchased for such Participant and the aggregate number of shares of Common Stock held on behalf of such Participant under the Plan.

(c)    INSUFFICIENT COMMON STOCK AVAILABLE. If, as of any Purchase Date, the aggregate amounts in Stock Purchase Accounts available for the purchase of shares of Common Stock pursuant to Section 5.2(a) would purchase a number of shares of Common Stock in excess of the number of shares of Common Stock then available for purchase under Section 3.1 of the Plan, (i) the number of shares of Common Stock which would otherwise be purchased for each Participant on such date shall be reduced proportionately to the extent necessary to eliminate such excess, (ii) the remaining balance to the credit of each Participant in each such Participant's Stock Purchase Accounts shall be refunded to each such Participant without interest as soon as administratively practicable, and (iii) the

- 5 -
233395v2

Plan shall terminate automatically upon the refund of the remaining balance in such Stock Purchase Accounts.

SECTION 5.3. WITHDRAWAL FROM PLAN PRIOR TO PURCHASE OF COMMON STOCK. In the event (i) a Participant elects in writing for any reason to withdraw from the Plan during an Offering Period or (ii) a Participant's employment with the Company terminates for any reason prior to the end of an Offering Period, the entire amount remaining to the credit of such Participant in such Participant's Stock Purchase Account shall be refunded to such Participant (or, if such Participant is deceased, to such Participant's beneficiary) without interest as soon as administratively practicable after such withdrawal or termination of employment (as the case may be).

ARTICLE VI
COMMITTEE

SECTION 6.1. POWERS OF THE COMMITTEE. The Committee shall administer the Plan. The Committee shall have all powers necessary to enable it to carry out its duties under the Plan properly. Not in limitation of the foregoing, the Committee shall have the authority to determine eligibility under the Plan, to designate Subsidiaries as eligible to participate in the Plan, to interpret the Plan, to prescribe forms, rules and procedures under the Plan, to adopt, amend, rescind, administer, and interpret such forms, rules and procedures and otherwise to do all things necessary or advisable to carry out the terms of the Plan. To the extent permitted by applicable law, the Committee in its discretion may delegate any or all of its powers under the Plan to one or more officers or employees of the Company.. The decision of the Committee upon all matters within the scope of its authority shall be final and conclusive on all persons, except to the extent otherwise provided by law.

SECTION 6.2. INDEMNIFICATION OF THE COMMITTEE. The Company agrees to indemnify and hold harmless the members of the Committee against any liabilities, loss, costs, or damage that they may incur in acting as such members and to assume the defense of any and allocations, suits, or proceedings against the members of the Committee, to the extent permitted by applicable law.

ARTICLE VII
AMENDMENT AND TERMINATION

SECTION 7.1. AMENDMENT OF THE PLAN. The Company expressly reserves the right, at any time and from time to time, to amend in whole or in part any of the terms and provisions of the Plan; provided, however, no amendment may without the approval of the shareholders of the Company increase the number of shares of Common Stock reserved under the Plan.

SECTION 7.2. TERMINATION OF PLAN. The Company expressly reserves the right, at any time and for whatever reason it may deem appropriate, to suspend or terminate the Plan. The Plan shall continue in effect until terminated pursuant to (i) the preceding sentence or (ii) Section 5.2(c). Upon any termination of the Plan, the entire amount credited to the Stock Purchase Account of each Participant shall be refunded to each such Participant without interest as soon as is administratively practicable.

SECTION 7.3. PROCEDURE FOR AMENDMENT OR TERMINATION. Any amendment to the Plan or termination of the Plan may be retroactive to the extent not prohibited by applicable law. Any amendment to the Plan or termination of the Plan shall be made by the Company by resolution of the Board of Directors (subject to Section 7.1) and shall not require the approval or consent of any Participant or beneficiary in order to be effective.

ARTICLE VIII
MISCELLANEOUS

SECTION 8.1. TRANSFERABILITY OF RIGHTS. Rights under the Plan are exercisable during a Participant's lifetime only by the Participant and such rights may not be sold, pledged, assigned or transferred in any manner.


- 6 -
233395v2

SECTION 8.2. NO EMPLOYMENT RIGHTS. Participation in the Plan shall not give any employee of the Company or any Subsidiary any right to remain employed or, upon termination of employment, any right or interest in the Plan, except as expressly provided herein.

SECTION 8.3. COMPLIANCE WITH LAW. No shares of Common Stock shall be issued under the Plan prior to compliance by the Company to the satisfaction of its counsel with any applicable laws.

SECTION 8.4. CONSTRUCTION. Article, Section, and paragraph headings have been inserted in the Plan for convenience of reference only and are to be ignored in any construction of the provisions hereof. If any provision of the Plan shall be invalid or unenforceable, the remaining provisions shall nevertheless be valid, enforceable, and fully effective. It is the intent that the Plan shall at all times constitute an "employee stock purchase plan" within the meaning of Section 423(b) of the Code, and the Plan shall be construed, and interpreted to remain such. The Plan shall be construed, administered, regulated, and governed by the laws of the United States to the extent applicable, and to the extent such laws are not applicable, by the laws of The Commonwealth of Massachusetts. Without limiting the foregoing, all Participants for an Offering Period shall have the same rights and privileges with respect to their rights to acquire shares of Common Stock under the Plan for such period, subject to the express terms hereof.




- 7 -
233395v2
 EX-31.1 3 a2016q210-q_exhibit311.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
CERTIFICATION
I, Jeffrey M. Leiden, certify that:
1.
I have reviewed this Quarterly Report on Form 10-Q of Vertex Pharmaceuticals Incorporated;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date:
August 1, 2016
/s/ Jeffrey M. Leiden
 
 
 
 
 
Jeffrey M. Leiden
 
 
Chief Executive Officer and President




 EX-31.2 4 a2016q210-q_exhibit312.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2
CERTIFICATION
I, Ian F. Smith, certify that:
1.
I have reviewed this Quarterly Report on Form 10-Q of Vertex Pharmaceuticals Incorporated;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date:
August 1, 2016
/s/ Ian F. Smith
 
 
 
 
 
Ian F. Smith
 
 
Executive Vice President and Chief Financial Officer



 EX-32.1 5 a2016q210-q_exhibit321.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1
SECTION 906 CEO/CFO CERTIFICATION
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) each of the undersigned officers of Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (the “Company”), does hereby certify, to such officer’s knowledge, that the Quarterly Report on Form 10-Q for the quarter ended June 30, 2016 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date:
August 1, 2016
 
 
 
/s/ Jeffrey M. Leiden
 
 
 
 
 
Jeffrey M. Leiden
 
 
Chief Executive Officer and President
 
 
 
Date:
August 1, 2016
 
 
 
/s/ Ian F. Smith
 
 
 
 
 
Ian F. Smith
 
 
Executive Vice President and Chief Financial Officer
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
 





 EX-101.INS 6 vrtx-20160630.xml XBRL INSTANCE DOCUMENT 0000875320 2016-01-01 2016-06-30 0000875320 2016-07-22 0000875320 2015-04-01 2015-06-30 0000875320 2015-01-01 2015-06-30 0000875320 2016-04-01 2016-06-30 0000875320 2016-06-30 0000875320 2015-12-31 0000875320 us-gaap:RetainedEarningsMember 2016-01-01 2016-06-30 0000875320 us-gaap:AdditionalPaidInCapitalMember 2015-01-01 2015-06-30 0000875320 us-gaap:ParentMember 2015-01-01 2015-06-30 0000875320 us-gaap:CommonStockMember 2015-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0000875320 us-gaap:RetainedEarningsMember 2014-12-31 0000875320 us-gaap:CommonStockMember 2016-06-30 0000875320 us-gaap:CommonStockMember 2015-01-01 2015-06-30 0000875320 us-gaap:NoncontrollingInterestMember 2015-12-31 0000875320 us-gaap:CommonStockMember 2014-12-31 0000875320 us-gaap:NoncontrollingInterestMember 2015-01-01 2015-06-30 0000875320 2014-12-31 0000875320 us-gaap:NoncontrollingInterestMember 2015-06-30 0000875320 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-06-30 0000875320 2015-06-30 0000875320 us-gaap:RetainedEarningsMember 2015-12-31 0000875320 us-gaap:ParentMember 2015-06-30 0000875320 us-gaap:CommonStockMember 2016-01-01 2016-06-30 0000875320 us-gaap:ParentMember 2016-01-01 2016-06-30 0000875320 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-01-01 2015-06-30 0000875320 us-gaap:RetainedEarningsMember 2016-06-30 0000875320 us-gaap:ParentMember 2016-06-30 0000875320 us-gaap:NoncontrollingInterestMember 2014-12-31 0000875320 us-gaap:CommonStockMember 2015-06-30 0000875320 us-gaap:NoncontrollingInterestMember 2016-01-01 2016-06-30 0000875320 us-gaap:AdditionalPaidInCapitalMember 2015-06-30 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-06-30 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-06-30 0000875320 us-gaap:AdditionalPaidInCapitalMember 2016-06-30 0000875320 us-gaap:ParentMember 2015-12-31 0000875320 us-gaap:NoncontrollingInterestMember 2016-06-30 0000875320 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0000875320 us-gaap:ParentMember 2014-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-12-31 0000875320 us-gaap:RetainedEarningsMember 2015-01-01 2015-06-30 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-06-30 0000875320 us-gaap:RetainedEarningsMember 2015-06-30 0000875320 vrtx:RebatesChargebacksAndDiscountsMember 2016-01-01 2016-06-30 0000875320 vrtx:CopayMitigationRebatesMember 2016-01-01 2016-06-30 0000875320 us-gaap:AllowanceForSalesReturnsMember 2016-01-01 2016-06-30 0000875320 vrtx:RebatesChargebacksAndDiscountsMember 2015-12-31 0000875320 us-gaap:AllowanceForTradeReceivablesMember 2016-01-01 2016-06-30 0000875320 us-gaap:AllowanceForSalesReturnsMember 2015-12-31 0000875320 us-gaap:AllowanceForTradeReceivablesMember 2015-12-31 0000875320 vrtx:CopayMitigationRebatesMember 2015-12-31 0000875320 vrtx:RebatesChargebacksAndDiscountsMember 2016-06-30 0000875320 vrtx:CopayMitigationRebatesMember 2016-06-30 0000875320 us-gaap:AllowanceForTradeReceivablesMember 2016-06-30 0000875320 us-gaap:AllowanceForSalesReturnsMember 2016-06-30 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:BioAxoneBiosciencesIncMember 2016-01-01 2016-06-30 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:BioAxoneBiosciencesIncMember 2015-01-01 2015-06-30 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:ParionSciencesIncMember 2015-04-01 2015-06-30 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:ParionSciencesIncMember 2016-01-01 2016-06-30 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:BioAxoneBiosciencesIncMember 2016-04-01 2016-06-30 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:BioAxoneBiosciencesIncMember 2015-04-01 2015-06-30 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:ParionSciencesIncMember 2015-01-01 2015-06-30 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:ParionSciencesIncMember 2016-04-01 2016-06-30 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2016-01-01 2016-06-30 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2015-01-01 2015-06-30 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2016-04-01 2016-06-30 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2015-04-01 2015-06-30 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2015-12-31 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2016-06-30 0000875320 vrtx:CRISPRTherapeuticsMember 2015-10-26 2015-10-26 0000875320 vrtx:BioAxoneBiosciencesIncMember 2014-10-01 2014-10-31 0000875320 vrtx:JanssenCollaborativeAgreementMember 2016-04-01 2016-06-30 0000875320 vrtx:BioAxoneBiosciencesIncMember 2014-10-01 2014-12-31 0000875320 vrtx:ParionSciencesIncMember 2015-06-04 2015-06-04 0000875320 vrtx:JanssenCollaborativeAgreementMember 2015-04-01 2015-06-30 0000875320 vrtx:CysticFibrosisFoundationTherapeuticsIncorporatedAgreementMember 2016-01-01 2016-03-31 0000875320 vrtx:CRISPRTherapeuticsMember 2015-10-26 0000875320 vrtx:CysticFibrosisFoundationTherapeuticsIncorporatedAgreementMember 2016-01-01 2016-06-30 0000875320 us-gaap:SubsequentEventMember vrtx:ModernaTherapeuticsInc.Member 2016-07-01 2016-07-31 0000875320 vrtx:ParionSciencesIncMember 2016-06-30 0000875320 vrtx:BioAxoneBiosciencesIncMember 2016-06-30 0000875320 vrtx:ParionSciencesIncMember vrtx:AdditionalEnacInhibitorsMember 2015-06-04 2015-06-04 0000875320 vrtx:BioAxoneBiosciencesIncMember 2014-10-31 0000875320 vrtx:CysticFibrosisFoundationTherapeuticsIncorporatedAgreementMember 2011-04-01 2011-04-30 0000875320 vrtx:ParionSciencesIncMember 2015-06-04 0000875320 vrtx:JanssenCollaborativeAgreementMember 2016-01-01 2016-06-30 0000875320 vrtx:ParionSciencesIncMember 2015-12-31 0000875320 vrtx:CRISPRTherapeuticsMember 2016-04-01 2016-06-30 0000875320 vrtx:ParionSciencesIncMember vrtx:EnacInhibitorsinCfMember 2015-06-04 2015-06-04 0000875320 vrtx:JanssenCollaborativeAgreementMember 2015-01-01 2015-06-30 0000875320 vrtx:JanssenCollaborativeAgreementMember 2014-01-01 2014-12-31 0000875320 vrtx:ParionSciencesIncMember vrtx:EnacInhibitorsinNonCfMember 2015-06-04 2015-06-04 0000875320 vrtx:BioAxoneBiosciencesIncMember 2015-12-31 0000875320 vrtx:CysticFibrosisFoundationTherapeuticsIncorporatedAgreementMember 2012-01-01 2012-12-31 0000875320 vrtx:CysticFibrosisFoundationTherapeuticsIncorporatedAgreementMember 2015-01-01 2015-06-30 0000875320 vrtx:CysticFibrosisFoundationTherapeuticsIncorporatedAgreementMember 2013-01-01 2013-12-31 0000875320 vrtx:CysticFibrosisFoundationTherapeuticsIncorporatedAgreementMember 2015-10-01 2015-12-31 0000875320 us-gaap:EmployeeStockOptionMember 2015-04-01 2015-06-30 0000875320 us-gaap:RestrictedStockMember 2016-01-01 2016-06-30 0000875320 us-gaap:RestrictedStockMember 2015-01-01 2015-06-30 0000875320 us-gaap:RestrictedStockMember 2016-04-01 2016-06-30 0000875320 us-gaap:EmployeeStockOptionMember 2016-04-01 2016-06-30 0000875320 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-06-30 0000875320 us-gaap:RestrictedStockMember 2015-04-01 2015-06-30 0000875320 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-06-30 0000875320 us-gaap:FairValueInputsLevel3Member 2016-06-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:BioAxoneBiosciencesIncMember 2016-06-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2015-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2015-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2015-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2015-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2015-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2015-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2015-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2015-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2015-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2015-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2015-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2015-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherAssetsMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2015-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2015-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2015-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2015-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-06-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-06-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-06-30 0000875320 us-gaap:FairValueMeasurementsRecurringMember 2016-06-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-06-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2016-06-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-06-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-06-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherAssetsMember us-gaap:FairValueMeasurementsRecurringMember 2016-06-30 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2016-06-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-06-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-06-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2016-06-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-06-30 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2016-06-30 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2016-06-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2016-06-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-06-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-06-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2016-06-30 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-06-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2016-06-30 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2016-06-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-06-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2016-06-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-06-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2016-06-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-06-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2016-06-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-06-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-06-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-06-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-06-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2016-06-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2016-06-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueMeasurementsRecurringMember 2016-06-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2016-06-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2016-06-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2016-06-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2016-06-30 0000875320 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2016-06-30 0000875320 us-gaap:CashAndCashEquivalentsMember 2015-12-31 0000875320 vrtx:CorporateDebtSecuritiesDueWithinOneYearMember 2016-06-30 0000875320 us-gaap:AvailableforsaleSecuritiesMember 2016-06-30 0000875320 vrtx:CashAndMoneyMarketFundsMember 2015-12-31 0000875320 us-gaap:CommercialPaperMember 2015-12-31 0000875320 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2015-12-31 0000875320 vrtx:CorporateDebtSecuritiesDueWithinOneYearMember 2015-12-31 0000875320 us-gaap:USTreasurySecuritiesMember 2016-06-30 0000875320 us-gaap:CorporateDebtSecuritiesMember 2015-12-31 0000875320 vrtx:U.S.GovernmentSponsoredEnterprisesDebtSecuritiesDueWithinOneYearMember 2015-12-31 0000875320 vrtx:CashAndMoneyMarketFundsMember 2016-06-30 0000875320 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2015-12-31 0000875320 vrtx:U.S.GovernmentSponsoredEnterprisesDebtSecuritiesDueWithinOneYearMember 2016-06-30 0000875320 us-gaap:CashAndCashEquivalentsMember 2016-06-30 0000875320 us-gaap:AvailableforsaleSecuritiesMember 2015-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2016-01-01 2016-06-30 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-01-01 2016-06-30 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-12-31 0000875320 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2015-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-06-30 0000875320 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2016-01-01 2016-06-30 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2016-06-30 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2015-12-31 0000875320 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2016-06-30 0000875320 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2015-01-01 2015-06-30 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2015-06-30 0000875320 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2015-06-30 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-01-01 2015-06-30 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2014-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2015-01-01 2015-06-30 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-06-30 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2014-12-31 0000875320 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2014-12-31 0000875320 currency:EUR us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-12-31 0000875320 currency:EUR us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-06-30 0000875320 currency:GBP us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-06-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-06-30 0000875320 currency:GBP us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-12-31 0000875320 currency:AUD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-12-31 0000875320 currency:AUD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-06-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:MaximumMember 2016-01-01 2016-06-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:MinimumMember 2016-01-01 2016-06-30 0000875320 us-gaap:OtherAssetsMember 2016-06-30 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember 2016-06-30 0000875320 us-gaap:OtherCurrentLiabilitiesMember 2016-06-30 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2016-06-30 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2015-12-31 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember 2015-12-31 0000875320 us-gaap:OtherAssetsMember 2015-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember 2015-12-31 0000875320 us-gaap:IndefinitelivedIntangibleAssetsMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:BioAxoneBiosciencesIncMember 2014-10-01 2014-10-31 0000875320 us-gaap:IndefinitelivedIntangibleAssetsMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:ParionSciencesIncMember 2014-10-01 2014-10-31 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:BioAxoneBiosciencesIncMember 2014-10-31 0000875320 us-gaap:SeniorLoansMember 2014-07-01 2014-07-31 0000875320 us-gaap:SeniorLoansMember us-gaap:MinimumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2014-07-01 2014-07-31 0000875320 us-gaap:BuildingMember vrtx:FanPierLeasesMember 2015-12-31 0000875320 us-gaap:ConstructionInProgressMember vrtx:FanPierLeasesMember 2015-12-31 0000875320 us-gaap:BuildingMember vrtx:FanPierLeasesMember 2016-06-30 0000875320 us-gaap:SecuredDebtMember 2014-07-31 0000875320 us-gaap:SeniorLoansMember 2015-12-31 0000875320 us-gaap:SeniorLoansMember 2014-07-31 0000875320 vrtx:SanDiegoLeaseMember 2015-12-02 0000875320 vrtx:FanPierLeasesMember 2011-12-31 0000875320 vrtx:SanDiegoLeaseMember 2015-12-02 2015-12-02 0000875320 vrtx:FanPierLeasesMember 2011-01-01 2011-12-31 0000875320 us-gaap:SeniorLoansMember 2015-10-01 2015-10-31 0000875320 vrtx:FanPierMoveMember 2016-01-01 2016-06-30 0000875320 us-gaap:OtherRestructuringMember 2016-01-01 2016-06-30 0000875320 vrtx:KendallRestructuringMember 2016-01-01 2016-06-30 0000875320 us-gaap:SeniorLoansMember 2016-06-30 0000875320 us-gaap:ConstructionInProgressMember vrtx:FanPierLeasesMember 2016-06-30 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2016-04-01 2016-06-30 0000875320 vrtx:EmployeeStockPurchasePlanMember 2016-01-01 2016-06-30 0000875320 vrtx:EmployeeRestrictedStockOptionMember 2015-04-01 2015-06-30 0000875320 vrtx:EmployeeStockPurchasePlanMember 2015-01-01 2015-06-30 0000875320 vrtx:EmployeeStockPurchasePlanMember 2015-04-01 2015-06-30 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2015-04-01 2015-06-30 0000875320 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-06-30 0000875320 vrtx:SellingGeneralAndAdministrativeExpenseMember 2016-01-01 2016-06-30 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-06-30 0000875320 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-06-30 0000875320 us-gaap:EmployeeStockOptionMember 2015-04-01 2015-06-30 0000875320 us-gaap:EmployeeStockOptionMember 2016-04-01 2016-06-30 0000875320 vrtx:EmployeeRestrictedStockOptionMember 2016-01-01 2016-06-30 0000875320 vrtx:SellingGeneralAndAdministrativeExpenseMember 2015-04-01 2015-06-30 0000875320 vrtx:SellingGeneralAndAdministrativeExpenseMember 2015-01-01 2015-06-30 0000875320 vrtx:EmployeeStockPurchasePlanMember 2016-04-01 2016-06-30 0000875320 vrtx:EmployeeRestrictedStockOptionMember 2015-01-01 2015-06-30 0000875320 vrtx:SellingGeneralAndAdministrativeExpenseMember 2016-04-01 2016-06-30 0000875320 vrtx:EmployeeRestrictedStockOptionMember 2016-04-01 2016-06-30 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-06-30 0000875320 vrtx:ExercisePriceRangeFromDollars120.01toDollars134.69Member 2016-06-30 0000875320 vrtx:ExercisePriceRangeFromDollars18.93toDollars20.00Member 2016-06-30 0000875320 vrtx:ExercisePriceRangefromDollars80.01toDollars100.00Member 2016-06-30 0000875320 vrtx:ExercisePriceRangefromDollars20.01toDollars40.00Member 2016-06-30 0000875320 vrtx:ExercisePriceRangefromDollars20.01toDollars40.00Member 2016-01-01 2016-06-30 0000875320 vrtx:ExercisePriceRangefromDollars60.01toDollars80.00Member 2016-01-01 2016-06-30 0000875320 vrtx:ExercisePriceRangefromDollars40.01toDollars60.00Member 2016-01-01 2016-06-30 0000875320 vrtx:ExercisePriceRangefromDollars40.01toDollars60.00Member 2016-06-30 0000875320 vrtx:ExercisePriceRangefromDollars60.01toDollars80.00Member 2016-06-30 0000875320 vrtx:ExercisePriceRangeFromDollars120.01toDollars134.69Member 2016-01-01 2016-06-30 0000875320 vrtx:ExercisePriceRangefromDollars100.01toDollars120.00Member 2016-06-30 0000875320 vrtx:ExercisePriceRangefromDollars100.01toDollars120.00Member 2016-01-01 2016-06-30 0000875320 vrtx:ExercisePriceRangeFromDollars18.93toDollars20.00Member 2016-01-01 2016-06-30 0000875320 vrtx:ExercisePriceRangefromDollars80.01toDollars100.00Member 2016-01-01 2016-06-30 0000875320 vrtx:EmployeeRestrictedStockOptionMember 2016-06-30 0000875320 us-gaap:EmployeeStockOptionMember 2016-06-30 0000875320 vrtx:EmployeeStockPurchasePlanMember 2016-06-30 0000875320 2008-01-01 2008-12-31 0000875320 vrtx:ParionSciencesIncMember 2016-01-01 2016-06-30 0000875320 vrtx:ParionSciencesIncMember 2016-04-01 2016-06-30 0000875320 2015-01-01 2015-12-31 0000875320 vrtx:KendallRestructuringMember 2015-04-01 2015-06-30 0000875320 vrtx:KendallRestructuringMember 2015-06-30 0000875320 vrtx:KendallRestructuringMember 2015-03-31 0000875320 vrtx:KendallRestructuringMember 2015-01-01 2015-06-30 0000875320 vrtx:KendallRestructuringMember 2014-12-31 0000875320 vrtx:KendallRestructuringMember 2016-04-01 2016-06-30 0000875320 vrtx:KendallRestructuringMember 2016-06-30 0000875320 vrtx:KendallRestructuringMember 2015-12-31 0000875320 vrtx:KendallRestructuringMember 2016-03-31 0000875320 vrtx:FanPierMoveMember 2014-12-31 0000875320 vrtx:FanPierMoveMember 2016-04-01 2016-06-30 0000875320 vrtx:FanPierMoveMember 2015-04-01 2015-06-30 0000875320 vrtx:FanPierMoveMember 2015-06-30 0000875320 vrtx:FanPierMoveMember 2016-06-30 0000875320 vrtx:FanPierMoveMember 2016-03-31 0000875320 vrtx:FanPierMoveMember 2015-12-31 0000875320 vrtx:FanPierMoveMember 2015-01-01 2015-06-30 0000875320 vrtx:FanPierMoveMember 2015-03-31 0000875320 vrtx:KendallRestructuringMember 2003-01-01 2003-12-31 0000875320 vrtx:FanPierMoveMember 2014-07-01 2014-09-30 0000875320 us-gaap:OtherRestructuringMember 2016-03-31 0000875320 us-gaap:OtherRestructuringMember 2015-06-30 0000875320 us-gaap:OtherRestructuringMember 2014-12-31 0000875320 us-gaap:OtherRestructuringMember 2016-04-01 2016-06-30 0000875320 us-gaap:OtherRestructuringMember 2015-03-31 0000875320 us-gaap:OtherRestructuringMember 2015-04-01 2015-06-30 0000875320 us-gaap:OtherRestructuringMember 2016-06-30 0000875320 us-gaap:OtherRestructuringMember 2015-12-31 0000875320 us-gaap:OtherRestructuringMember 2015-01-01 2015-06-30 xbrli:shares vrtx:term_extension vrtx:lease utreg:sqft iso4217:USD xbrli:shares vrtx:segment vrtx:target xbrli:pure iso4217:USD vrtx:building vrtx:facility false --12-31 Q2 2016 2016-06-30 10-Q 0000875320 247778698 Large Accelerated Filer VERTEX PHARMACEUTICALS INC / MA 27167000 103362000 78756000 209285000 28318000 193542000 79845000 301705000 74942000 676000 51302000 1129000 177639000 189356000 305820000 7100000 275165000 7059000 917000 2011000 -123000 -971000 -1707000 -1963000 7000 249000 1824000 3778000 126000 -2080000 -3390000 3565000 326000 -7281000 6197500000 6350244000 122682000 122682000 0 122682000 119114000 119187000 -73000 119187000 63261000 41632000 21629000 120645000 79849000 40796000 61942000 40640000 21302000 117414000 75088000 42326000 11933000 3355000 11933000 3355000 12231000 3506000 12231000 3506000 1100000 120000 170000 2498587000 2548982000 1407153000 1454150000 372663000 292720000 0 665383000 275738000 312098000 0 587836000 327694000 465570000 -1198000 423000 -1621000 -1073000 548000 -1621000 48720000 320000 48400000 58150000 750000 57400000 28000000 179000000 28700000 231400000 15545000 17446000 42923000 34317000 625259000 870543000 714768000 605866000 0 0 199507000 85994000 34889000 11533000 0 0 0 0 0 0 34889000 11533000 199507000 85994000 110696000 0 0 110696000 245284000 -108902000 0.01 0.01 500000000 500000000 246306818 247703932 246306818 247703932 2427000 2440000 -191346000 -390078000 -63016000 -111370000 -32144000 -32242000 28374000 33903000 -223490000 -422320000 -34642000 -77467000 166000 161000 0 33213000 15409000 24790000 44154000 93943000 337240000 647734000 428255000 840665000 0.05 300000000 0.072 0.062 75000000 4600000 3400000 5300000 16296000 11468000 9714000 7411000 110439000 110438000 132810000 132810000 30428000 31378000 901000 7405000 5766000 11570000 5766000 11570000 4865000 4165000 901000 7405000 0 0 901000 7405000 0 769000 0 769000 0 132000 0 132000 901000 7405000 P18M P1M 1451000 4377000 1098000 1958000 -0.78 -1.61 -0.26 -0.43 -0.78 -1.61 -0.26 -0.43 -1306000 -90000 1153000 2037000 928000 1773000 176251000 201858000 5546000 P2Y7M28D P2Y6M26D P7M21D 0.075 0.071 0 901000 0 901000 0 7405000 0 7405000 605000 5161000 1604000 9966000 0 605000 0 605000 0 5161000 0 5161000 0 1604000 0 1604000 0 -7317000 0 -7317000 0 -88000 0 -88000 0 9966000 0 9966000 769000 132000 7317000 88000 50384000 19391000 50384000 19391000 -1293000 -1579000 -2835000 -3674000 -190861000 -389266000 -18021000 -48638000 30131000 29653000 30430000 29590000 18130000 17511000 17500000 23615000 20573000 20600000 1022000 1237000 -3033000 -23821000 21197000 12954000 8098000 -14562000 -9303000 -7131000 9426000 7779000 6346000 22858000 15397000 7971000 21975000 0 -2277000 -8397000 -21111000 -42418000 -20155000 -40853000 42885000 41325000 7816000 15374000 57207000 66589000 8696000 5408000 40695000 45807000 1404959000 1380137000 2498587000 2548982000 506167000 622855000 200000000 296500000 0 0 87162000 99123000 141409000 0 0 0 0 99123000 141409000 87162000 0 0 131900000 33142000 164853000 135675000 0 0 0 0 0 0 164853000 135675000 131900000 33142000 153661000 153661000 187491000 187491000 86611000 25955000 492481000 -160490000 -332502000 25723000 -188848000 -387454000 -64525000 -106156000 -32144000 -32144000 -32242000 -32242000 28374000 28374000 33903000 33903000 164317000 164317000 30000000 0 1 -171164000 -343149000 3353000 -10977000 6912000 455000 14203000 383000 -20000 -1370000 130000 1220000 -3154000 1847000 200000 -5201000 1828000 1220000 -3461000 -5201000 -2498000 -2624000 -3974000 130000 -2624000 1220000 -2624000 1509000 -5214000 -213000 200000 -5214000 -5201000 -5214000 -4280000 -3974000 4999000 -213000 -46000 130000 -29000 200000 284340000 284340000 284340000 284340000 284300000 255300000 14374000 38215000 31778000 300000 30648000 310000 -6045000 -3436000 1414000 -3699000 -1219000 3192000 -87000 159000 893000 3095000 2584000 1223000 22351000 6569000 234000 3096000 3833000 673000 6252000 7764000 14441000 7538000 125655000 470077000 80000000 0 23978000 27892000 0.01 0.01 1000000 1000000 0 0 0 0 0 0 50935000 3138000 56256000 3001000 87850000 33702000 13386000 0 741725000 332316000 -220992000 -419696000 -32242000 -387454000 -387454000 -36151000 -72253000 33903000 -106156000 -106156000 697715000 502300000 690607000 495700000 2604000 2604000 0 0 2060000 2060000 0 0 7100000 14700000 4300000 7800000 184000 209000 223858000 439457000 271008000 526868000 21900000 78910000 78910000 70513000 70513000 22083000 22085000 2128000 950000 975000 203000 -1144000 1256000 -2022000 -378000 343000 205000 149000 -11000 1030000 456000 382000 192000 869000 33390000 11596000 845000 11137000 9506000 902000 9017000 9924000 1450000 5964000 7944000 1262000 5449000 7224000 1233000 4863000 6388000 7894000 7683000 7464000 4801000 -26012000 -2892000 -5261784000 -5367940000 166076000 304585000 431608000 829688000 5077000 11869000 5282000 8878000 160388000 291263000 425651000 820061000 94394000 180254000 111652000 216866000 223863000 74921000 71296000 221576000 120645000 117414000 120.01 18.93 100.01 20.01 40.01 60.01 80.01 6490000 420000 137000 500000 1962000 1657000 734000 1080000 12231000 1497000 137000 1644000 1964000 2066000 1368000 3555000 134.69 20.00 120 40 60 80 100 37687000 24902000 1825000 66646000 52071000 3965000 31826000 29608000 1436000 58086000 57141000 3960000 63.32 129.84 18.93 109.27 34.23 48.66 75.39 88.91 79.37 130.61 18.93 109.32 34.24 48.14 75.90 90.68 P7Y2M16D P9Y18D P1Y7M10D P8Y6M26D P3Y5M12D P6Y26D P7Y7M13D P8Y7M6D 241764000 244342000 246307000 247704000 2578000 1397000 87354000 87333000 21000 0 87354000 33570000 33557000 13000 0 33570000 939967000 981354000 1096183000 917000 5777154000 2385000 21177000 1075006000 -4705450000 1048216000 -1707000 5987169000 2406000 153252000 894964000 -5092904000 1093628000 1824000 6197500000 2427000 153661000 939967000 -5261784000 1168845000 -3390000 6350244000 2440000 187491000 981354000 -5367940000 24554000 11723000 400000 400000 0 0 0 -1989000 -205000 -77000 5000 -1712000 49296000 1228000 2089000 1310000 44669000 69043000 2051000 2185000 897000 63910000 240757000 240129000 244482000 244124000 240757000 240129000 244482000 244124000 2 10200000 1042462000 327694000 714768000 34889000 99123000 11533000 85994000 582352000 141409000 87162000 1071436000 465570000 605866000 164853000 33142000 605866000 135675000 131900000 1042336000 327568000 714768000 34889000 98877000 11533000 85994000 582352000 141515000 87176000 1071110000 465244000 605866000 164575000 33138000 605866000 135663000 131868000 246000 246000 0 0 246000 0 0 0 0 0 351000 351000 0 278000 4000 0 34000 35000 120000 120000 0 0 0 0 0 0 106000 14000 25000 25000 0 0 0 0 22000 3000 220000000 P30D 230000000 490000000 370000000 420000000 275000000 30000000 20000000 3100000 P90D P90D 360000000 75000000 75000000 6 P180D P270D P10Y P6M 80000000 75000000 20000000 10000000 35000000 P1Y 611000 1453000 0 675000 749000 0 472611000 472374000 473000000 472800000 P2Y 18900000 0 0 0 0 2 2 0.09 P15Y P5Y P16Y 90000000.0 9300000 9300000 13900000 13900000 2 P5Y P10Y 0 3075000 160000000.0 0 2799000 0 5275000 2361000 3008000 4769000 6016000 0.5 3 400000 80509000 1288000 9935000 4220000 65066000 58773000 260000 9762000 4638000 44113000 70200000 11300000 29000000 29000000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company") in accordance with accounting principles generally accepted in the United States of America ("GAAP"). </font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements reflect the operations of (i) the Company, (ii) its wholly-owned subsidiaries and (iii) consolidated variable interest entities (VIEs). All material intercompany balances and transactions have been eliminated. The Company operates in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">one</font><font style="font-family:inherit;font-size:10pt;"> segment, pharmaceuticals.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, which are contained in the Company's Annual Report on Form&#160;10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> that was filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on </font><font style="font-family:inherit;font-size:10pt;">February&#160;16, 2016</font><font style="font-family:inherit;font-size:10pt;"> (the "</font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> Annual Report on Form&#160;10-K").</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Marketable Securities</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the Company&#8217;s cash, cash equivalents and marketable securities is shown below:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross <br clear="none"/>Unrealized <br clear="none"/>Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross <br clear="none"/>Unrealized <br clear="none"/>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of June 30, 2016</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">605,866</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">605,866</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">605,866</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">605,866</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">U.S. Treasury securities (due within 1&#160;year)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33,138</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33,142</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities (due within 1&#160;year)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">131,868</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">131,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper (due within 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">164,575</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">278</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">164,853</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities (due within 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">135,663</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">135,675</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">465,244</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">351</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(25</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">465,570</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,071,110</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">351</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(25</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,071,436</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2015</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">582,352</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">582,352</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">85,994</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">85,994</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34,889</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34,889</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,533</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,533</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">714,768</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">714,768</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities (due within 1&#160;year)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">87,176</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">87,162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper (due within 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">98,877</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">246</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">99,123</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities (due within 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">141,515</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(106</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">141,409</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">327,568</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">246</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(120</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">327,694</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,042,336</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">246</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(120</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,042,462</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has a limited number of marketable securities in insignificant loss positions as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, which the Company does not intend to sell and has concluded it will not be required to sell before recovery of the amortized costs for the investment at maturity. There were no charges recorded for other-than-temporary declines in fair value of marketable securities nor gross realized gains or losses recognized in </font><font style="font-family:inherit;font-size:10pt;">the three and six months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaborative Arrangements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cystic Fibrosis Foundation Therapeutics Incorporated</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2011, the Company entered into an amendment (the &#8220;April 2011 Amendment&#8221;) to its existing collaboration agreement with Cystic Fibrosis Foundation Therapeutics Incorporated (&#8220;CFFT&#8221;) pursuant to which CFFT agreed to provide financial support for (i)&#160;development activities for VX-661, a compound that targets the processing and trafficking defect of the F508del CFTR proteins discovered under the collaboration, and (ii)&#160;additional research and development activities directed at discovering new compounds targeting the processing and trafficking defect of the F508del protein. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the April 2011 Amendment, CFFT agreed to provide the Company with up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;"> in funding over approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">five</font><font style="font-family:inherit;font-size:10pt;"> years for corrector compound research and development activities. The Company retains the right to develop and commercialize KALYDECO (ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor), lumacaftor and VX-661. The Company recognized </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> collaborative revenues from this collaboration during </font><font style="font-family:inherit;font-size:10pt;">the three and six months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the original agreement, as amended prior to the April 2011 Amendment, the Company agreed to pay CFFT tiered royalties calculated as a percentage, ranging from single digits to sub-teens, of annual net sales of any approved drugs first synthesized or tested during the research term that ended in 2008, including ivacaftor, lumacaftor and VX-661. The April 2011 Amendment provides for a tiered royalty in the same range on net sales of corrector compounds first synthesized or tested during the research term that ended in February 2014. In each of 2012 and 2013, CFFT earned a commercial milestone payment of </font><font style="font-family:inherit;font-size:10pt;">$9.3 million</font><font style="font-family:inherit;font-size:10pt;"> from the Company upon achievement of certain sales levels for KALYDECO. In each of the fourth quarter of 2015 and first quarter of 2016, CFFT earned a commercial milestone payment of </font><font style="font-family:inherit;font-size:10pt;">$13.9 million</font><font style="font-family:inherit;font-size:10pt;"> from the Company upon achievement of certain sales levels of lumacaftor. There are no additional commercial milestone payments payable by the Company to CFFT related to sales levels for KALYDECO or ORKAMBI. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company began marketing KALYDECO in the United States and certain countries in the European Union in 2012 and began marketing ORKAMBI in the United States in 2015. The Company received approval for ORKAMBI in the European Union in 2015 and in Canada and Australia in 2016. The Company has royalty obligations to CFFT for ivacaftor, lumacaftor and VX-661 until the expiration of patents covering that compound. The Company has patents in the United States and European Union covering the composition-of-matter of ivacaftor that expire in 2027 and 2025, respectively, subject to potential patent extensions. The Company has patents in the United States and European Union covering the composition-of-matter of lumacaftor that expire in 2030 and 2026, respectively, subject to potential extension. The Company has patents in the United States and European Union covering the composition-of-matter of VX-661 that expire in 2027 and 2028, respectively, subject to potential extension.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">CRISPR Therapeutics AG</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 26, 2015, the Company entered into a strategic collaboration, option and license agreement (the "CRISPR Agreement") with CRISPR Therapeutics AG and its affiliates ("CRISPR") to collaborate on the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene editing technology. The Company has the exclusive right to license up to </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> CRISPR-Cas9-based targets. In connection with the CRISPR Agreement, the Company made an upfront payment to CRISPR of </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;"> and a </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;"> investment in CRISPR pursuant to a convertible loan agreement that converted into preferred stock in January 2016. The Company expensed </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;"> to research and development, and the </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;"> investment was recorded at cost and is classified as a long-term asset on the Company&#8217;s condensed consolidated balance sheet. In the second quarter of 2016, the Company made an additional preferred stock investment in CRISPR of approximately </font><font style="font-family:inherit;font-size:10pt;">$3.1 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company will fund all of the discovery activities conducted pursuant to the CRISPR Agreement. For potential hemoglobinapathy treatments, including treatments for sickle cell disease, the Company and CRISPR will share equally all research and development costs and worldwide revenues. For other targets that the Company elects to license, the Company would lead all development and global commercialization activities. For each of up to </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> targets that the Company elects to license, other than hemoglobinapathy targets, CRISPR has the potential to receive up to </font><font style="font-family:inherit;font-size:10pt;">$420.0 million</font><font style="font-family:inherit;font-size:10pt;"> in development, regulatory and commercial milestones and royalties on net product sales. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company may terminate the CRISPR Agreement upon </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;"> days&#8217; notice to CRISPR prior to any product receiving marketing approval or upon </font><font style="font-family:inherit;font-size:10pt;">270</font><font style="font-family:inherit;font-size:10pt;"> days&#8217; notice after a product has received marketing approval. The CRISPR Agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, the CRISPR Agreement will continue in effect until the expiration of the Company's payment obligations under the CRISPR Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Variable Interest Entities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has entered into several agreements pursuant to which it has licensed rights to certain drug candidates from third-party collaborators, which has resulted in the consolidation of the third parties' financial statements into the Company's condensed consolidated financial statements as VIEs. In order to account for </font><font style="font-family:inherit;font-size:10pt;">the fair value of the contingent milestone and royalty payments</font><font style="font-family:inherit;font-size:10pt;"> related to these collaborations under GAAP, the Company uses present-value models based on assumptions regarding the probability of achieving the relevant milestones, estimates regarding the timing of achieving the milestones, estimates of future product sales and the appropriate discount rates. The Company bases its estimate of the probability of achieving the relevant milestones on industry data for similar assets and its own experience. The discount rates used in the valuation model represent a measure of credit risk and market risk associated with settling the liabilities. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period. Changes in these assumptions could have a material effect on the fair value of the contingent milestone and royalty payments. The following collaborations are reflected in the Company's financial statements as consolidated VIEs:</font></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Parion Sciences,&#160;Inc.</font></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">License and Collaboration Agreement</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 4, 2015, the Company entered into a strategic collaboration and license agreement (the "Parion Agreement") with Parion Sciences, Inc. (&#8220;Parion&#8221;).&#160; Pursuant to the agreement, the Company is collaborating with Parion to develop investigational epithelial sodium channel (&#8220;ENaC&#8221;) inhibitors, including VX-371 (formerly P-1037) and VX-551 (formerly P-1055), for the potential treatment of cystic fibrosis, or CF, and other pulmonary diseases.&#160; The Company is leading development activities for VX-371 and VX-551 and is responsible for all costs, subject to certain exceptions, related to development and commercialization of the compounds.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the Parion Agreement, the Company has worldwide development and commercial rights to Parion&#8217;s lead investigational ENaC inhibitors, VX-371 and VX-551, for the potential treatment of CF and all other pulmonary diseases and has the option to select additional compounds discovered in Parion&#8217;s research program.&#160; Parion received an </font><font style="font-family:inherit;font-size:10pt;">$80.0 million</font><font style="font-family:inherit;font-size:10pt;"> up-front payment and has the potential to receive up to an additional (i) </font><font style="font-family:inherit;font-size:10pt;">$490.0 million</font><font style="font-family:inherit;font-size:10pt;"> in development and regulatory milestone payments for development of ENaC inhibitors in CF, including </font><font style="font-family:inherit;font-size:10pt;">$360.0 million</font><font style="font-family:inherit;font-size:10pt;"> related to global filing and approval milestones, (ii) </font><font style="font-family:inherit;font-size:10pt;">$370.0 million</font><font style="font-family:inherit;font-size:10pt;"> in development and regulatory milestones for VX-371 and VX-551 in non-CF pulmonary indications and (iii)&#160;</font><font style="font-family:inherit;font-size:10pt;">$230.0 million</font><font style="font-family:inherit;font-size:10pt;"> in development and regulatory milestones should the Company elect to develop an additional ENaC inhibitor from Parion&#8217;s research program. The Company has agreed to pay Parion tiered royalties that range from the low double digits to mid-teens as a percentage of potential sales of licensed products.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company may terminate the Parion Agreement upon </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;"> days&#8217; notice to Parion prior to any licensed product receiving marketing approval or upon </font><font style="font-family:inherit;font-size:10pt;">180</font><font style="font-family:inherit;font-size:10pt;"> days&#8217; notice after a licensed product has received marketing approval. If the Company experiences a change of control prior to the initiation of the first Phase 3 clinical trial for a licensed product, Parion may terminate the Parion Agreement upon </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> days&#8217; notice, subject to the Company's right to receive specified royalties on any subsequent commercialization of licensed products. The Parion Agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, the Parion Agreement will continue in effect until the expiration of the Company's royalty obligations, which expire on a country-by-country basis on the later of (i)&#160;the date the last-to-expire patent covering a licensed product expires or (ii)&#160;</font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;"> years after the first commercial sale in the country.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that Parion is a VIE based on, among other factors, the significance to Parion of the ENaC inhibitors licensed to the Company pursuant to the Parion Agreement and on the Company's power to direct the activities that most significantly affect the economic performance of Parion. &#160;Accordingly, the Company consolidated Parion's financial statements beginning on June&#160;4, 2015. However, the Company's interests in Parion are limited to those accorded to the Company in the Parion Agreement. </font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recorded </font><font style="font-family:inherit;font-size:10pt;">$255.3 million</font><font style="font-family:inherit;font-size:10pt;"> of intangible assets on the Company's condensed consolidated balance sheet for Parion's in-process research and development assets. These in-process research and development assets relate to Parion's pulmonary ENaC platform, including the intellectual property related to VX-371 and VX-551, that are licensed by Parion to the Company. The difference between the fair value of the consideration and the fair value of Parion's assets (including the fair value of intangible assets) and liabilities was allocated to goodwill. The measurement period for purchase accounting was closed during the quarter. There were no purchase accounting adjustments recorded during the measurement period.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">BioAxone Biosciences, Inc.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2014, the Company entered into a license and collaboration agreement (the &#8220;BioAxone Agreement&#8221;) with BioAxone Biosciences, Inc. (&#8220;BioAxone&#8221;), a privately-held biotechnology company, which resulted in the consolidation of BioAxone as a VIE beginning on October 1, 2014. The Company paid BioAxone initial payments of </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> in the fourth quarter of 2014. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BioAxone has the potential to receive up to </font><font style="font-family:inherit;font-size:10pt;">$90.0 million</font><font style="font-family:inherit;font-size:10pt;"> in milestones and fees, including development, regulatory and milestone payments and a license continuation fee. In addition, BioAxone would receive royalties and commercial milestones on future net product sales of VX-210, if any. The Company recorded an in-process research and development intangible asset of </font><font style="font-family:inherit;font-size:10pt;">$29.0 million</font><font style="font-family:inherit;font-size:10pt;"> for VX-210 and a corresponding deferred tax liability of </font><font style="font-family:inherit;font-size:10pt;">$11.3 million</font><font style="font-family:inherit;font-size:10pt;"> attributable to BioAxone. The Company holds an option to purchase BioAxone at a predetermined price. The option expires on the earliest of (a) the day the FDA accepts the Biologics License Application submission for VX-210, (b) the day the Company elects to continue the license instead of exercising the option to purchase BioAxone and (c) March 15, 2018, subject to the Company&#8217;s option to extend this date by </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> year. </font></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Aggregate VIE Financial Information</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">An aggregate summary of net loss attributable to noncontrolling interest related to the Company's VIEs for </font><font style="font-family:inherit;font-size:10pt;">the three and six months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> is as follows:</font></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.42857142857143%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Loss attributable to noncontrolling interest before provision for income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,835</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,293</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,674</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,579</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Provision for income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">17,511</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">29,653</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">20,573</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">29,590</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Increase) decrease in fair value of contingent milestone and royalty payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(48,720</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,198</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(58,150</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,073</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net (income) loss attributable to noncontrolling interest</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(28,374</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">32,144</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(33,903</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">32,242</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The increases in </font><font style="font-family:inherit;font-size:10pt;">the fair value of the contingent milestone and royalty payments</font><font style="font-family:inherit;font-size:10pt;"> in </font><font style="font-family:inherit;font-size:10pt;">the three and six months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> were primarily due to a Phase 2 clinical trial of VX-371, a compound being developed pursuant to the Parion Agreement, achieving its primary safety endpoint in the second quarter of 2016. The fair value of the contingent milestone and royalty payments also reflects changes in market interest rates and the time value of money. During </font><font style="font-family:inherit;font-size:10pt;">the three and six months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the increase (decrease) in </font><font style="font-family:inherit;font-size:10pt;">the fair value of the contingent milestone and royalty payments</font><font style="font-family:inherit;font-size:10pt;"> related to the Company's VIEs was as follows:</font></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.42857142857143%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Parion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">48,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,621</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">57,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,621</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">BioAxone</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">320</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">423</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">750</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">548</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the contingent milestone and royalty payments related to the Parion Agreement and the BioAxone Agreement was </font><font style="font-family:inherit;font-size:10pt;">$231.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$28.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the contingent milestone and royalty payments related to the Parion collaboration and the BioAxone collaboration was </font><font style="font-family:inherit;font-size:10pt;">$179.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$28.0 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes items related to the Company's VIEs included in the Company's condensed consolidated balance sheets as of the dates set forth in the table:</font></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.42857142857143%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restricted cash and cash equivalents (VIE)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">70,513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">78,910</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,001</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,138</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">284,340</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">284,340</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,391</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,391</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">455</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,129</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">676</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Taxes payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,723</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24,554</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,059</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,100</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Deferred tax liability, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">132,810</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">110,438</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">310</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">300</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Noncontrolling interest</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">187,491</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">153,661</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has recorded the VIEs' cash and cash equivalents as restricted cash and cash equivalents (VIE) because (i)&#160;the Company does not have any interest in or control over the VIEs' cash and cash equivalents and (ii)&#160;the Company's agreements with each VIE do not provide for the VIEs' cash and cash equivalents to be used for the development of the assets that the Company licensed from the applicable VIE. Assets recorded as a result of consolidating the Company's VIEs' financial condition into the Company's balance sheet do not represent additional assets that could be used to satisfy claims against the Company's general assets. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Outlicense Arrangements</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the ordinary course of the Company's business, the Company has entered into various agreements pursuant to which it has outlicensed rights to certain drug candidates to third-party collaborators. Although the Company does not consider any of these outlicense arrangements to be material, the most notable of these outlicense arrangements is described below. Pursuant to these outlicense arrangements, our collaborators are responsible for all costs related to the continued development of such drug candidates. Depending on the terms of the arrangements, the Company's collaborators may be required to make upfront payments, milestone payments upon the achievement of certain product research and development objectives and/or pay royalties on future sales, if any, of commercial products resulting from the collaboration. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Janssen Pharmaceuticals, Inc.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2014, the Company entered into an agreement (the &#8220;Janssen Influenza Agreement&#8221;) with Janssen Pharmaceuticals, Inc. (&#8220;Janssen Inc.&#8221;), which was amended in October 2014 to clarify certain roles and responsibilities of the parties. </font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the Janssen Influenza Agreement, Janssen Inc. has an exclusive worldwide license to develop and commercialize certain drug candidates for the treatment of influenza, including VX-787. The Company received non-refundable payments of </font><font style="font-family:inherit;font-size:10pt;">$35.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Janssen Inc. in 2014, which were recorded as collaborative revenue. The Company has the potential to receive development, regulatory and commercial milestone payments as well as royalties on future product sales, if any. Janssen Inc. may terminate the Janssen Influenza Agreement, subject to certain exceptions, upon </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> months' notice.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Janssen Inc. is responsible for costs related to the development and commercialization of the compounds. During </font><font style="font-family:inherit;font-size:10pt;">the three and six months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded reimbursement for these development activities of </font><font style="font-family:inherit;font-size:10pt;">$4.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$7.8 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. During </font><font style="font-family:inherit;font-size:10pt;">the three and six months ended June 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded reimbursement for these development activities of </font><font style="font-family:inherit;font-size:10pt;">$7.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$14.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The reimbursements are recorded as a reduction to development expense in the Company's </font><font style="font-family:inherit;font-size:10pt;">condensed consolidated statements of operations</font><font style="font-family:inherit;font-size:10pt;"> primarily due to the fact that Janssen Inc. directs the activities and selects the suppliers associated with these activities. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Subsequent Event</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Moderna Therapeutics, Inc.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2016, the Company entered into a strategic collaboration and licensing agreement (the "Moderna Agreement") with Moderna Therapeutics, Inc. ("Moderna") pursuant to which the parties are seeking to identify and develop messenger Ribonucleic Acid ("mRNA") Therapeutics&#8482; for the treatment of CF. In connection with the Moderna Agreement in the third quarter of 2016, the Company made an upfront payment to Moderna of </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> and made a </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> investment in Moderna pursuant to a convertible promissory note. Moderna has the potential to receive&#160;future development and regulatory milestones of up to&#160;</font><font style="font-family:inherit;font-size:10pt;">$275.0 million</font><font style="font-family:inherit;font-size:10pt;">, including </font><font style="font-family:inherit;font-size:10pt;">$220.0 million</font><font style="font-family:inherit;font-size:10pt;">&#160;in approval and reimbursement milestones, as well as tiered royalty payments on future sales.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the collaboration, Moderna&#160;will lead discovery efforts and the Company will lead all preclinical, development and commercialization activities associated with the advancement of mRNA Therapeutics that result from this collaboration and will fund all expenses related to the collaboration.</font></div><div style="line-height:120%;padding-bottom:20px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company may terminate the Moderna Agreement by providing advanced notice to Moderna, with the required length of notice dependent on whether any product developed under the Moderna Agreement has received marketing approval. The Moderna Agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, the Moderna Agreement will continue in effect until the expiration of the Company's payment obligations under the Moderna Agreement.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and Contingencies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financing Arrangements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company had irrevocable stand-by letters of credit outstanding that were issued in connection with property leases and other similar agreements totaling </font><font style="font-family:inherit;font-size:10pt;">$21.9 million</font><font style="font-family:inherit;font-size:10pt;"> that are cash collateralized. The cash used to support these letters of credit is included in restricted cash, as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, on the Company's condensed consolidated balance sheet.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Litigation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 28, 2014, a purported shareholder class action </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Local No. 8 IBEW Retirement Plan &amp; Trust v. Vertex Pharmaceuticals Incorporated, et al.</font><font style="font-family:inherit;font-size:10pt;"> was filed in the United States District Court for the District of Massachusetts, naming the Company and certain of the Company's current and former officers and directors as defendants. The lawsuit alleged that the Company made material misrepresentations and/or omissions of material fact in the Company's disclosures during the period from May 7, 2012 through May 29, 2012, all in violation of Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. The purported class consists of all persons (excluding defendants) who purchased the Company&#8217;s common stock between May 7, 2012 and May 29, 2012. The plaintiffs seek unspecified monetary damages, costs and attorneys&#8217; fees as well as disgorgement of the proceeds from certain individual defendants&#8217; sales of the Company&#8217;s stock. On October 8, 2014, the Court approved Local No. 8 IBEW Retirement Fund as lead plaintiff, and Scott and Scott LLP as lead counsel for the plaintiff and the putative class. On February 23, 2015, the Company filed a reply to the plaintiffs&#8217; opposition to its motion to dismiss.&#160; The court heard oral argument on the motion to dismiss on March 6, 2015 and took the motion under advisement. On September 30, 2015, the court granted the Company's motion to dismiss. On October 15, 2015, the plaintiff filed a notice of appeal. The First Circuit Court of Appeals issued a scheduling order on December 24, 2015. On February 2, 2016, the Plaintiff filed their opening brief and the Company filed its opposition brief on March 7, 2016. On March 24, 2016, the plaintiff filed their reply brief. Oral argument on the appeal took place on July 26, 2016. The Company believes the claims to be without merit and intend to vigorously defend the litigation. </font><font style="font-family:inherit;font-size:10pt;">As of June 30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company has not recorded any reserves for this purported class action.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Guaranties and Indemnifications</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As permitted under Massachusetts law, the Company&#8217;s Articles of Organization and By-laws provide that the Company will indemnify certain of its officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that the Company could be required to make under these indemnification provisions is unlimited. However, the Company has purchased directors&#8217; and officers&#8217; liability insurance policies that could reduce its monetary exposure and enable it to recover a portion of any future amounts paid. No indemnification claims currently are outstanding, and the Company believes the estimated fair value of these indemnification arrangements is minimal.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company customarily agrees in the ordinary course of its business to indemnification provisions in agreements with clinical trial investigators and sites in its drug development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for the Company and its real estate leases. The Company also customarily agrees to certain indemnification provisions in its drug discovery, development and commercialization collaboration agreements. With respect to the Company&#8217;s clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator&#8217;s institution relating to personal injury or property damage, violations of law or certain breaches of the Company&#8217;s contractual obligations arising out of the research or clinical testing of the Company&#8217;s compounds or drug candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by the Company, to violations of law by the Company or to certain breaches of the Company&#8217;s contractual obligations. The indemnification provisions appearing in the Company&#8217;s collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for its collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although the Company believes the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that the Company could be required to make under these provisions is generally unlimited. The Company has purchased insurance policies covering personal injury, property damage and general liability that reduce its exposure for indemnification and would enable it in many cases to recover all or a portion of any future amounts paid. The Company has never paid any material amounts to defend lawsuits or settle claims related to these indemnification provisions. Accordingly, the Company believes the estimated fair value of these indemnification arrangements is minimal.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Contingencies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a reserve for contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> material contingent liabilities accrued as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Other Comprehensive (Loss) Income</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the Company's changes in accumulated other comprehensive (loss) income by component is shown below:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign Currency Translation Adjustment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Holding Gains (Losses) on Marketable Securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Gains on Foreign Currency Forward Contracts, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">126</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,778</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,824</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other comprehensive (loss) income before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5,201</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,847</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,154</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Amounts reclassified from accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,060</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,060</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net current period other comprehensive (loss) income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5,201</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(213</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5,214</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at June 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,281</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">326</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,565</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,390</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign Currency Translation Adjustment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Holding (Losses) Gains on Marketable Securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Foreign Currency Forward Contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(971</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(123</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">917</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other comprehensive (loss) income before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,220</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">130</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,370</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(20</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Amounts reclassified from accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,604</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,604</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net current period other comprehensive (loss) income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,220</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">130</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,974</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,624</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at June 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">249</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,963</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,707</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Long-term Obligations</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fan Pier Leases</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2011, the Company entered into </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> lease agreements, pursuant to which the Company leases approximately </font><font style="font-family:inherit;font-size:10pt;">1.1 million</font><font style="font-family:inherit;font-size:10pt;"> square feet of office and laboratory space in </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> buildings (the &#8220;Buildings&#8221;) at Fan Pier in Boston, Massachusetts (the &#8220;Fan Pier Leases&#8221;). The Company commenced lease payments in December 2013, and will make lease payments pursuant to the Fan Pier Leases through December 2028. The Company has an option to extend the term of the Fan Pier Leases for an additional </font><font style="font-family:inherit;font-size:10pt;">ten years</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because the Company was involved in the construction project, the Company was deemed for accounting purposes to be the owner of the Buildings during the construction period and recorded project construction costs incurred by the landlord. Upon completion of the Buildings, the Company evaluated the Fan Pier Leases and determined that the Fan Pier Leases did not meet the criteria for &#8220;sale-leaseback&#8221; treatment. Accordingly, the Company began depreciating the asset and incurring interest expense related to the financing obligation in 2013. The Company bifurcates its lease payments pursuant to the Fan Pier Leases into (i)&#160;a portion that is allocated to the Buildings and (ii)&#160;a portion that is allocated to the land on which the Buildings were constructed. The portion of the lease obligations allocated to the land is treated as an operating lease that commenced in 2011.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net, included </font><font style="font-family:inherit;font-size:10pt;">$495.7 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$502.3 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to construction costs for the Buildings. The carrying value of the Company's lease agreement liability for the Buildings was </font><font style="font-family:inherit;font-size:10pt;">$472.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$473.0 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">San Diego Lease</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 2, 2015, the Company entered into a lease agreement for 3215 Merryfield Row, San Diego, California with ARE-SD Region No. 23, LLC. Pursuant to this agreement, the Company agreed to lease approximately </font><font style="font-family:inherit;font-size:10pt;">170,000</font><font style="font-family:inherit;font-size:10pt;"> square feet of office and laboratory space in a building to be built in San Diego, California. The lease will commence upon completion of the building, scheduled for the second half of 2017, and will extend for </font><font style="font-family:inherit;font-size:10pt;">16</font><font style="font-family:inherit;font-size:10pt;"> years from the commencement date. Pursuant to the lease agreement, during the initial </font><font style="font-family:inherit;font-size:10pt;">16</font><font style="font-family:inherit;font-size:10pt;">-year term, the Company will pay an average of approximately </font><font style="font-family:inherit;font-size:10pt;">$10.2 million</font><font style="font-family:inherit;font-size:10pt;"> per year in aggregate rent, exclusive of operating expenses. The Company has the option to extend the lease term for up to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> additional </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year terms.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Term Loan</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2014, the Company entered into a credit agreement with the lenders party thereto, and Macquarie US Trading LLC ("Macquarie"), as administrative agent. The credit agreement provides for a </font><font style="font-family:inherit;font-size:10pt;">$300.0 million</font><font style="font-family:inherit;font-size:10pt;"> senior secured term loan ("Term Loan"). The credit agreement also provides that, subject to satisfaction of certain conditions, the Company may request that the lenders establish an incremental senior secured term loan facility in an aggregate amount not to exceed </font><font style="font-family:inherit;font-size:10pt;">$200.0 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Term Loan initially bore interest at a rate of </font><font style="font-family:inherit;font-size:10pt;">7.2%</font><font style="font-family:inherit;font-size:10pt;"> per annum, which was reduced to </font><font style="font-family:inherit;font-size:10pt;">6.2%</font><font style="font-family:inherit;font-size:10pt;"> per annum based on the FDA's approval of ORKAMBI. The Term Loan bears interest at a rate of LIBOR plus </font><font style="font-family:inherit;font-size:10pt;">5.0%</font><font style="font-family:inherit;font-size:10pt;"> per annum during the third year of the term.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The maturity date of all loans under the facilities is July 9, 2017. Interest is payable quarterly and on the maturity date. In October 2015, the Company amended the terms of the credit agreement to provide for, among other things, a modification to the repayment schedule of the loan. As amended, the Company is required to repay principal on the Term Loan in quarterly installments of </font><font style="font-family:inherit;font-size:10pt;">$75 million</font><font style="font-family:inherit;font-size:10pt;"> from October 1, 2016 through the maturity date. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company may prepay the Term Loan, in whole or in part, at any time; provided that prepayments prior to the July 9, 2016 are subject to a make-whole premium to ensure Macquarie receives approximately the present value of </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> years of interest payments over the life of the loan. The Company accounted for the amendment as a debt modification, as opposed to an extinguishment of debt, based on an insignificant change to the present value of the future cash flows relating to the credit agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's obligations under the Term Loan are unconditionally guaranteed by certain of its domestic subsidiaries. All obligations under the Term Loan, and the guarantees of those obligations, are secured, subject to certain exceptions, by substantially all of the Company's assets and the assets of all guarantors, including the pledge of all or a portion of the equity interests of certain of its subsidiaries. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The credit agreement requires that the Company maintain, on a quarterly basis, a minimum level of KALYDECO net revenues. Further, the credit agreement includes negative covenants, subject to exceptions, restricting or limiting the Company's ability and the ability of its subsidiaries to, among other things, incur additional indebtedness, grant liens, engage in certain investment, acquisition and disposition transactions, pay dividends, repurchase capital stock and enter into transactions with affiliates. The credit agreement also contains customary representations and warranties, affirmative covenants and events of default, including payment defaults, breach of representations and warranties, covenant defaults and cross defaults. If an event of default occurs, the administrative agent would be entitled to take various actions, including the acceleration of amounts due under outstanding loans. There have been no events of default as of or during the period ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on the Company's evaluation of the Term Loan, the Company determined that the Term Loan contains several embedded derivatives. These embedded derivatives are clearly and closely related to the host instrument because they relate to the Company's credit risk; therefore, they do not require bifurcation from the host instrument, the Term Loan.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company incurred </font><font style="font-family:inherit;font-size:10pt;">$5.3 million</font><font style="font-family:inherit;font-size:10pt;"> in fees paid to Macquarie that were recorded as a discount on the Term Loan and are being recorded as interest expense using the effective interest method over the term of the loan in the Company&#8217;s </font><font style="font-family:inherit;font-size:10pt;">condensed consolidated statements of operations</font><font style="font-family:inherit;font-size:10pt;">. </font><font style="font-family:inherit;font-size:10pt;">As of June 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, the unamortized discount associated with the Term Loan that was included in the senior secured term loan caption on the Company&#8217;s condensed consolidated balance sheet was </font><font style="font-family:inherit;font-size:10pt;">$3.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$4.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Hedging</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company maintains a hedging program intended to mitigate the effect of changes in foreign exchange rates for a portion of the Company&#8217;s forecasted product revenues denominated in certain foreign currencies. The program includes foreign currency forward contracts that are designated as cash flow hedges under GAAP having contractual durations from </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">eighteen</font><font style="font-family:inherit;font-size:10pt;"> months. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company formally documents the relationship between foreign currency forward contracts (hedging instruments) and forecasted product revenues (hedged items), as well as the Company's risk management objective and strategy for undertaking various hedging activities, which includes matching all foreign currency forward contracts that are designated as cash flow hedges to forecasted transactions. The Company also formally assesses, both at the hedge&#8217;s inception and on an ongoing basis, whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If the Company determines that a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, the Company would discontinue hedge accounting treatment prospectively. The Company measures effectiveness based on the change in fair value of the forward contracts and the fair value of the hypothetical foreign currency forward contracts with terms that match the critical terms of the risk being hedged. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, all hedges were determined to be highly effective and the Company had not recorded any ineffectiveness related to the hedging program.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the notional amount of the Company&#8217;s outstanding foreign currency forward contracts designated as cash flow hedges:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.52380952380952%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Foreign Currency</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">193,542</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">103,362</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">British pound sterling</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">79,845</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">78,756</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Australian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">28,318</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">27,167</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">301,705</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">209,285</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the fair value of the Company's outstanding foreign currency forward contracts designated as cash flow hedges under GAAP included on the Company's condensed consolidated balance sheets:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.84126984126983%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of June 30, 2016</font></div></td></tr><tr><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liabilities</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Classification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Classification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid and other current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,966</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, current portion</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,317</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,604</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, excluding current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(88</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,570</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,405</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.84126984126983%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liabilities</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Classification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Classification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid and other current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,161</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, current portion</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(769</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">605</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, excluding current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(132</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,766</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(901</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the potential effect of offsetting derivatives by type of financial instrument on the Company's condensed consolidated balance sheets:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.03174603174604%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of June 30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Recognized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Offset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Presented</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Not Offset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Legal Offset</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Foreign currency forward contracts</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,570</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,570</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,405</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,165</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,405</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,405</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,405</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.03174603174604%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Recognized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Offset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Presented</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Not Offset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Legal Offset</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Foreign currency forward contracts</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,766</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,766</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(901</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,865</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(901</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(901</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">901</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock-based Compensation Expense</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During </font><font style="font-family:inherit;font-size:10pt;">the three and six months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized the following stock-based compensation expense:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock-based compensation expense by type of award:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">31,826</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">37,687</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">58,086</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">66,646</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restricted stock and restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">29,608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24,902</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">57,141</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">52,071</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">ESPP share issuances</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,436</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,825</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,960</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,965</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less stock-based compensation expense capitalized to inventories</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(928</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,153</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,773</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,037</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total stock-based compensation included in costs and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">61,942</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">63,261</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">117,414</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">120,645</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock-based compensation expense by line item:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Research and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">40,640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">41,632</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">75,088</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">79,849</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Sales, general and administrative expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,302</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,629</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">42,326</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">40,796</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total stock-based compensation included in costs and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">61,942</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">63,261</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">117,414</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">120,645</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the Company's unrecognized stock-based compensation expense, net of estimated forfeitures, by type of award and the weighted-average period over which that expense is expected to be recognized:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:80.55555555555556%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:25%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of June&#160;30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unrecognized Expense,<br clear="none"/>Net of <br clear="none"/>Estimated Forfeitures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Recognition <br clear="none"/>Period</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in years)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Type of award:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">176,251</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.66</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restricted stock and restricted stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">201,858</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.57</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">ESPP share issuances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,546</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.64</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information about stock options outstanding and exercisable at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.28571428571429%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Range of Exercise Prices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number <br clear="none"/>Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Remaining <br clear="none"/>Contractual Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number <br clear="none"/>Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(per share)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(per share)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$18.93&#8211;$20.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">137</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">137</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$20.01&#8211;$40.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,964</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.45</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34.24</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,962</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34.23</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$40.01&#8211;$60.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,066</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">48.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,657</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">48.66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$60.01&#8211;$80.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,368</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.62</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">75.90</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">734</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">75.39</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$80.01&#8211;$100.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,555</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">90.68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">88.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$100.01&#8211;$120.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,644</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8.57</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">109.32</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">109.27</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$120.01&#8211;$134.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,497</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">130.61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">420</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">129.84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,231</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">79.37</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,490</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">63.32</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Earnings Per Share</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period, excluding restricted stock and restricted stock units that have been issued but are not yet vested. Diluted net loss per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period when the effect is dilutive. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company did not include the securities in the following table in the computation of the net loss per share attributable to Vertex common shareholders calculations because the effect would have been anti-dilutive during each period:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,231</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,231</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Unvested restricted stock and restricted stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,506</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,355</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,506</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,355</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the Company&#8217;s financial assets and liabilities reflects the Company&#8217;s estimate of amounts that it would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company&#8217;s assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.4920634920635%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:88%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;1:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;2:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Observable inputs other than Level&#160;1 inputs. Examples of Level&#160;2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;3:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unobservable inputs based on the Company&#8217;s assessment of the assumptions that market participants would use in pricing the asset or liability.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s investment strategy is focused on capital preservation. The Company invests in instruments that meet the credit quality standards outlined in the Company&#8217;s investment policy. This policy also limits the amount of credit exposure to any one issue or type of instrument. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s investments were in money market funds, short-term government-sponsored enterprise securities, U.S. Treasury securities, corporate debt securities and commercial paper.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, all of the Company&#8217;s financial assets that were subject to fair value measurements were valued using observable inputs. The Company&#8217;s financial assets valued based on Level&#160;1 inputs consisted of money market funds, short-term government-sponsored enterprise securities and U.S. Treasury securities. The Company&#8217;s financial assets valued based on Level 2 inputs consisted of corporate debt securities and commercial paper, which consisted of investments in highly-rated investment-grade corporations. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the Company&#8217;s financial assets (excluding VIE cash and cash equivalents) and liabilities subject to fair value measurements:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value Measurements as <br clear="none"/>of June 30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value Hierarchy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Financial assets carried at fair value:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">110,696</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">110,696</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">U.S. Treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33,142</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33,142</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">131,900</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">131,900</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">135,675</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">135,675</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">164,853</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">164,853</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid and other current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,966</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,966</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,604</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,604</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total financial assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">587,836</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">275,738</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">312,098</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Financial liabilities carried at fair value:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,317</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,317</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, excluding current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(88</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(88</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total financial liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,405</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,405</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.42857142857143%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:54%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements as <br clear="none"/>of December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value Hierarchy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Financial instruments carried at fair value (asset position):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">199,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">199,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">85,994</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">85,994</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34,889</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34,889</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,533</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,533</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">87,162</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">87,162</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">99,123</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">99,123</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">141,409</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">141,409</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid and other current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,161</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,161</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">605</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">605</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total financial assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">665,383</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">372,663</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">292,720</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Financial instruments carried at fair value (liability position):</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(769</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(769</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, excluding current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(132</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(132</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total financial liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(901</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(901</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's VIEs invested in cash equivalents consisting of money market funds of </font><font style="font-family:inherit;font-size:10pt;">$70.2 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, which are valued based on Level 1 inputs. These cash equivalents are not included in the table above. The Company&#8217;s noncontrolling interest related to VIEs includes </font><font style="font-family:inherit;font-size:10pt;">the fair value of the contingent milestone and royalty payments</font><font style="font-family:inherit;font-size:10pt;">, which are valued based on Level 3 inputs. Please refer to Note C, &#8220;Collaborative Arrangements,&#8221; for further information.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of June 30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the fair value and carrying value of the Company's Term Loan was </font><font style="font-family:inherit;font-size:10pt;">$296.5 million</font><font style="font-family:inherit;font-size:10pt;">. The fair value of the Company's Term Loan was estimated based on Level 3 inputs computed using the effective interest rate of the Term Loan. The effective interest rate considers the timing and amount of estimated future interest payments as well as current market rates. Please refer to Note K, "Long-term Obligations" for further information regarding the Company's Term Loan.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intangible Assets and Goodwill</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangible Assets</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, in-process research and development intangible assets of </font><font style="font-family:inherit;font-size:10pt;">$284.3 million</font><font style="font-family:inherit;font-size:10pt;"> were recorded on the Company's condensed consolidated balance sheet. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2015, in connection with entering into the Parion Agreement, the Company recorded an in-process research and development intangible asset of </font><font style="font-family:inherit;font-size:10pt;">$255.3 million</font><font style="font-family:inherit;font-size:10pt;"> based on the Company&#8217;s estimate of the fair value of Parion&#8217;s lead investigational ENaC inhibitors, including VX-371 and VX-551, that were licensed by the Company from Parion. The Company aggregated the fair value of the ENaC inhibitors into a single intangible asset because the phase, nature and risks of development as well as the amount and timing of benefits associated with the assets were similar. In October 2014, the Company recorded an in-process research and development intangible asset of </font><font style="font-family:inherit;font-size:10pt;">$29.0 million</font><font style="font-family:inherit;font-size:10pt;"> based on the Company&#8217;s estimate of the fair value of VX-210, a drug candidate for patients with spinal cord injuries that was licensed by the Company from BioAxone. The Company used discount rates of </font><font style="font-family:inherit;font-size:10pt;">7.1%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">7.5%</font><font style="font-family:inherit;font-size:10pt;"> in the present-value models to estimate the fair values of the ENaC inhibitors and VX-210 intangible assets, respectively. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, goodwill of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$50.4 million</font><font style="font-family:inherit;font-size:10pt;"> was recorded on the Company's condensed consolidated balance sheet.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is subject to United States federal, state, and foreign income taxes. For </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">the three and six months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded a </font><font style="font-family:inherit;font-size:10pt;">provision for income taxes</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;">$18.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$23.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The provision for income taxes recorded in </font><font style="font-family:inherit;font-size:10pt;">the three and six months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> included </font><font style="font-family:inherit;font-size:10pt;">$17.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$20.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to the Company's VIEs' income tax provision. The Company has no liability for taxes payable by the Company's VIEs and the income tax provision and related liability have been allocated to noncontrolling interest (VIE). For </font><font style="font-family:inherit;font-size:10pt;">the three and six months ended June 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded a </font><font style="font-family:inherit;font-size:10pt;">provision for income taxes</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;">$30.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$30.4 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, primarily related to the Company's VIEs' income tax provision. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company had unrecognized tax benefits of </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">. The Company recognizes interest and penalties related to income taxes as a component of income tax expense. </font><font style="font-family:inherit;font-size:10pt;">As of June 30, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> interest and penalties have been accrued. The Company does not expect that its unrecognized tax benefits will materially increase within the next twelve months. The Company did not recognize any material interest or penalties related to uncertain tax positions as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">. In 2016, it is reasonably possible that the Company will reduce the balance of its unrecognized tax benefits by approximately </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> due to the application of statute of limitations and settlements with taxing authorities, all of which would reduce the Company&#8217;s effective tax rate.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company continues to maintain a valuation allowance against certain deferred tax assets where it is more likely than not that the deferred tax asset will not be realized because of its extended history of annual losses. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company files United States federal income tax returns and income tax returns in various state, local and foreign jurisdictions. The Company is no longer subject to any tax assessment from an income tax examination in the United States before 2011 or any other major taxing jurisdiction for years before 2009, except where the Company has net operating losses or tax credit carryforwards that originated before 2009. The Company currently is under examination by the Internal Revenue Service for the year ended December 31, 2011 and in Delaware, Canada and Quebec for varying periods including the years ended December 31, 2011 through 2014. No adjustments have been reported. The Company is not under examination by any other jurisdictions for any tax year. The Company concluded audits with Pennsylvania and Texas during 2016 and Massachusetts and New York during 2015 with no material adjustments.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company currently intends to reinvest the total amount of its unremitted earnings. At </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, foreign earnings, which were not significant, have been retained indefinitely by foreign subsidiary companies for reinvestment; therefore, no provision has been made for income taxes that would be payable upon the distribution of such earnings, and it would not be practicable to determine the amount of the related unrecognized deferred income tax liability. Upon repatriation of those earnings, in the form of dividends or otherwise, the Company would be subject to United States federal income taxes (subject to an adjustment for foreign tax credits) and withholding taxes payable to the various foreign countries.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inventories</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consisted of the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.52380952380952%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,408</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,696</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Work-in-process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">45,807</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">40,695</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,374</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,816</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">66,589</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">57,207</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued amended guidance applicable to leases that will be effective for the year ending December 31, 2019. Early adoption is permitted. This update requires an entity to recognize assets and liabilities for leases with lease terms of more than 12 months on the balance sheet. The Company is in the process of evaluating the new guidance and determining the expected effect on its consolidated financial statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2016, the FASB issued amended guidance applicable to share-based compensation to employees that will be effective for the year ending December 31, 2017. Early adoption is permitted. This update simplifies the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The Company is in the process of evaluating the new guidance and determining the expected effect on its consolidated financial statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For a discussion of other recent accounting pronouncements please refer to Note&#160;A, &#8220;Nature of Business and Accounting Policies&#8212;Recent Accounting Pronouncements,&#8221; in the </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> Annual Report on Form&#160;10-K. The Company did not adopt any new accounting pronouncements during the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> that had a material effect on its condensed consolidated financial statements.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation and Accounting Policies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company") in accordance with accounting principles generally accepted in the United States of America ("GAAP"). </font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements reflect the operations of (i) the Company, (ii) its wholly-owned subsidiaries and (iii) consolidated variable interest entities (VIEs). All material intercompany balances and transactions have been eliminated. The Company operates in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">one</font><font style="font-family:inherit;font-size:10pt;"> segment, pharmaceuticals.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, which are contained in the Company's Annual Report on Form&#160;10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> that was filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on </font><font style="font-family:inherit;font-size:10pt;">February&#160;16, 2016</font><font style="font-family:inherit;font-size:10pt;"> (the "</font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> Annual Report on Form&#160;10-K").</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates and Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. Significant estimates in these condensed consolidated financial statements have been made in connection with the calculation of revenues, inventories, research and development expenses, stock-based compensation expense, restructuring expense, the fair value of intangible assets, goodwill, contingent consideration, noncontrolling interest, the consolidation of VIEs, leases, the fair value of cash flow hedges and the provision for or benefit from income taxes. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's significant accounting policies are described in Note&#160;A, "Nature of Business and Accounting Policies," in the </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> Annual Report on Form&#160;10-K.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued amended guidance applicable to leases that will be effective for the year ending December 31, 2019. Early adoption is permitted. This update requires an entity to recognize assets and liabilities for leases with lease terms of more than 12 months on the balance sheet. The Company is in the process of evaluating the new guidance and determining the expected effect on its consolidated financial statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2016, the FASB issued amended guidance applicable to share-based compensation to employees that will be effective for the year ending December 31, 2017. Early adoption is permitted. This update simplifies the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The Company is in the process of evaluating the new guidance and determining the expected effect on its consolidated financial statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For a discussion of other recent accounting pronouncements please refer to Note&#160;A, &#8220;Nature of Business and Accounting Policies&#8212;Recent Accounting Pronouncements,&#8221; in the </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> Annual Report on Form&#160;10-K. The Company did not adopt any new accounting pronouncements during the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> that had a material effect on its condensed consolidated financial statements.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Arrangements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Sale of HIV Protease Inhibitor Royalty Stream</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2008, the Company sold to a third party its rights to receive royalty payments from GlaxoSmithKline&#160;plc, net of royalty amounts to be earned by and due to a third party, for a one-time cash payment of </font><font style="font-family:inherit;font-size:10pt;">$160.0 million</font><font style="font-family:inherit;font-size:10pt;">. These royalty payments relate to net sales of HIV protease inhibitors, which had been developed pursuant to a collaboration agreement between the Company and GlaxoSmithKline&#160;plc. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">$18.9 million</font><font style="font-family:inherit;font-size:10pt;"> in deferred revenues related to the one-time cash payment, which it is recognizing over the life of the collaboration agreement with GlaxoSmithKline&#160;plc based on the units-of-revenue method. In addition, the Company continues to recognize royalty revenues equal to the amount of the third-party subroyalty and an offsetting royalty expense for the third-party subroyalty payment.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring Liabilities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2003 Kendall Restructuring</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2003, the Company adopted a plan to restructure its operations to coincide with its increasing internal emphasis on advancing drug candidates through clinical development to commercialization. The restructuring liability relates to specialized laboratory and office space that is leased to the Company pursuant to a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">15</font><font style="font-family:inherit;font-size:10pt;">-year lease that terminates in 2018. The Company has not used more than </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> of this space since it adopted the plan to restructure its operations in 2003. This unused laboratory and office space currently is subleased to third parties. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The activities related to the restructuring liability for </font><font style="font-family:inherit;font-size:10pt;">the three and six months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,224</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,506</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,944</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,596</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,833</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,584</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,764</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(6,569</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash received from subleases</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,008</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,799</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,275</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restructuring expense (income)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(11</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">203</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">192</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(378</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,388</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,924</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,388</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,924</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fan Pier Move Restructuring</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the relocation of its Massachusetts operations to Fan Pier in Boston, Massachusetts, which commenced in 2013, the Company is incurring restructuring charges related to its remaining lease obligations at its facilities in Cambridge, Massachusetts. The majority of these restructuring charges were recorded in the third quarter of 2014 upon decommissioning </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> facilities in Cambridge. During the first quarter of 2015, the Company terminated </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> of these lease agreements resulting in a credit to restructuring expense equal to the difference between the Company&#8217;s estimated future cash flows related to its lease obligations for these facilities and the termination payment paid to the Company&#8217;s landlord on the effective date of the termination. The third major facility included in this restructuring activity is </font><font style="font-family:inherit;font-size:10pt;">120,000</font><font style="font-family:inherit;font-size:10pt;"> square feet of the </font><font style="font-family:inherit;font-size:10pt;">Kendall Square Facility</font><font style="font-family:inherit;font-size:10pt;"> that the Company continued to use for its operations following its </font><font style="font-family:inherit;font-size:10pt;">2003 Kendall Restructuring</font><font style="font-family:inherit;font-size:10pt;">. The rentable square footage in this portion of the </font><font style="font-family:inherit;font-size:10pt;">Kendall Square Facility</font><font style="font-family:inherit;font-size:10pt;"> was subleased to a third party in February 2015. The Company will continue to incur charges through April 2018 related to the difference between the Company&#8217;s estimated future cash flows related to this portion of the </font><font style="font-family:inherit;font-size:10pt;">Kendall Square Facility</font><font style="font-family:inherit;font-size:10pt;">, which include an estimate for sublease income to be received from the Company's sublessee and its actual cash flows. The Company discounted the estimated cash flows related to this restructuring activity at a discount rate of </font><font style="font-family:inherit;font-size:10pt;">9%</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The activities related to the restructuring liability for </font><font style="font-family:inherit;font-size:10pt;">the three and six months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,449</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,137</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,964</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33,390</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,096</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,095</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(6,252</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(22,351</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash received from subleases</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,361</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,769</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restructuring expense (income)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">149</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">975</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">382</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,022</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,863</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,863</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Restructuring Activities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has engaged in several other restructuring activities that are unrelated to its </font><font style="font-family:inherit;font-size:10pt;">2003 Kendall Restructuring</font><font style="font-family:inherit;font-size:10pt;"> and the </font><font style="font-family:inherit;font-size:10pt;">Fan Pier Move Restructuring</font><font style="font-family:inherit;font-size:10pt;">. The most significant activity commenced in October 2013 when the Company adopted a restructuring plan that included (i) a workforce reduction primarily related to the commercial support of INCIVEK following the continued and rapid decline in the number of patients being treated with INCIVEK as new medicines for the treatment of HCV infection neared approval and (ii) the write-off of certain assets. This action resulted from the Company's decision to focus its investment on future opportunities in CF and other research and development programs.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The activities related to the Company's other restructuring liabilities for </font><font style="font-family:inherit;font-size:10pt;">the three and six months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,262</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">845</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,450</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">869</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(234</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(893</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(673</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,223</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restructuring expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">205</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">950</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">456</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,256</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,233</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">902</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,233</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">902</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the Company's changes in accumulated other comprehensive (loss) income by component is shown below:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign Currency Translation Adjustment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Holding Gains (Losses) on Marketable Securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Gains on Foreign Currency Forward Contracts, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">126</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,778</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,824</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other comprehensive (loss) income before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5,201</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,847</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,154</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Amounts reclassified from accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,060</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,060</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net current period other comprehensive (loss) income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5,201</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(213</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5,214</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at June 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,281</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">326</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,565</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,390</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign Currency Translation Adjustment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Holding (Losses) Gains on Marketable Securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Foreign Currency Forward Contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(971</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(123</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">917</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other comprehensive (loss) income before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,220</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">130</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,370</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(20</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Amounts reclassified from accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,604</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,604</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net current period other comprehensive (loss) income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,220</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">130</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,974</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,624</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at June 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">249</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,963</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,707</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company did not include the securities in the following table in the computation of the net loss per share attributable to Vertex common shareholders calculations because the effect would have been anti-dilutive during each period:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,231</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,231</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Unvested restricted stock and restricted stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,506</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,355</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,506</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,355</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the Company&#8217;s cash, cash equivalents and marketable securities is shown below:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross <br clear="none"/>Unrealized <br clear="none"/>Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross <br clear="none"/>Unrealized <br clear="none"/>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of June 30, 2016</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">605,866</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">605,866</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">605,866</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">605,866</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">U.S. Treasury securities (due within 1&#160;year)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33,138</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33,142</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities (due within 1&#160;year)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">131,868</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">131,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper (due within 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">164,575</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">278</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">164,853</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities (due within 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">135,663</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">135,675</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">465,244</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">351</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(25</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">465,570</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,071,110</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">351</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(25</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,071,436</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2015</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">582,352</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">582,352</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">85,994</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">85,994</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34,889</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34,889</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,533</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,533</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">714,768</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">714,768</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities (due within 1&#160;year)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">87,176</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">87,162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper (due within 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">98,877</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">246</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">99,123</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities (due within 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">141,515</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(106</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">141,409</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">327,568</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">246</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(120</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">327,694</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,042,336</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">246</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(120</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,042,462</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During </font><font style="font-family:inherit;font-size:10pt;">the three and six months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized the following stock-based compensation expense:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock-based compensation expense by type of award:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">31,826</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">37,687</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">58,086</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">66,646</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restricted stock and restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">29,608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24,902</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">57,141</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">52,071</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">ESPP share issuances</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,436</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,825</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,960</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,965</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less stock-based compensation expense capitalized to inventories</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(928</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,153</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,773</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,037</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total stock-based compensation included in costs and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">61,942</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">63,261</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">117,414</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">120,645</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock-based compensation expense by line item:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Research and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">40,640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">41,632</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">75,088</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">79,849</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Sales, general and administrative expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,302</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,629</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">42,326</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">40,796</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total stock-based compensation included in costs and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">61,942</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">63,261</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">117,414</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">120,645</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the Company&#8217;s financial assets (excluding VIE cash and cash equivalents) and liabilities subject to fair value measurements:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value Measurements as <br clear="none"/>of June 30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value Hierarchy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Financial assets carried at fair value:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">110,696</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">110,696</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">U.S. Treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33,142</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33,142</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">131,900</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">131,900</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">135,675</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">135,675</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">164,853</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">164,853</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid and other current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,966</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,966</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,604</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,604</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total financial assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">587,836</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">275,738</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">312,098</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Financial liabilities carried at fair value:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,317</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,317</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, excluding current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(88</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(88</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total financial liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,405</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,405</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.42857142857143%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:54%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements as <br clear="none"/>of December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value Hierarchy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Financial instruments carried at fair value (asset position):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">199,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">199,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">85,994</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">85,994</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34,889</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34,889</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,533</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,533</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">87,162</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">87,162</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">99,123</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">99,123</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">141,409</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">141,409</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid and other current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,161</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,161</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">605</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">605</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total financial assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">665,383</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">372,663</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">292,720</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Financial instruments carried at fair value (liability position):</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(769</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(769</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, excluding current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(132</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(132</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total financial liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(901</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(901</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the fair value of the Company's outstanding foreign currency forward contracts designated as cash flow hedges under GAAP included on the Company's condensed consolidated balance sheets:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.84126984126983%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of June 30, 2016</font></div></td></tr><tr><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liabilities</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Classification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Classification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid and other current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,966</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, current portion</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,317</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,604</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, excluding current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(88</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,570</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,405</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.84126984126983%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liabilities</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Classification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Classification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid and other current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,161</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, current portion</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(769</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">605</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, excluding current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(132</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,766</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(901</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consisted of the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.52380952380952%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,408</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,696</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Work-in-process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">45,807</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">40,695</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,374</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,816</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">66,589</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">57,207</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the notional amount of the Company&#8217;s outstanding foreign currency forward contracts designated as cash flow hedges:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.52380952380952%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Foreign Currency</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">193,542</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">103,362</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">British pound sterling</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">79,845</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">78,756</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Australian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">28,318</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">27,167</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">301,705</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">209,285</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The activities related to the Company's other restructuring liabilities for </font><font style="font-family:inherit;font-size:10pt;">the three and six months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,262</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">845</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,450</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">869</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(234</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(893</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(673</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,223</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restructuring expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">205</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">950</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">456</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,256</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,233</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">902</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,233</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">902</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The activities related to the restructuring liability for </font><font style="font-family:inherit;font-size:10pt;">the three and six months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,449</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,137</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,964</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33,390</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,096</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,095</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(6,252</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(22,351</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash received from subleases</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,361</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,769</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restructuring expense (income)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">149</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">975</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">382</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,022</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,863</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,863</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The activities related to the restructuring liability for </font><font style="font-family:inherit;font-size:10pt;">the three and six months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,224</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,506</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,944</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,596</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,833</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,584</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,764</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(6,569</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash received from subleases</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,008</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,799</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,275</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restructuring expense (income)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(11</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">203</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">192</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(378</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,388</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,924</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,388</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,924</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information about stock options outstanding and exercisable at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.28571428571429%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Range of Exercise Prices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number <br clear="none"/>Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Remaining <br clear="none"/>Contractual Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number <br clear="none"/>Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(per share)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(per share)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$18.93&#8211;$20.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">137</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">137</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$20.01&#8211;$40.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,964</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.45</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34.24</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,962</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34.23</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$40.01&#8211;$60.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,066</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">48.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,657</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">48.66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$60.01&#8211;$80.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,368</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.62</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">75.90</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">734</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">75.39</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$80.01&#8211;$100.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,555</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">90.68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">88.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$100.01&#8211;$120.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,644</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8.57</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">109.32</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">109.27</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$120.01&#8211;$134.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,497</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">130.61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">420</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">129.84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,231</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">79.37</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,490</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">63.32</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates and Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. Significant estimates in these condensed consolidated financial statements have been made in connection with the calculation of revenues, inventories, research and development expenses, stock-based compensation expense, restructuring expense, the fair value of intangible assets, goodwill, contingent consideration, noncontrolling interest, the consolidation of VIEs, leases, the fair value of cash flow hedges and the provision for or benefit from income taxes. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During </font><font style="font-family:inherit;font-size:10pt;">the three and six months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the increase (decrease) in </font><font style="font-family:inherit;font-size:10pt;">the fair value of the contingent milestone and royalty payments</font><font style="font-family:inherit;font-size:10pt;"> related to the Company's VIEs was as follows:</font></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.42857142857143%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Parion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">48,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,621</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">57,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,621</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">BioAxone</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">320</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">423</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">750</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">548</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the potential effect of offsetting derivatives by type of financial instrument on the Company's condensed consolidated balance sheets:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.03174603174604%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of June 30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Recognized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Offset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Presented</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Not Offset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Legal Offset</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Foreign currency forward contracts</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,570</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,570</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,405</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,165</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,405</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,405</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,405</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.03174603174604%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Recognized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Offset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Presented</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Not Offset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Legal Offset</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Foreign currency forward contracts</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,766</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,766</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(901</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,865</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(901</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(901</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">901</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Product Revenues, Net </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company sells its products principally to a limited number of specialty pharmacy providers and selected regional wholesalers in North America as well as government-owned and supported customers in international markets (collectively, its &#8220;Customers&#8221;). The Company's Customers in North America subsequently resell the products to patients and health care providers. The Company recognizes net revenues from product sales upon delivery to the Customer as long as (i)&#160;there is persuasive evidence that an arrangement exists between the Company and the Customer, (ii)&#160;collectibility is reasonably assured and (iii)&#160;the price is fixed or determinable. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to conclude that the price is fixed or determinable, the Company must be able to (i)&#160;calculate its gross product revenues from sales to Customers and (ii)&#160;reasonably estimate its net product revenues upon delivery to its Customers' locations. The Company calculates gross product revenues based on the price that the Company charges its Customers. The Company estimates its net product revenues by deducting from its gross product revenues (a)&#160;trade allowances, such as invoice discounts for prompt payment and Customer fees, (b)&#160;estimated government and private payor rebates, chargebacks and discounts, (c)&#160;estimated reserves for expected product returns and (d)&#160;estimated costs of co-pay assistance programs for patients, as well as other incentives for certain indirect customers.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company makes significant estimates and judgments that materially affect the Company's recognition of net product revenues. In certain instances, the Company may be unable to reasonably conclude that the price is fixed or determinable at the time of delivery, in which case it defers the recognition of revenues. Once the Company is able to determine that the price is fixed or determinable, it recognizes the revenues associated with the units in which revenue recognition was deferred.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes activity in each of the product revenue allowance and reserve categories for the </font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">: </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.42857142857143%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Trade <br clear="none"/>Allowances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Rebates, <br clear="none"/>Chargebacks <br clear="none"/>and Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Product <br clear="none"/>Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Other <br clear="none"/>Incentives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,089</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">44,669</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,228</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">49,296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Provision related to current period sales</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,935</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">65,066</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,288</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,220</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">80,509</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Adjustments related to prior period sales</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,712</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(205</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,989</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Credits/payments made</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(9,762</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(44,113</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(260</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,638</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(58,773</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at June 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,185</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">63,910</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,051</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">897</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">69,043</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the three and six months ended June 30, 2016, the Company sold ORKAMBI in France pursuant to early access programs. The Company has not recognized any product revenues based on these sales because the price is not fixed or determinable due to the ongoing negotiations regarding the reimbursement rate for ORKAMBI in France. If the negotiated reimbursement rate in France is lower than the price currently being paid by Customers in France under these programs, the Company would reimburse the difference between such prices to the Customers. The cash received from sales in France is included as a liability on the Company's condensed consolidated balance sheet, and the increase in "other liabilities, current portion" from December 31, 2015 to June 30, 2016 is primarily due to this liability.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">An aggregate summary of net loss attributable to noncontrolling interest related to the Company's VIEs for </font><font style="font-family:inherit;font-size:10pt;">the three and six months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> is as follows:</font></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.42857142857143%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Loss attributable to noncontrolling interest before provision for income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,835</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,293</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,674</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,579</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Provision for income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">17,511</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">29,653</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">20,573</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">29,590</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Increase) decrease in fair value of contingent milestone and royalty payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(48,720</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,198</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(58,150</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,073</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net (income) loss attributable to noncontrolling interest</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(28,374</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">32,144</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(33,903</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">32,242</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes items related to the Company's VIEs included in the Company's condensed consolidated balance sheets as of the dates set forth in the table:</font></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.42857142857143%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restricted cash and cash equivalents (VIE)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">70,513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">78,910</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,001</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,138</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">284,340</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">284,340</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,391</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,391</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">455</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,129</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">676</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Taxes payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,723</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24,554</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,059</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,100</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Deferred tax liability, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">132,810</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">110,438</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">310</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">300</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Noncontrolling interest</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">187,491</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">153,661</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes activity in each of the product revenue allowance and reserve categories for the </font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">: </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.42857142857143%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Trade <br clear="none"/>Allowances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Rebates, <br clear="none"/>Chargebacks <br clear="none"/>and Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Product <br clear="none"/>Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Other <br clear="none"/>Incentives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,089</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">44,669</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,228</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">49,296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Provision related to current period sales</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,935</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">65,066</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,288</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,220</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">80,509</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Adjustments related to prior period sales</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,712</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(205</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,989</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Credits/payments made</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(9,762</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(44,113</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(260</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,638</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(58,773</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at June 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,185</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">63,910</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,051</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">897</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">69,043</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the Company's unrecognized stock-based compensation expense, net of estimated forfeitures, by type of award and the weighted-average period over which that expense is expected to be recognized:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:80.55555555555556%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:25%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of June&#160;30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unrecognized Expense,<br clear="none"/>Net of <br clear="none"/>Estimated Forfeitures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Recognition <br clear="none"/>Period</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in years)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Type of award:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">176,251</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.66</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restricted stock and restricted stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">201,858</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.57</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">ESPP share issuances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,546</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.64</font></div></td></tr></table></div></div></div> EX-101.SCH 7 vrtx-20160630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2108100 - Disclosure - Accumulated Other Comprehensive (Loss) Income link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Accumulated Other Comprehensive (Loss) Income Accumulated Other Comprehensive (Loss) Income (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Basis of Presentation and Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2401402 - Disclosure - Basis of Presentation and Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Basis of Presentation and Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Collaborative Arrangement - Cystic Fibrosis Foundation Therapeutics Incorporated (Details) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Collaborative Arrangements link:presentationLink link:calculationLink link:definitionLink 2404406 - Disclosure - Collaborative Arrangements - Aggregate VIE Financial Information (Details) link:presentationLink link:calculationLink link:definitionLink 2404405 - Disclosure - Collaborative Arrangements Collaborative Arrangements - BioAxone Biosciences, Inc. (Details) link:presentationLink link:calculationLink link:definitionLink 2404407 - Disclosure - Collaborative Arrangements Collaborative Arrangements - Janssen Pharmaceuticals, Inc. (Details) link:presentationLink link:calculationLink link:definitionLink 2404408 - Disclosure - Collaborative Arrangements Collaborative Arrangements - Moderna Therapeutics, Inc. (Details) link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Collaborative Arrangements - CRISPR Therapeutics AG (Details) link:presentationLink link:calculationLink link:definitionLink 2404404 - Disclosure - Collaborative Arrangements - Parion Sciences, Inc. (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Collaborative Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 2122100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2422401 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 1003501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Condensed Consolidated Balance Sheets (unaudited) link:presentationLink link:calculationLink link:definitionLink 1006000 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Statements of Operations (unaudited) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Statements of Operations (unaudited) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Condensed Consolidated Statements of Shareholders' Equity and Noncontrolling Interest (unaudited) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Hedging link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Hedging (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Hedging (Tables) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2419401 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Intangible Assets and Goodwill link:presentationLink link:calculationLink link:definitionLink 2413401 - Disclosure - Intangible Assets and Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Inventories - Schedule of Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Long-term Obligations link:presentationLink link:calculationLink link:definitionLink 2415401 - Disclosure - Long-term Obligations - Fan Pier Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Long-term Obligations - San Diego Lease (Details) link:presentationLink link:calculationLink link:definitionLink 2415403 - Disclosure - Long-term Obligations - Term Loan (Details) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Marketable Securities link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 2118100 - Disclosure - Other Arrangements link:presentationLink link:calculationLink link:definitionLink 2418401 - Disclosure - Other Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Product Revenues, Net link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Product Revenues, Net (Details) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - Product Revenues, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2120100 - Disclosure - Restructuring Liabilities link:presentationLink link:calculationLink link:definitionLink 2420403 - Disclosure - Restructuring Liabilities - Activity Related to Restructuring Liability (Details) link:presentationLink link:calculationLink link:definitionLink 2420402 - Disclosure - Restructuring Liabilities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2320301 - Disclosure - Restructuring Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Stock-based Compensation Expense link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - Stock-based Compensation Expense - Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2416403 - Disclosure - Stock-based Compensation Expense - Stock Options Outstanding and Exercisable (Details) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - Stock-based Compensation Expense (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 vrtx-20160630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 vrtx-20160630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 vrtx-20160630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Organization, Consolidation and Presentation of Financial Statements [Abstract] Schedule of Collaborative Arrangement Activity Net Loss Attributable to Noncontrolling Interest Schedule of Collaborative Arrangement Activity Net Loss Attributable to Noncontrolling Interest [Table Text Block] Represents the summary of activity related to the Alios Collaboration. Changes In Fair Value Of Contingent Consideration [Table Text Block] Changes In Fair Value Of Contingent Consideration [Table Text Block] Changes In Fair Value Of Contingent Consideration Schedule Of Collaborative Arrangement Summary Of Items Related To Variable Interest Entities Schedule Of Collaborative Arrangement Summary Of Items Related To Variable Interest Entities [Table Text Block] Represents details pertaining to Variable Interest Entities assets and liabilities included in the company's condensed consolidated balance sheets. Equity [Abstract] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Foreign Currency Translation Adjustment Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Unrealized Holding Gains (Losses) on Marketable Securities Accumulated Net Investment Gain (Loss) Attributable to Parent [Member] Unrealized Gains on Foreign Currency Forward Contracts, net of tax Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Balance at balance sheet date Accumulated Other Comprehensive Income (Loss), Net of Tax Other comprehensive (loss) income before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Amounts reclassified from accumulated other comprehensive loss Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Total changes in other comprehensive loss Other Comprehensive Income (Loss), Net of Tax Balance at balance sheet date Derivative Instruments and Hedging Activities Disclosure [Abstract] Hedging Derivative Instruments and Hedging Activities Disclosure [Text Block] Cash and Cash Equivalents [Abstract] Marketable Securities Cash, Cash Equivalents, and Marketable Securities [Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Stock-based compensation expense by line item Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Unrecognized stock-based compensation expense, net of estimated forfeitures Schedule of Unrecognized Share-based Compensation Expense [Table Text Block] Disclosure as of the latest balance-sheet date presented of the total compensation cost related to outstanding, nonvested share-based compensation awards not yet recognized, net of estimated forfeitures, and the weighted average period over which those unrecognized costs are expected to be reported. Stock options outstanding and exercisable Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block] Fair Value Disclosures [Abstract] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Variable Interest Entities [Axis] Variable Interest Entities [Axis] Variable Interest Entity, Classification [Domain] Variable Interest Entity, Classification [Domain] Variable Interest Entity, Primary Beneficiary Variable Interest Entity, Primary Beneficiary [Member] Asset Class [Axis] Asset Class [Axis] Asset Class [Domain] Asset Class [Domain] Prepaid and other current assets Prepaid Expenses and Other Current Assets [Member] Other Assets Other Assets [Member] Other liabilities, current portion Other Current Liabilities [Member] Other liabilities, excluding current portion Other Noncurrent Liabilities [Member] Collaborative Arrangements by Agreement [Axis] Collaborative Arrangements by Agreement [Axis] Significant terms of collaboration arrangements, by individual agreement. Collaborative Arrangement Agreement [Domain] Collaborative Arrangement Agreement [Domain] Listing of significant collaboration agreements. BioAxone Biosciences Inc BioAxone Biosciences Inc [Member] BioAxone Biosciences Inc [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Foreign currency forward contracts Foreign Exchange Forward [Member] Fair Value by Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Recurring basis Fair Value, Measurements, Recurring [Member] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Level 1 Fair Value, Inputs, Level 1 [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Investment Type [Axis] Investment Type [Axis] Investment Type Categorization [Domain] Investments [Domain] Money market funds Money Market Funds [Member] Commercial paper Commercial Paper [Member] U.S. Treasury securities US Treasury Securities [Member] Government-sponsored enterprise securities US Government-sponsored Enterprises Debt Securities [Member] Corporate debt securities Corporate Debt Securities [Member] Fair value of financial assets and liabilities Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Financial assets carried at fair value: Assets, Fair Value Disclosure [Abstract] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Marketable securities Marketable Securities Foreign currency forward contracts Foreign Currency Cash Flow Hedge Derivative at Fair Value, Net Total financial assets Assets, Fair Value Disclosure Financial instruments carried at fair value (liability position): Liabilities, Fair Value Disclosure [Abstract] Derivative liability current Derivative Liability, Current Derivative liability noncurrent Derivative Liability, Noncurrent Total financial liabilities Financial Liabilities Fair Value Disclosure Cash and cash equivalents Variable Interest Entity, Consolidated, Carrying Amount, Cash and Cash Equivalents Variable Interest Entity, Consolidated, Carrying Amount, Cash and Cash Equivalents Term loan fair value Loans Payable, Fair Value Disclosure Summary of cash, cash equivalents and marketable securities Cash, Cash Equivalents and Investments [Table Text Block] Derivative [Table] Derivative [Table] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Hedging Designation [Axis] Hedging Designation [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Designated as hedging instrument Designated as Hedging Instrument [Member] Other assets Currency [Axis] Currency [Axis] All Currencies [Domain] All Currencies [Domain] Euro Euro Member Countries, Euro British pound sterling United Kingdom, Pounds Australian dollar Australia, Dollars Foreign Currency Forward Contract Hedging Relationship [Axis] Hedging Relationship [Axis] Hedging Relationship [Domain] Hedging Relationship [Domain] Cash Flow Hedging Cash Flow Hedging [Member] Derivative [Line Items] Derivative [Line Items] Derivative term Derivative, Term of Contract Notional amount of foreign currency forward contract Derivative, Notional Amount Foreign Currency Cash Flow Hedge Derivative at Fair Value [Abstract] Foreign Currency Cash Flow Hedge Derivative at Fair Value, Net [Abstract] Fair Value - assets Foreign Currency Cash Flow Hedge Asset at Fair Value Fair Value - liabilities Foreign Currency Cash Flow Hedge Liability at Fair Value Offsetting Derivative Assets [Abstract] Offsetting Derivative Assets [Abstract] Gross Amounts Recognized Derivative Asset, Fair Value, Gross Asset Gross Amounts Offset Derivative Asset Fair Value Gross Asset Collateral And Other Set Off Against Gross Assets Subject To Offsetting Enforceable Master Netting Arrangement Or Similar Agreement Derivative, Asset Fair Value, Gross Asset, Collateral And Other Set Off Against Gross Assets Subject To Offsetting Enforceable Master Netting Arrangement Or Similar Agreement Gross Amounts Presented Derivative Asset Gross Amounts Not Offset Derivative Asset, Not Offset, Policy Election Deduction Legal Offset Derivative Asset, Fair Value, Amount Offset Against Collateral Offsetting Derivative Liabilities [Abstract] Offsetting Derivative Liabilities [Abstract] Gross Amounts Recognized Derivative Liability, Fair Value, Gross Liability Gross Amounts Offset Derivative Liability Fair Value Gross Liability Collateral And Other Set Off Against Gross Assets Subject To Offsetting Enforceable Master Netting Arrangement Or Similar Agreement Derivative Liability, Fair Value, Gross Liability, Collateral and Other Set Off Against Gross Assets Subject to Offsetting Enforceable Master Netting Arrangement or Similar Agreement Gross Amounts Presented Derivative Liability Gross Amounts Not Offset Derivative Liability, Not Offset, Policy Election Deduction Legal Offset Derivative Liability, Fair Value, Amount Offset Against Collateral Accounting Policies [Abstract] Number of operating segments Number of Operating Segments Collaborative Arrangements Collaborative Arrangement Disclosure [Text Block] Statement of Financial Position [Abstract] Assets Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Marketable securities, available for sale Available-for-sale Securities, Current Restricted cash and cash equivalents (VIE) Restricted Cash and Cash Equivalents, Current Accounts receivable, net Accounts Receivable, Net, Current Inventories Inventory, Net Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Property and equipment, net Property, Plant and Equipment, Net Intangible assets Other Indefinite-lived Intangible Assets Goodwill Goodwill Cost method investment in CRISPR Cost Method Investments Notes receivable Notes, Loans and Financing Receivable, Net, Noncurrent Restricted cash Restricted Cash and Cash Equivalents, Noncurrent Other assets Other Assets, Noncurrent Total assets Assets Liabilities and Shareholders’ Equity Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued expenses Accrued Liabilities, Current Deferred revenues, current portion Deferred Revenue, Current Accrued restructuring expenses, current portion Restructuring Reserve, Current Capital lease obligations, current portion Capital Lease Obligations, Current Senior secured term loan, current portion Senior Notes, Current Other liabilities, current portion Other Liabilities, Current Total current liabilities Liabilities, Current Deferred revenues, excluding current portion Deferred Revenue, Noncurrent Accrued restructuring expenses, excluding current portion Restructuring Reserve, Noncurrent Capital lease obligations, excluding current portion Capital Lease Obligations, Noncurrent Deferred tax liability Deferred Tax Liabilities, Net, Noncurrent Construction financing lease obligation, excluding current portion Construction Financing Obligation, Noncurrent Represents the noncurrent portion of a lease liability recorded as a result of capitalizing the landlord's costs of constructing facilities associated with building leases. Senior secured term loan, net of current portion and discount Senior Notes, Noncurrent Other liabilities, excluding current portion Other Liabilities, Noncurrent Total liabilities Liabilities Commitments and contingencies Commitments and Contingencies Shareholders’ equity: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding at June 30, 2016 and December 31, 2015 Preferred Stock, Value, Issued Common stock, $0.01 par value; 500,000,000 and 500,000,000 shares authorized at June 30, 2016 and December 31, 2015, respectively; 247,703,932 and 246,306,818 shares issued and outstanding at June 30, 2016 and December 31, 2015, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated other comprehensive (loss) income Accumulated deficit Retained Earnings (Accumulated Deficit) Total Vertex shareholders' equity Stockholders' Equity Attributable to Parent Noncontrolling interest Stockholders' Equity Attributable to Noncontrolling Interest Total shareholders’ equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Total liabilities and shareholders’ equity Liabilities and Equity Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Axis] Exercise Price Range [Axis] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] $18.93–$20.00 Exercise Price Range From Dollars 18.93 to Dollars 20.00 [Member] Represents the range of exercise prices from $18.93 to $20.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. $20.01–$40.00 Exercise Price Range from Dollars 20.01 to Dollars 40.00 [Member] Represents the range of exercise prices from $20.01 to $40.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. $40.01–$60.00 Exercise Price Range from Dollars 40.01 to Dollars 60.00 [Member] Represents the range of exercise prices from $40.01 to $60.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. $60.01–$80.00 Exercise Price Range from Dollars 60.01 to Dollars 80.00 [Member] Represents the range of exercise prices from $60.01 to $80.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. $80.01–$100.00 Exercise Price Range from Dollars 80.01 to Dollars 100.00 [Member] Represents the range of exercise prices from $80.01 to $100.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. $100.01–$120.00 Exercise Price Range from Dollars 100.01 to Dollars 120.00 [Member] Represents the range of exercise prices from $100.01 to $120.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. $120.01–$134.69 Exercise Price Range From Dollars 120.01 to Dollars 134.69 [Member] Represents the range of exercise prices from $120.01 to $134.69 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. Share-based Compensation Arrangement by Share-based Payment Award Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Exercise price, low end of range (usd per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit Exercise price, high end of range (usd per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit Exercise price range, options outstanding (in shares) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options Exercise price range, options outstanding, weighted-average remaining contractual life (in years) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price Exercise price range, options exercisable (in shares) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price Income Statement [Abstract] Revenues: Revenues [Abstract] Product revenues, net Sales Revenue, Goods, Net Royalty revenues Royalty Revenue Collaborative revenues Collaborative Revenues The aggregate revenue from collaborative revenues. It includes the revenues earned by the entity from nonrefundable, up-front license fees; net reimbursements of research and/or development efforts, including manufacturing services; and milestone payments. Total revenues Revenues Costs and expenses: Costs and Expenses [Abstract] Cost of product revenues Cost of Goods Sold Royalty expenses Direct Operating Cost, Royalty Expense Research and development expenses Research and Development Expense Sales, general and administrative expenses Selling, General and Administrative Expense Restructuring expenses (income), net Restructuring Charges Total costs and expenses Costs and Expenses Income (loss) from operations Operating Income (Loss) Interest expense, net Interest Income (Expense), Net Other (expenses) income, net Other Nonoperating Income (Expense) Loss before provision for income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest Provision for income taxes Income Tax Expense (Benefit) Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest (Income) loss attributable to noncontrolling interest Net Income (Loss) Attributable to Noncontrolling Interest Net loss attributable to Vertex Net Income (Loss) Attributable to Parent Net loss: Earnings Per Share [Abstract] Basic (usd per share) Earnings Per Share, Basic Diluted (usd per share) Earnings Per Share, Diluted Shares used in per share calculations: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Moderna Therapeutics, Inc. Moderna Therapeutics, Inc. [Member] Moderna Therapeutics, Inc. [Member] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaborative Arrangement Up-front License Fee Collaborative Arrangement Up-front License Fee The amount of the up-front license fee paid by the entity pursuant to a collaborative arrangement. Collaborative Arrangement, Investment in Collaborative Partner, Amount Collaborative Arrangement, Investment in Collaborative Partner, Amount Collaborative Arrangement, Investment in Collaborative Partner, Amount Prior to marketing approval, time period of notice required to terminate (in days) Collaborative Arrangement, Prior to Marketing Approval, Time Period of Notice Required to Terminate Collaborative Arrangement, Prior to Marketing Approval, Time Period of Notice Required to Terminate Collaborative arrangement development and regulatory potential milestone payments maximum Collaborative Arrangement Development And Regulatory Potential Milestone Payments Maximum Represents the potential milestone amount to be paid by the entity under the collaboration agreement if drug candidates are approved and commercialized. Collaborative Arrangement Approval and Reimbursement Milestones Collaborative Arrangement Approval and Reimbursement Milestones Collaborative Arrangement Approval and Reimbursement Milestones Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract] Net loss Changes in other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax [Abstract] Unrealized holding gains (losses) on marketable securities Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Unrealized gains (losses) on foreign currency forward contracts, net of tax Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Comprehensive loss Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive (income) loss attributable to noncontrolling interest Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Comprehensive loss attributable to Vertex Comprehensive Income (Loss), Net of Tax, Attributable to Parent Income Tax Disclosure [Abstract] Schedule of Collaborative Arrangement Agreements [Table] Schedule of Collaborative Arrangement Agreements [Table] A schedule reflecting significant collaboration agreements in which the entity is a participant. Parion Sciences, Inc Parion Sciences, Inc [Member] Parion Sciences, Inc Schedule of Collaborative Arrangement Agreements [Line Items] Schedule of Collaborative Arrangement Agreements [Line Items] -- None. No documentation exists for this element. -- Unrecognized tax benefits Unrecognized Tax Benefits Income taxes, interest and penalties accrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Income taxes, material interest or penalties related to uncertain tax positions Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Estimated reduction in unrecognized tax benefits in next fiscal year Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations and Settlements with Taxing Authorities, Estimated in Next Fiscal Year Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations and Settlements with Taxing Authorities, Estimated in Next Fiscal Year Product Revenues [Abstract] Product Revenues [Abstract] Valuation and Qualifying Accounts Disclosure [Table] Valuation and Qualifying Accounts Disclosure [Table] Valuation Allowances and Reserves Type [Axis] Valuation Allowances and Reserves Type [Axis] Valuation Allowances and Reserves [Domain] Valuation Allowances and Reserves [Domain] Trade Allowances Allowance for Trade Receivables [Member] Rebates, Chargebacks and Discounts Rebates Chargebacks and Discounts [Member] A valuation allowance for amounts due to the entity for rebates, chargebacks and discounts in the normal course of business that are expected to be uncollectible. Product Returns Allowance for Sales Returns [Member] Other Incentives Copay Mitigation Rebates [Member] A valuation allowance for amounts due to the entity for copay mitigation rebates in the normal course of business that are expected to be uncollectible. Valuation and Qualifying Accounts Disclosure [Line Items] Valuation and Qualifying Accounts Disclosure [Line Items] Product Revenue Allowance and Reserve [Roll Forward] Movement in Valuation Allowances and Reserves [Roll Forward] Balance at December 31, 2015 Valuation Allowances and Reserves, Balance Provision related to current period sales Valuation Allowances and Reserves Provision Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs, charged to product revenues. Adjustments related to prior period sales Valuation Allowances and Reserves, Adjustments Credits/payments made Valuation Allowances and Reserves, Sales Credits or Payments, Current Represents the credits or payments to allowances and reserves. Balance at June 30, 2016 Schedule of Cash Flow Hedging Instruments Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block] Schedule of Foreign Exchange Contracts Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block] Derivatives Offsetting Derivatives Offsetting [Table Text Block] [Table Text Block] for Derivatives Offsetting [Table] Inventory Disclosure [Abstract] Inventories Inventory Disclosure [Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Stock options Employee Stock Option [Member] Unvested restricted stock and restricted stock units Restricted Stock [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Schedule of product revenue allowances and reserve categories Schedule of Valuation and Qualifying Accounts [Table Text Block] Tabular disclosure of product revenues allowances and reserve accounts (their beginning and ending balances, as well as reconciliation by type of activity during the period). Up-front payment Maximum license fees and milestone payments Maximum license fees and milestone payments Maximum license fees and milestone payments In-process research and development intangible asset Variable Interest Entity, Consolidated, Carrying Amount, In-Process Research and Development Intangible Asset Variable Interest Entity, Consolidated, Carrying Amount, In-Process Research and Development Intangible Asset Deferred tax liability attributable to BioAxone Variable Interest Entity, Consolidated, Carrying Amount, Deferred Tax Liability Variable Interest Entity, Consolidated, Carrying Amount, Deferred Tax Liability Purchase option, term of extension of expiration date (in years) Collaborative Arrangements, Purchase Option, Term of Extension of Expiration Date Collaborative Arrangements, Purchase Option, Term of Extension of Expiration Date Preferred stock, par value (usd per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized Preferred Stock, Shares Authorized Preferred stock, shares issued Preferred Stock, Shares Issued Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Common stock, par value (usd per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized Common Stock, Shares Authorized Common stock, shares issued Common Stock, Shares, Issued Common stock, shares outstanding Common Stock, Shares, Outstanding Janssen Janssen Collaborative Agreement [Member] Collaboration agreement entered into with Janssen Pharmaceutical, N.V. for the development, manufacture and commercialization of a product of the entity. Reimbursement for development and commercialization of compounds Reimbursement Revenue Time period of notice required to terminate Collaborative Arrangement, Time Period of Notice Required to Terminate Collaborative Arrangement, Time Period of Notice Required to Terminate Cystic Fibrosis Foundation Therapeutics Incorporated Cystic Fibrosis Foundation Therapeutics Incorporated Agreement [Member] Collaboration agreement entered into with Cystic Fibrosis Foundation Therapeutics Inc., for the development, manufacture and commercialization of a product of the entity. Collaborative funding Collaborative Arrangement Research Development Funding This element represents the funding under collaborative agreement 2011 amendment for research and development. Number of years over which funding will be made (in years) Number of Years over which Research Development Funding will be Made This element represents the number of years over which research and development funding will be made as per the collaboration agreement 2011 amendment. Milestone Revenues Milestone Revenues This element represents the revenues recorded for milestone payments received. Long-term Debt and Capital Lease Obligations [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Senior Secured Term Loan Facility Secured Debt [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Senior Secured Term Loan Senior Loans [Member] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] LIBOR London Interbank Offered Rate (LIBOR) [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Face amount of term loan Debt Instrument, Face Amount Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Interest rate, stated percentage Debt Instrument, Interest Rate, Stated Percentage Contingent interest rate (percent) Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum Basis spread on variable rate (percent) Debt Instrument, Basis Spread on Variable Rate Amount of principal repayment on quarterly installment payments from October 1, 2016 through maturity Debt Instrument, Periodic Payment, Principal Debt instrument, repayment provision, period over which present value of interest payments is determined (in years) Debt Instrument, Repayment Provision, Period Over Which Present Value of Interest Payments is Determined Debt Instrument, Repayment Provision, Period Over Which Present Value of Interest Payments is Determined Unamortized discount on term loan Debt Instrument, Unamortized Discount Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table] Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table] Schedule of the cash and cash equivalents and available-for-sale investments held by the entity. Schedule of Cash, Cash Equivalents and Available-for-sale Securities Types of Financial Instruments [Axis] Schedule of Cash, Cash Equivalents and Available-for-sale Securities Types of Financial Instruments [Axis] This element represents a number of concepts which capture the categories of financial instruments classified as cash and cash equivalents and available-for-sale investments. Types of Financial Instruments [Domain] Types of Financial Instruments [Domain] Provides general categories of financial instruments included as cash, cash equivalents and available-for-sale investments. Total cash and cash equivalents Cash and Cash Equivalents [Member] Cash and money market funds Cash and Money Market Funds [Member] Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time. Corporate debt securities Total marketable securities Available-for-sale Securities [Member] U.S. Treasury securities (due within 1 year) Government-sponsored enterprise securities (due within 1 year) U.S. Government Sponsored Enterprises Debt Securities, Due Within One Year [Member] U.S. Government Sponsored Enterprises Debt Securities, Due Within One Year [Member] Commercial paper (due within 1 year) Commercial Paper, Not Included with Cash and Cash Equivalents [Member] Corporate debt securities (due within 1 year) Corporate Debt Securities, Due Within One Year [Member] Corporate Debt Securities, Due Within One Year [Member] Summary of cash, cash equivalents and marketable securities Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Line Items] -- None. No documentation exists for this element. -- Amortized Cost Cash, Cash Equivalents, Available-for-sale Securities, Amortized Cost This item represents the cost of cash and cash equivalents and debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any. Gross Unrealized Gains Cash, Cash Equivalents, Available-for-sale Securities, Gross Unrealized Gain This item represents the gross unrealized gains for cash, cash equivalents and securities which are categorized neither as held-to-maturity nor trading securities. Such gross unrealized gains are the excess of the fair value over the carrying value as of the reporting date. Gross Unrealized Losses Cash, Cash Equivalents, Available-for-sale Securities, Unrealized Loss, Gross This item represents the gross unrealized losses for cash, cash equivalents and securities which are categorized neither as held-to-maturity nor trading securities. Such gross unrealized losses are the excess of the carrying value over the fair value as of the reporting date. Fair Value Cash, Cash Equivalents and Available-for-sale Securities, Fair Value This item represents the fair value of cash, cash equivalents and debt and equity securities, which are categorized neither as held-to-maturity nor trading. Restructuring and Related Activities [Abstract] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Restructuring Plan [Axis] Restructuring Plan [Axis] Restructuring Plan [Domain] Restructuring Plan [Domain] Kendall Restructuring Kendall Restructuring [Member] Kendall Restructuring [Member] Fan Pier Move Restructuring Fan Pier Move [Member] Fan Pier Move [Member] Other Restructuring Other Restructuring [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Activity related to restructuring liability Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Potential gross common equivalent shares Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Stock-based Compensation Expense Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Stock-based compensation expense Share-based Compensation Depreciation and amortization expense Depreciation, Depletion and Amortization Deferred income taxes Increase (Decrease) in Other Deferred Liability Other non-cash items, net Other Noncash Income (Expense) Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable, net Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Accrued restructuring expense Restructuring Reserve, Period Increase (Decrease) Deferred revenues Increase (Decrease) in Deferred Revenue Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of marketable securities Payments to Acquire Available-for-sale Securities Maturities of marketable securities Proceeds from Sale and Maturity of Available-for-sale Securities Payment for acquisition of variable interest entity Payments to Acquire Intangible Assets Expenditures for property and equipment Payments to Acquire Property, Plant, and Equipment Increase in restricted cash and cash equivalents Increase (Decrease) in Restricted Cash Investment in CRISPR Series B preferred stock Payment to Acquire Preferred Stock Payment to Acquire Preferred Stock Decrease in restricted cash and cash equivalents (VIE) Increase (Decrease) in Restricted Cash and Investments (Increase) decrease in other assets Payments for (Proceeds from) Other Investing Activities Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Issuances of common stock under benefit plans Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options Payments on capital lease obligations Payments of Financing Costs Proceeds from capital lease financing Proceeds from Long-term Capital Lease Obligations Payments on construction financing lease obligation Repayments of Long-term Capital Lease Obligations Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Effect of changes in exchange rates on cash Effect of Exchange Rate on Cash and Cash Equivalents Net (decrease) increase in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents—beginning of period Cash and cash equivalents—end of period Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Cash paid for interest Interest Paid Cash paid for income taxes Income Taxes Paid Issuances of common stock exercises from employee benefit plans receivable Conversion of Stock, Amount Issued Income Taxes Income Tax Disclosure [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Use of Estimates and Summary of Significant Accounting Policies Use of Estimates, Policy [Policy Text Block] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Schedule of Inventories by Type Schedule of Inventory, Current [Table Text Block] Restructuring Liabilities Restructuring and Related Activities Disclosure [Text Block] Financial assets subject to fair value measurements (excluding restricted cash and cash equivalents (Alios)) Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Statement, Equity Components [Axis] Total Vertex Shareholders’ Equity Parent [Member] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Accumulated Other Comprehensive (Loss) Income AOCI Attributable to Parent [Member] Accumulated Deficit Retained Earnings [Member] Noncontrolling Interest Noncontrolling Interest [Member] Statement Statement [Line Items] Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Balance (shares) Shares, Outstanding Balance Other comprehensive loss, net of tax Issuance of common stock under benefit plans (shares) Stock Issued During Period, Shares, Employee Benefit Plan Issuance of common stock under benefit plans Stock Issued During Period, Value, Employee Benefit Plan Stock-based compensation expense Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Noncontrolling interest upon consolidation Noncontrolling Interest, Increase from Business Combination Balance (shares) Balance Other Income and Expenses [Abstract] Sale of HIV Protease Inhibitor Royalty Stream Sale of HIV Protease Inhibitor Royalty Stream Gross proceeds from sale of royalty rights receivable from GlaxoSmithKline Proceeds from Sale of Royalty Rights The cash inflow from the sale of the entity's right to receive future royalty payments. Deferred revenue royalty purchase agreement Deferred Revenue Royalty Purchase Agreement This element represents the carrying value of deferred revenue recorded with regard to agreement to sell rights to receive royalty payments, as on the balance sheet date. Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Name of Property [Axis] Name of Property [Axis] Name of Property [Domain] Name of Property [Domain] Fan Pier Leases Fan Pier Leases [Member] Represents the fan pier leases. Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Buildings Building [Member] Construction in progress Construction in Progress [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Number of leases Lease Agreement, Number of Leases Represents the number of leases entered by the reporting entity. Area of real estate property (in square feet) Area of Real Estate Property Number of buildings under lease agreement Lease Agreements Number of Buildings Represents number of buildings under lease agreements. Optional term of lease agreement (in years) Optional Term of Lease Agreement Represents additional period to extend term of lease agreement. Construction financing lease obligation, current and noncurrent Construction financing lease obligation, current and noncurrent Represents the current noncurrent portion of a lease liability recorded as a result of capitalizing the landlord's costs of constructing facilities associated with building leases. Long-term Obligations Debt Disclosure [Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets and Goodwill Goodwill and Intangible Assets Disclosure [Text Block] Drug Candidate [Axis] Drug Candidate [Axis] Potential drug candidate that milestone payments are based upon Drug Candidate [Domain] Drug Candidate [Domain] [Domain] for Potential drug candidate that milestone payments are based upon ENaC Inhibitors in CF Enac Inhibitors in Cf [Member] ENaC Inhibitors in CF Enac Inhibitors in Non Cf Enac Inhibitors in Non Cf [Member] ENaC Inhibitors in Non-CF Additional Enac Inhibitors Additional Enac Inhibitors [Member] Additional ENaC Inhibitors Collaborative arrangement regulatory potential milestone payments maximum, global filling and approval Collaborative Arrangement Regulatory Potential Milestone Payments Maximum Represents the potential milestone amount to be paid by the entity under the collaboration agreement if drug candidates are commercialized. Subsequent to marketing approval, time period of notice required to terminate (in days) Collaborative Arrangement, Subsequent to Marketing Approval, Time Period of Notice Required to Terminate Collaborative Arrangement, Subsequent to Marketing Approval, Time Period of Notice Required to Terminate Change of control prior to clinical trial, time period of notice required to terminate (in days) Collaborative Arrangement, Change of Control Prior to Clinical Trial, Time Period of Notice Required to Terminate Collaborative Arrangement, Change of Control Prior to Clinical Trial, Time Period of Notice Required to Terminate Term of agreement following first commercial sale (in years) Collaborative Arrangement, Term of Agreement Following First Commercial Sale Collaborative Arrangement, Term of Agreement Following First Commercial Sale Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract] Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract] Loss attributable to noncontrolling interest before provision for income taxes Income (Loss) from Continuing Operations Attributable to Noncontrolling Interest Provision for income taxes (Increase) decrease in fair value of contingent milestone and royalty payments Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Net (income) loss attributable to noncontrolling interest Contingent consideration, liability Business Combination, Contingent Consideration, Liability Variable Interest Entity, Consolidated, Carrying Amount, Assets and Liabilities, Net: Variable Interest Entity, Consolidated, Carrying Amount, Assets and Liabilities, Net [Abstract] Intangible assets Other assets Accounts payable Taxes payable Taxes Payable, Current Other current liabilities Deferred tax liability, net Other liabilities Noncontrolling interest Document and Entity Information [Abstract] Document and Entity Information [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Document Type Document Type Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Product Revenues, Net Product Revenues Disclosure [Text Block] Product Revenues Disclosure [Text Block] Basis of Presentation and Accounting Policies Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Fair Value Measurements Fair Value Disclosures [Text Block] Lease term (in years) Lease Term Total length of time of a real estate lease, stated in years. Restructuring and related activities, leased office space, maximum percentage used - not more than Restructuring and Related Activities, Leased Office Space, Maximum Percentage Used Maximum of percentage used of leased office space. Number of facilities decommissioned Restructuring and Related Activities, Number of Facilities Decommissioned Restructuring and Related Activities, Number of Facilities Decommissioned Number of leases terminated Number Of Lease Terminated Number Of Lease Terminated Discount rate related to leases (percent) Lease Restructuring Liability Accrual Discount Rate The credit-adjusted risk-free discount rate applied to the undiscounted amount of projected cash inflows and/or outflows to arrive at the present value of the lease restructuring liability recorded as of the balance sheet date. Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis] Income Statement Location [Axis] Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain] Income Statement Location [Domain] Research and development expenses Research and Development Expense [Member] Sales, general and administrative expenses Selling General and Administrative Expense [Member] The allocation (or location) of expense to (in) selling, general and administrative expense. Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type and Plan Name [Axis] Award Type [Axis] Award Type [Domain] Equity Award [Domain] Stock options Restricted stock and restricted stock units Employee Restricted Stock Option [Member] An arrangement whereby certain members of senior management are entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. ESPP share issuances Employee Stock Purchase Plan [Member] Employee Stock Purchase Plan [Member] Stock-based compensation expense: Share-based Compensation Allocation [Abstract] -- None. No documentation exists for this element. -- Stock-based compensation expense by type of award: Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost Less stock-based compensation expense capitalized to inventories Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount Total stock-based compensation included in costs and expenses Allocated Share-based Compensation Expense Type of award: Employee Service Share-based Compensation, Aggregate Disclosures [Abstract] Unrecognized Expense, Net of Estimated Forfeitures Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Weighted-average recognition period (in years) Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Earnings Per Share Earnings Per Share [Text Block] Schedule of Indefinite-Lived Intangible Assets by Major Class [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Indefinite-lived Intangible Assets Indefinite-lived Intangible Assets [Member] Indefinite-Lived Intangible Assets [Line Items] Indefinite-lived Intangible Assets [Line Items] Fair value inputs, discount rate (percent) Fair Value Inputs, Discount Rate San Diego Lease San Diego Lease [Member] San Diego Lease [Member] Length of lease Lessee Leasing Arrangements, Capital Leases, Term of Contract Lessee Leasing Arrangements, Capital Leases, Term of Contract Average yearly aggregate rent Average Yearly Aggregate Rent, Exclusive of Operating Expenses Average Yearly Aggregate Rent, Exclusive of Operating Expenses Amount of optional renewal terms Amount of Optional Renewal Terms Amount of Optional Renewal Terms Optional renewal term length Lessee Leasing Arrangements, Capital Leases, Renewal Term Lessee Leasing Arrangements, Capital Leases, Renewal Term Restructuring activities Restructuring Reserve [Roll Forward] Liability, beginning of the period Restructuring Reserve Cash payments Payments for Restructuring Cash received from subleases Restructuring Reserve Settled with Cash Receipt from Sublease Amount of cash received in the period to fully or partially offset a specified, previously accrued type of restructuring cost. Restructuring expense (income) Liability, end of the period Accumulated Other Comprehensive (Loss) Income Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Accumulated Other Comprehensive (Loss) Income Comprehensive Income (Loss) Note [Text Block] CRISPR Therapeutics CRISPRTherapeutics [Member] CRISPR Therapeutics AG collaboration. Right to license, number of targets (up to) Collaborative Arrangement, Right to License, Number of Targets Collaborative Arrangement, Right to License, Number of Targets Investment in collaborative partner, pursuant to convertible loan agreement Other Arrangements Other Nonoperating Income and Expense [Text Block] Commitments and Contingencies Disclosure [Abstract] Restricted cash and cash equivalents Restricted Cash and Cash Equivalents Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Raw materials Inventory, Raw Materials, Net of Reserves Work-in-process Inventory, Work in Process, Net of Reserves Finished goods Inventory, Finished Goods, Net of Reserves Total EX-101.PRE 11 vrtx-20160630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.5.0.2
Document and Entity Information - shares
 6 Months Ended
Jun. 30, 2016
Jul. 22, 2016
Document and Entity Information [Abstract]    
Entity Registrant Name VERTEX PHARMACEUTICALS INC / MA  
Entity Central Index Key 0000875320  
Current Fiscal Year End Date --12-31  
Entity Filer Category Large Accelerated Filer  
Document Type 10-Q  
Document Period End Date Jun. 30, 2016  
Document Fiscal Year Focus 2016  
Document Fiscal Period Focus Q2  
Amendment Flag false  
Entity Common Stock, Shares Outstanding   247,778,698
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements of Operations (unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Revenues:        
Product revenues, net $ 425,651 $ 160,388 $ 820,061 $ 291,263
Royalty revenues 5,282 5,077 8,878 11,869
Collaborative revenues 675 611 749 1,453
Total revenues 431,608 166,076 829,688 304,585
Costs and expenses:        
Cost of product revenues 44,154 15,409 93,943 24,790
Royalty expenses 1,098 1,451 1,958 4,377
Research and development expenses 271,008 223,858 526,868 439,457
Sales, general and administrative expenses 111,652 94,394 216,866 180,254
Restructuring expenses (income), net 343 2,128 1,030 (1,144)
Total costs and expenses 428,255 337,240 840,665 647,734
Income (loss) from operations 3,353 (171,164) (10,977) (343,149)
Interest expense, net (20,155) (21,111) (40,853) (42,418)
Other (expenses) income, net (1,219) 1,414 3,192 (3,699)
Loss before provision for income taxes (18,021) (190,861) (48,638) (389,266)
Provision for income taxes 18,130 30,131 23,615 30,430
Net loss (36,151) (220,992) (72,253) (419,696)
(Income) loss attributable to noncontrolling interest (28,374) 32,144 (33,903) 32,242
Net loss attributable to Vertex $ (64,525) $ (188,848) $ (106,156) $ (387,454)
Net loss:        
Basic (usd per share) $ (0.26) $ (0.78) $ (0.43) $ (1.61)
Diluted (usd per share) $ (0.26) $ (0.78) $ (0.43) $ (1.61)
Shares used in per share calculations:        
Basic (in shares) 244,482 240,757 244,124 240,129
Diluted (in shares) 244,482 240,757 244,124 240,129
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements of Comprehensive Loss (unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]        
Net loss $ (36,151) $ (220,992) $ (72,253) $ (419,696)
Changes in other comprehensive loss:        
Unrealized holding gains (losses) on marketable securities (29) (46) 200 130
Unrealized gains (losses) on foreign currency forward contracts, net of tax 4,999 (4,280) (213) (3,974)
Foreign currency translation adjustment (3,461) 1,828 (5,201) 1,220
Total changes in other comprehensive loss 1,509 (2,498) (5,214) (2,624)
Comprehensive loss (34,642) (223,490) (77,467) (422,320)
Comprehensive (income) loss attributable to noncontrolling interest (28,374) 32,144 (33,903) 32,242
Comprehensive loss attributable to Vertex $ (63,016) $ (191,346) $ (111,370) $ (390,078)
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Balance Sheets (unaudited) - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents $ 605,866 $ 714,768
Marketable securities, available for sale 465,570 327,694
Restricted cash and cash equivalents (VIE) 70,513 78,910
Accounts receivable, net 189,356 177,639
Inventories 66,589 57,207
Prepaid expenses and other current assets 56,256 50,935
Total current assets 1,454,150 1,407,153
Property and equipment, net 690,607 697,715
Intangible assets 284,340 284,340
Goodwill 50,384 50,384
Cost method investment in CRISPR 33,213 0
Notes receivable 0 30,000
Restricted cash 22,085 22,083
Other assets 14,203 6,912
Total assets 2,548,982 2,498,587
Current liabilities:    
Accounts payable 51,302 74,942
Accrued expenses 275,165 305,820
Deferred revenues, current portion 11,468 16,296
Accrued restructuring expenses, current portion 7,683 7,894
Capital lease obligations, current portion 17,446 15,545
Senior secured term loan, current portion 221,576 71,296
Other liabilities, current portion 38,215 14,374
Total current liabilities 622,855 506,167
Deferred revenues, excluding current portion 7,411 9,714
Accrued restructuring expenses, excluding current portion 4,801 7,464
Capital lease obligations, excluding current portion 34,317 42,923
Deferred tax liability 132,810 110,439
Construction financing lease obligation, excluding current portion 472,374 472,611
Senior secured term loan, net of current portion and discount 74,921 223,863
Other liabilities, excluding current portion 30,648 31,778
Total liabilities 1,380,137 1,404,959
Commitments and contingencies
Shareholders’ equity:    
Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding at June 30, 2016 and December 31, 2015 0 0
Common stock, $0.01 par value; 500,000,000 and 500,000,000 shares authorized at June 30, 2016 and December 31, 2015, respectively; 247,703,932 and 246,306,818 shares issued and outstanding at June 30, 2016 and December 31, 2015, respectively 2,440 2,427
Additional paid-in capital 6,350,244 6,197,500
Accumulated other comprehensive (loss) income (3,390) 1,824
Accumulated deficit (5,367,940) (5,261,784)
Total Vertex shareholders' equity 981,354 939,967
Noncontrolling interest 187,491 153,661
Total shareholders’ equity 1,168,845 1,093,628
Total liabilities and shareholders’ equity $ 2,548,982 $ 2,498,587
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Jun. 30, 2016
Dec. 31, 2015
Statement of Financial Position [Abstract]    
Preferred stock, par value (usd per share) $ 0.01 $ 0.01
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value (usd per share) $ 0.01 $ 0.01
Common stock, shares authorized 500,000,000 500,000,000
Common stock, shares issued 247,703,932 246,306,818
Common stock, shares outstanding 247,703,932 246,306,818
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements of Shareholders' Equity and Noncontrolling Interest (unaudited) - USD ($)
shares in Thousands, $ in Thousands
Total
Total Vertex Shareholders’ Equity
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive (Loss) Income
Accumulated Deficit
Noncontrolling Interest
Balance (shares) at Dec. 31, 2014     241,764        
Balance at Dec. 31, 2014 $ 1,096,183 $ 1,075,006 $ 2,385 $ 5,777,154 $ 917 $ (4,705,450) $ 21,177
Increase (Decrease) in Stockholders' Equity              
Other comprehensive loss, net of tax (2,624) (2,624)     (2,624)    
Net loss (419,696) (387,454)       (387,454) (32,242)
Issuance of common stock under benefit plans (shares)     2,578        
Issuance of common stock under benefit plans 87,354 87,354 $ 21 87,333     0
Stock-based compensation expense 122,682 122,682   122,682     0
Noncontrolling interest upon consolidation 164,317           164,317
Balance (shares) at Jun. 30, 2015     244,342        
Balance at Jun. 30, 2015 1,048,216 894,964 $ 2,406 5,987,169 (1,707) (5,092,904) 153,252
Balance (shares) at Dec. 31, 2015     246,307        
Balance at Dec. 31, 2015 1,093,628 939,967 $ 2,427 6,197,500 1,824 (5,261,784) 153,661
Increase (Decrease) in Stockholders' Equity              
Other comprehensive loss, net of tax (5,214) (5,214)     (5,214)    
Net loss (72,253) (106,156)       (106,156) 33,903
Issuance of common stock under benefit plans (shares)     1,397        
Issuance of common stock under benefit plans 33,570 33,570 $ 13 33,557     0
Stock-based compensation expense 119,114 119,187   119,187     (73)
Balance (shares) at Jun. 30, 2016     247,704        
Balance at Jun. 30, 2016 $ 1,168,845 $ 981,354 $ 2,440 $ 6,350,244 $ (3,390) $ (5,367,940) $ 187,491
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Cash flows from operating activities:    
Net loss $ (72,253) $ (419,696)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense 117,414 120,645
Depreciation and amortization expense 31,378 30,428
Deferred income taxes 22,858 6,346
Other non-cash items, net 3,436 6,045
Changes in operating assets and liabilities:    
Accounts receivable, net (12,954) (21,197)
Inventories (7,779) (9,426)
Prepaid expenses and other assets (7,971) (15,397)
Accounts payable (23,821) (3,033)
Accrued expenses and other liabilities (14,562) 8,098
Accrued restructuring expense (2,892) (26,012)
Deferred revenues (7,131) (9,303)
Net cash provided by (used in) operating activities 25,723 (332,502)
Cash flows from investing activities:    
Purchases of marketable securities (470,077) (125,655)
Maturities of marketable securities 332,316 741,725
Payment for acquisition of variable interest entity 0 80,000
Expenditures for property and equipment (27,892) (23,978)
Increase in restricted cash and cash equivalents 0 (21,975)
Investment in CRISPR Series B preferred stock (3,075) 0
Decrease in restricted cash and cash equivalents (VIE) 8,397 2,277
(Increase) decrease in other assets (159) 87
Net cash (used in) provided by investing activities (160,490) 492,481
Cash flows from financing activities:    
Issuances of common stock under benefit plans 33,702 87,850
Payments on capital lease obligations (7,538) (14,441)
Proceeds from capital lease financing 0 13,386
Payments on construction financing lease obligation (209) (184)
Net cash provided by financing activities 25,955 86,611
Effect of changes in exchange rates on cash (90) (1,306)
Net (decrease) increase in cash and cash equivalents (108,902) 245,284
Cash and cash equivalents—beginning of period 714,768 625,259
Cash and cash equivalents—end of period 605,866 870,543
Supplemental disclosure of cash flow information:    
Cash paid for interest 41,325 42,885
Cash paid for income taxes 1,237 1,022
Issuances of common stock exercises from employee benefit plans receivable $ 161 $ 166
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.5.0.2
Basis of Presentation and Accounting Policies
 6 Months Ended
Jun. 30, 2016
Accounting Policies [Abstract]  
Basis of Presentation and Accounting Policies
Basis of Presentation and Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company") in accordance with accounting principles generally accepted in the United States of America ("GAAP").
The condensed consolidated financial statements reflect the operations of (i) the Company, (ii) its wholly-owned subsidiaries and (iii) consolidated variable interest entities (VIEs). All material intercompany balances and transactions have been eliminated. The Company operates in one segment, pharmaceuticals.

Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended June 30, 2016 and 2015.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2015, which are contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2015 that was filed with the Securities and Exchange Commission (the “SEC”) on February 16, 2016 (the "2015 Annual Report on Form 10-K").
Use of Estimates and Summary of Significant Accounting Policies
The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. Significant estimates in these condensed consolidated financial statements have been made in connection with the calculation of revenues, inventories, research and development expenses, stock-based compensation expense, restructuring expense, the fair value of intangible assets, goodwill, contingent consideration, noncontrolling interest, the consolidation of VIEs, leases, the fair value of cash flow hedges and the provision for or benefit from income taxes. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
The Company's significant accounting policies are described in Note A, "Nature of Business and Accounting Policies," in the 2015 Annual Report on Form 10-K.
Recent Accounting Pronouncements
In 2016, the Financial Accounting Standards Board (“FASB”) issued amended guidance applicable to leases that will be effective for the year ending December 31, 2019. Early adoption is permitted. This update requires an entity to recognize assets and liabilities for leases with lease terms of more than 12 months on the balance sheet. The Company is in the process of evaluating the new guidance and determining the expected effect on its consolidated financial statements.

In 2016, the FASB issued amended guidance applicable to share-based compensation to employees that will be effective for the year ending December 31, 2017. Early adoption is permitted. This update simplifies the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The Company is in the process of evaluating the new guidance and determining the expected effect on its consolidated financial statements.

For a discussion of other recent accounting pronouncements please refer to Note A, “Nature of Business and Accounting Policies—Recent Accounting Pronouncements,” in the 2015 Annual Report on Form 10-K. The Company did not adopt any new accounting pronouncements during the six months ended June 30, 2016 that had a material effect on its condensed consolidated financial statements.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.5.0.2
Product Revenues, Net
 6 Months Ended
Jun. 30, 2016
Product Revenues [Abstract]  
Product Revenues, Net
Product Revenues, Net
The Company sells its products principally to a limited number of specialty pharmacy providers and selected regional wholesalers in North America as well as government-owned and supported customers in international markets (collectively, its “Customers”). The Company's Customers in North America subsequently resell the products to patients and health care providers. The Company recognizes net revenues from product sales upon delivery to the Customer as long as (i) there is persuasive evidence that an arrangement exists between the Company and the Customer, (ii) collectibility is reasonably assured and (iii) the price is fixed or determinable.
In order to conclude that the price is fixed or determinable, the Company must be able to (i) calculate its gross product revenues from sales to Customers and (ii) reasonably estimate its net product revenues upon delivery to its Customers' locations. The Company calculates gross product revenues based on the price that the Company charges its Customers. The Company estimates its net product revenues by deducting from its gross product revenues (a) trade allowances, such as invoice discounts for prompt payment and Customer fees, (b) estimated government and private payor rebates, chargebacks and discounts, (c) estimated reserves for expected product returns and (d) estimated costs of co-pay assistance programs for patients, as well as other incentives for certain indirect customers.
The Company makes significant estimates and judgments that materially affect the Company's recognition of net product revenues. In certain instances, the Company may be unable to reasonably conclude that the price is fixed or determinable at the time of delivery, in which case it defers the recognition of revenues. Once the Company is able to determine that the price is fixed or determinable, it recognizes the revenues associated with the units in which revenue recognition was deferred.
The following table summarizes activity in each of the product revenue allowance and reserve categories for the six months ended June 30, 2016:
 
Trade
Allowances
 
Rebates,
Chargebacks
and Discounts
 
Product
Returns
 
Other
Incentives
 
Total
 
(in thousands)
Balance at December 31, 2015
$
2,089

 
$
44,669

 
$
1,228

 
$
1,310

 
$
49,296

Provision related to current period sales
9,935

 
65,066

 
1,288

 
4,220

 
80,509

Adjustments related to prior period sales
(77
)
 
(1,712
)
 
(205
)
 
5

 
(1,989
)
Credits/payments made
(9,762
)
 
(44,113
)
 
(260
)
 
(4,638
)
 
(58,773
)
Balance at June 30, 2016
$
2,185

 
$
63,910

 
$
2,051

 
$
897

 
$
69,043


In the three and six months ended June 30, 2016, the Company sold ORKAMBI in France pursuant to early access programs. The Company has not recognized any product revenues based on these sales because the price is not fixed or determinable due to the ongoing negotiations regarding the reimbursement rate for ORKAMBI in France. If the negotiated reimbursement rate in France is lower than the price currently being paid by Customers in France under these programs, the Company would reimburse the difference between such prices to the Customers. The cash received from sales in France is included as a liability on the Company's condensed consolidated balance sheet, and the increase in "other liabilities, current portion" from December 31, 2015 to June 30, 2016 is primarily due to this liability.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.5.0.2
Collaborative Arrangements
 6 Months Ended
Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Collaborative Arrangements
Collaborative Arrangements
Cystic Fibrosis Foundation Therapeutics Incorporated
In April 2011, the Company entered into an amendment (the “April 2011 Amendment”) to its existing collaboration agreement with Cystic Fibrosis Foundation Therapeutics Incorporated (“CFFT”) pursuant to which CFFT agreed to provide financial support for (i) development activities for VX-661, a compound that targets the processing and trafficking defect of the F508del CFTR proteins discovered under the collaboration, and (ii) additional research and development activities directed at discovering new compounds targeting the processing and trafficking defect of the F508del protein.
Under the April 2011 Amendment, CFFT agreed to provide the Company with up to $75.0 million in funding over approximately five years for corrector compound research and development activities. The Company retains the right to develop and commercialize KALYDECO (ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor), lumacaftor and VX-661. The Company recognized no collaborative revenues from this collaboration during the three and six months ended June 30, 2016 and 2015.
In the original agreement, as amended prior to the April 2011 Amendment, the Company agreed to pay CFFT tiered royalties calculated as a percentage, ranging from single digits to sub-teens, of annual net sales of any approved drugs first synthesized or tested during the research term that ended in 2008, including ivacaftor, lumacaftor and VX-661. The April 2011 Amendment provides for a tiered royalty in the same range on net sales of corrector compounds first synthesized or tested during the research term that ended in February 2014. In each of 2012 and 2013, CFFT earned a commercial milestone payment of $9.3 million from the Company upon achievement of certain sales levels for KALYDECO. In each of the fourth quarter of 2015 and first quarter of 2016, CFFT earned a commercial milestone payment of $13.9 million from the Company upon achievement of certain sales levels of lumacaftor. There are no additional commercial milestone payments payable by the Company to CFFT related to sales levels for KALYDECO or ORKAMBI.
The Company began marketing KALYDECO in the United States and certain countries in the European Union in 2012 and began marketing ORKAMBI in the United States in 2015. The Company received approval for ORKAMBI in the European Union in 2015 and in Canada and Australia in 2016. The Company has royalty obligations to CFFT for ivacaftor, lumacaftor and VX-661 until the expiration of patents covering that compound. The Company has patents in the United States and European Union covering the composition-of-matter of ivacaftor that expire in 2027 and 2025, respectively, subject to potential patent extensions. The Company has patents in the United States and European Union covering the composition-of-matter of lumacaftor that expire in 2030 and 2026, respectively, subject to potential extension. The Company has patents in the United States and European Union covering the composition-of-matter of VX-661 that expire in 2027 and 2028, respectively, subject to potential extension.
CRISPR Therapeutics AG
On October 26, 2015, the Company entered into a strategic collaboration, option and license agreement (the "CRISPR Agreement") with CRISPR Therapeutics AG and its affiliates ("CRISPR") to collaborate on the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene editing technology. The Company has the exclusive right to license up to six CRISPR-Cas9-based targets. In connection with the CRISPR Agreement, the Company made an upfront payment to CRISPR of $75.0 million and a $30.0 million investment in CRISPR pursuant to a convertible loan agreement that converted into preferred stock in January 2016. The Company expensed $75.0 million to research and development, and the $30.0 million investment was recorded at cost and is classified as a long-term asset on the Company’s condensed consolidated balance sheet. In the second quarter of 2016, the Company made an additional preferred stock investment in CRISPR of approximately $3.1 million.
The Company will fund all of the discovery activities conducted pursuant to the CRISPR Agreement. For potential hemoglobinapathy treatments, including treatments for sickle cell disease, the Company and CRISPR will share equally all research and development costs and worldwide revenues. For other targets that the Company elects to license, the Company would lead all development and global commercialization activities. For each of up to six targets that the Company elects to license, other than hemoglobinapathy targets, CRISPR has the potential to receive up to $420.0 million in development, regulatory and commercial milestones and royalties on net product sales.
The Company may terminate the CRISPR Agreement upon 90 days’ notice to CRISPR prior to any product receiving marketing approval or upon 270 days’ notice after a product has received marketing approval. The CRISPR Agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, the CRISPR Agreement will continue in effect until the expiration of the Company's payment obligations under the CRISPR Agreement.
Variable Interest Entities
The Company has entered into several agreements pursuant to which it has licensed rights to certain drug candidates from third-party collaborators, which has resulted in the consolidation of the third parties' financial statements into the Company's condensed consolidated financial statements as VIEs. In order to account for the fair value of the contingent milestone and royalty payments related to these collaborations under GAAP, the Company uses present-value models based on assumptions regarding the probability of achieving the relevant milestones, estimates regarding the timing of achieving the milestones, estimates of future product sales and the appropriate discount rates. The Company bases its estimate of the probability of achieving the relevant milestones on industry data for similar assets and its own experience. The discount rates used in the valuation model represent a measure of credit risk and market risk associated with settling the liabilities. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period. Changes in these assumptions could have a material effect on the fair value of the contingent milestone and royalty payments. The following collaborations are reflected in the Company's financial statements as consolidated VIEs:
Parion Sciences, Inc.
License and Collaboration Agreement

On June 4, 2015, the Company entered into a strategic collaboration and license agreement (the "Parion Agreement") with Parion Sciences, Inc. (“Parion”).  Pursuant to the agreement, the Company is collaborating with Parion to develop investigational epithelial sodium channel (“ENaC”) inhibitors, including VX-371 (formerly P-1037) and VX-551 (formerly P-1055), for the potential treatment of cystic fibrosis, or CF, and other pulmonary diseases.  The Company is leading development activities for VX-371 and VX-551 and is responsible for all costs, subject to certain exceptions, related to development and commercialization of the compounds.

Pursuant to the Parion Agreement, the Company has worldwide development and commercial rights to Parion’s lead investigational ENaC inhibitors, VX-371 and VX-551, for the potential treatment of CF and all other pulmonary diseases and has the option to select additional compounds discovered in Parion’s research program.  Parion received an $80.0 million up-front payment and has the potential to receive up to an additional (i) $490.0 million in development and regulatory milestone payments for development of ENaC inhibitors in CF, including $360.0 million related to global filing and approval milestones, (ii) $370.0 million in development and regulatory milestones for VX-371 and VX-551 in non-CF pulmonary indications and (iii) $230.0 million in development and regulatory milestones should the Company elect to develop an additional ENaC inhibitor from Parion’s research program. The Company has agreed to pay Parion tiered royalties that range from the low double digits to mid-teens as a percentage of potential sales of licensed products.

The Company may terminate the Parion Agreement upon 90 days’ notice to Parion prior to any licensed product receiving marketing approval or upon 180 days’ notice after a licensed product has received marketing approval. If the Company experiences a change of control prior to the initiation of the first Phase 3 clinical trial for a licensed product, Parion may terminate the Parion Agreement upon 30 days’ notice, subject to the Company's right to receive specified royalties on any subsequent commercialization of licensed products. The Parion Agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, the Parion Agreement will continue in effect until the expiration of the Company's royalty obligations, which expire on a country-by-country basis on the later of (i) the date the last-to-expire patent covering a licensed product expires or (ii) ten years after the first commercial sale in the country.

The Company determined that Parion is a VIE based on, among other factors, the significance to Parion of the ENaC inhibitors licensed to the Company pursuant to the Parion Agreement and on the Company's power to direct the activities that most significantly affect the economic performance of Parion.  Accordingly, the Company consolidated Parion's financial statements beginning on June 4, 2015. However, the Company's interests in Parion are limited to those accorded to the Company in the Parion Agreement.

The Company recorded $255.3 million of intangible assets on the Company's condensed consolidated balance sheet for Parion's in-process research and development assets. These in-process research and development assets relate to Parion's pulmonary ENaC platform, including the intellectual property related to VX-371 and VX-551, that are licensed by Parion to the Company. The difference between the fair value of the consideration and the fair value of Parion's assets (including the fair value of intangible assets) and liabilities was allocated to goodwill. The measurement period for purchase accounting was closed during the quarter. There were no purchase accounting adjustments recorded during the measurement period.
BioAxone Biosciences, Inc.
In October 2014, the Company entered into a license and collaboration agreement (the “BioAxone Agreement”) with BioAxone Biosciences, Inc. (“BioAxone”), a privately-held biotechnology company, which resulted in the consolidation of BioAxone as a VIE beginning on October 1, 2014. The Company paid BioAxone initial payments of $10.0 million in the fourth quarter of 2014.
BioAxone has the potential to receive up to $90.0 million in milestones and fees, including development, regulatory and milestone payments and a license continuation fee. In addition, BioAxone would receive royalties and commercial milestones on future net product sales of VX-210, if any. The Company recorded an in-process research and development intangible asset of $29.0 million for VX-210 and a corresponding deferred tax liability of $11.3 million attributable to BioAxone. The Company holds an option to purchase BioAxone at a predetermined price. The option expires on the earliest of (a) the day the FDA accepts the Biologics License Application submission for VX-210, (b) the day the Company elects to continue the license instead of exercising the option to purchase BioAxone and (c) March 15, 2018, subject to the Company’s option to extend this date by one year.
Aggregate VIE Financial Information

An aggregate summary of net loss attributable to noncontrolling interest related to the Company's VIEs for the three and six months ended June 30, 2016 and 2015 is as follows:
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2016
 
2015
 
2016
 
2015
 
(in thousands)
Loss attributable to noncontrolling interest before provision for income taxes
$
2,835

 
$
1,293

 
$
3,674

 
$
1,579

Provision for income taxes
17,511

 
29,653

 
20,573

 
29,590

(Increase) decrease in fair value of contingent milestone and royalty payments
(48,720
)
 
1,198

 
(58,150
)
 
1,073

Net (income) loss attributable to noncontrolling interest
$
(28,374
)
 
$
32,144

 
$
(33,903
)
 
$
32,242



The increases in the fair value of the contingent milestone and royalty payments in the three and six months ended June 30, 2016 were primarily due to a Phase 2 clinical trial of VX-371, a compound being developed pursuant to the Parion Agreement, achieving its primary safety endpoint in the second quarter of 2016. The fair value of the contingent milestone and royalty payments also reflects changes in market interest rates and the time value of money. During the three and six months ended June 30, 2016 and 2015, the increase (decrease) in the fair value of the contingent milestone and royalty payments related to the Company's VIEs was as follows:
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2016
 
2015
 
2016
 
2015
 
(in thousands)
Parion
$
48,400

 
$
(1,621
)
 
$
57,400

 
$
(1,621
)
BioAxone
320

 
423

 
750

 
548



As of June 30, 2016, the fair value of the contingent milestone and royalty payments related to the Parion Agreement and the BioAxone Agreement was $231.4 million and $28.7 million, respectively. As of December 31, 2015, the fair value of the contingent milestone and royalty payments related to the Parion collaboration and the BioAxone collaboration was $179.0 million and $28.0 million, respectively.

The following table summarizes items related to the Company's VIEs included in the Company's condensed consolidated balance sheets as of the dates set forth in the table:
 
June 30, 2016
 
December 31, 2015
 
(in thousands)
Restricted cash and cash equivalents (VIE)
$
70,513

 
$
78,910

Prepaid expenses and other current assets
3,001

 
3,138

Intangible assets
284,340

 
284,340

Goodwill
19,391

 
19,391

Other assets
383

 
455

Accounts payable
1,129

 
676

Taxes payable
11,723

 
24,554

Other current liabilities
7,059

 
7,100

Deferred tax liability, net
132,810

 
110,438

Other liabilities
310

 
300

Noncontrolling interest
187,491

 
153,661



The Company has recorded the VIEs' cash and cash equivalents as restricted cash and cash equivalents (VIE) because (i) the Company does not have any interest in or control over the VIEs' cash and cash equivalents and (ii) the Company's agreements with each VIE do not provide for the VIEs' cash and cash equivalents to be used for the development of the assets that the Company licensed from the applicable VIE. Assets recorded as a result of consolidating the Company's VIEs' financial condition into the Company's balance sheet do not represent additional assets that could be used to satisfy claims against the Company's general assets.
Outlicense Arrangements
In the ordinary course of the Company's business, the Company has entered into various agreements pursuant to which it has outlicensed rights to certain drug candidates to third-party collaborators. Although the Company does not consider any of these outlicense arrangements to be material, the most notable of these outlicense arrangements is described below. Pursuant to these outlicense arrangements, our collaborators are responsible for all costs related to the continued development of such drug candidates. Depending on the terms of the arrangements, the Company's collaborators may be required to make upfront payments, milestone payments upon the achievement of certain product research and development objectives and/or pay royalties on future sales, if any, of commercial products resulting from the collaboration.

Janssen Pharmaceuticals, Inc.
In June 2014, the Company entered into an agreement (the “Janssen Influenza Agreement”) with Janssen Pharmaceuticals, Inc. (“Janssen Inc.”), which was amended in October 2014 to clarify certain roles and responsibilities of the parties.

Pursuant to the Janssen Influenza Agreement, Janssen Inc. has an exclusive worldwide license to develop and commercialize certain drug candidates for the treatment of influenza, including VX-787. The Company received non-refundable payments of $35.0 million from Janssen Inc. in 2014, which were recorded as collaborative revenue. The Company has the potential to receive development, regulatory and commercial milestone payments as well as royalties on future product sales, if any. Janssen Inc. may terminate the Janssen Influenza Agreement, subject to certain exceptions, upon six months' notice.
Janssen Inc. is responsible for costs related to the development and commercialization of the compounds. During the three and six months ended June 30, 2016, the Company recorded reimbursement for these development activities of $4.3 million and $7.8 million, respectively. During the three and six months ended June 30, 2015, the Company recorded reimbursement for these development activities of $7.1 million and $14.7 million, respectively. The reimbursements are recorded as a reduction to development expense in the Company's condensed consolidated statements of operations primarily due to the fact that Janssen Inc. directs the activities and selects the suppliers associated with these activities.
Subsequent Event
Moderna Therapeutics, Inc.
In July 2016, the Company entered into a strategic collaboration and licensing agreement (the "Moderna Agreement") with Moderna Therapeutics, Inc. ("Moderna") pursuant to which the parties are seeking to identify and develop messenger Ribonucleic Acid ("mRNA") Therapeutics™ for the treatment of CF. In connection with the Moderna Agreement in the third quarter of 2016, the Company made an upfront payment to Moderna of $20.0 million and made a $20.0 million investment in Moderna pursuant to a convertible promissory note. Moderna has the potential to receive future development and regulatory milestones of up to $275.0 million, including $220.0 million in approval and reimbursement milestones, as well as tiered royalty payments on future sales.
Under the terms of the collaboration, Moderna will lead discovery efforts and the Company will lead all preclinical, development and commercialization activities associated with the advancement of mRNA Therapeutics that result from this collaboration and will fund all expenses related to the collaboration.
The Company may terminate the Moderna Agreement by providing advanced notice to Moderna, with the required length of notice dependent on whether any product developed under the Moderna Agreement has received marketing approval. The Moderna Agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, the Moderna Agreement will continue in effect until the expiration of the Company's payment obligations under the Moderna Agreement.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.5.0.2
Earnings Per Share
 6 Months Ended
Jun. 30, 2016
Earnings Per Share [Abstract]  
Earnings Per Share
Earnings Per Share
Basic net loss per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period, excluding restricted stock and restricted stock units that have been issued but are not yet vested. Diluted net loss per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period when the effect is dilutive.
The Company did not include the securities in the following table in the computation of the net loss per share attributable to Vertex common shareholders calculations because the effect would have been anti-dilutive during each period:
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2016
 
2015
 
2016
 
2015
 
(in thousands)
Stock options
12,231

 
11,933

 
12,231

 
11,933

Unvested restricted stock and restricted stock units
3,506

 
3,355

 
3,506

 
3,355
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.5.0.2
Fair Value Measurements
 6 Months Ended
Jun. 30, 2016
Fair Value Disclosures [Abstract]  
Fair Value Measurements
Fair Value Measurements
The fair value of the Company’s financial assets and liabilities reflects the Company’s estimate of amounts that it would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company’s assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:
Level 1:
Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2:
Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
Level 3:
Unobservable inputs based on the Company’s assessment of the assumptions that market participants would use in pricing the asset or liability.
The Company’s investment strategy is focused on capital preservation. The Company invests in instruments that meet the credit quality standards outlined in the Company’s investment policy. This policy also limits the amount of credit exposure to any one issue or type of instrument. As of June 30, 2016, the Company’s investments were in money market funds, short-term government-sponsored enterprise securities, U.S. Treasury securities, corporate debt securities and commercial paper.
As of June 30, 2016, all of the Company’s financial assets that were subject to fair value measurements were valued using observable inputs. The Company’s financial assets valued based on Level 1 inputs consisted of money market funds, short-term government-sponsored enterprise securities and U.S. Treasury securities. The Company’s financial assets valued based on Level 2 inputs consisted of corporate debt securities and commercial paper, which consisted of investments in highly-rated investment-grade corporations.
The following table sets forth the Company’s financial assets (excluding VIE cash and cash equivalents) and liabilities subject to fair value measurements:
 
Fair Value Measurements as
of June 30, 2016
 
 
 
Fair Value Hierarchy
 
Total
 
Level 1
 
Level 2
 
Level 3
 
(in thousands)
Financial assets carried at fair value:
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
110,696

 
$
110,696

 
$
—

 
$
—

Marketable securities:
 
 
 
 
 
 
 
U.S. Treasury securities
33,142

 
33,142

 
—

 
—

Government-sponsored enterprise securities
131,900

 
131,900

 
—

 
—

Corporate debt securities
135,675

 
—

 
135,675

 
—

Commercial paper
164,853

 
—

 
164,853

 
—

Prepaid and other current assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
9,966

 
—

 
9,966

 
—

Other assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
1,604

 
—

 
1,604

 
—

Total financial assets
$
587,836


$
275,738

 
$
312,098

 
$
—

Financial liabilities carried at fair value:
 
 
 
 
 
 
 
Other liabilities, current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
$
(7,317
)
 
$
—

 
$
(7,317
)
 
$
—

Other liabilities, excluding current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
(88
)
 
—

 
(88
)
 
—

Total financial liabilities
$
(7,405
)
 
$
—

 
$
(7,405
)
 
$
—


 
Fair Value Measurements as
of December 31, 2015
 
 
 
Fair Value Hierarchy
 
Total
 
Level 1
 
Level 2
 
Level 3
 
(in thousands)
Financial instruments carried at fair value (asset position):
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
199,507

 
$
199,507

 
$
—

 
$
—

Government-sponsored enterprise securities
85,994

 
85,994

 
—

 
—

Commercial paper
34,889

 
—

 
34,889

 
—

Corporate debt securities
11,533

 
—

 
11,533

 
—

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities
87,162

 
87,162

 
—

 
—

Commercial paper
99,123

 
—

 
99,123

 
—

Corporate debt securities
141,409

 
—

 
141,409

 
—

Prepaid and other current assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
5,161

 
—

 
5,161

 
—

Other assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
605

 
$
—

 
605

 
$
—

Total financial assets
$
665,383

 
$
372,663

 
$
292,720

 
$
—

Financial instruments carried at fair value (liability position):
 
 
 
 
 
 
 
Other liabilities, current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
$
(769
)
 
$
—

 
$
(769
)
 
$
—

Other liabilities, excluding current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
(132
)
 
—

 
(132
)
 
—

Total financial liabilities
$
(901
)
 
$
—

 
$
(901
)
 
$
—


The Company's VIEs invested in cash equivalents consisting of money market funds of $70.2 million as of June 30, 2016, which are valued based on Level 1 inputs. These cash equivalents are not included in the table above. The Company’s noncontrolling interest related to VIEs includes the fair value of the contingent milestone and royalty payments, which are valued based on Level 3 inputs. Please refer to Note C, “Collaborative Arrangements,” for further information.
As of June 30, 2016, the fair value and carrying value of the Company's Term Loan was $296.5 million. The fair value of the Company's Term Loan was estimated based on Level 3 inputs computed using the effective interest rate of the Term Loan. The effective interest rate considers the timing and amount of estimated future interest payments as well as current market rates. Please refer to Note K, "Long-term Obligations" for further information regarding the Company's Term Loan.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.5.0.2
Marketable Securities
 6 Months Ended
Jun. 30, 2016
Cash and Cash Equivalents [Abstract]  
Marketable Securities
Marketable Securities
A summary of the Company’s cash, cash equivalents and marketable securities is shown below:
 
Amortized Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Fair Value
 
(in thousands)
As of June 30, 2016
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
Cash and money market funds
$
605,866

 
$
—

 
$
—

 
$
605,866

Total cash and cash equivalents
$
605,866

 
$
—

 
$
—

 
$
605,866

Marketable securities:
 
 
 
 
 
 
 
U.S. Treasury securities (due within 1 year)
$
33,138

 
$
4

 
$
—

 
$
33,142

Government-sponsored enterprise securities (due within 1 year)
131,868

 
35

 
(3
)
 
131,900

Commercial paper (due within 1 year)
164,575

 
278

 
—

 
164,853

Corporate debt securities (due within 1 year)
135,663

 
34

 
(22
)
 
135,675

Total marketable securities
$
465,244

 
$
351

 
$
(25
)
 
$
465,570

Total cash, cash equivalents and marketable securities
$
1,071,110

 
$
351

 
$
(25
)
 
$
1,071,436

 
 
 
 
 
 
 
 
As of December 31, 2015
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
Cash and money market funds
$
582,352

 
$
—

 
$
—

 
$
582,352

Government-sponsored enterprise securities
85,994

 
—

 
—

 
85,994

Commercial paper
34,889

 
—

 
—

 
34,889

Corporate debt securities
11,533

 
—

 
—

 
11,533

Total cash and cash equivalents
$
714,768

 
$
—

 
$
—

 
$
714,768

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities (due within 1 year)
$
87,176

 
$
—

 
$
(14
)
 
$
87,162

Commercial paper (due within 1 year)
98,877

 
246

 
—

 
99,123

Corporate debt securities (due within 1 year)
141,515

 
—

 
(106
)
 
141,409

Total marketable securities
$
327,568

 
$
246

 
$
(120
)
 
$
327,694

Total cash, cash equivalents and marketable securities
$
1,042,336

 
$
246

 
$
(120
)
 
$
1,042,462


The Company has a limited number of marketable securities in insignificant loss positions as of June 30, 2016, which the Company does not intend to sell and has concluded it will not be required to sell before recovery of the amortized costs for the investment at maturity. There were no charges recorded for other-than-temporary declines in fair value of marketable securities nor gross realized gains or losses recognized in the three and six months ended June 30, 2016 and 2015.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.5.0.2
Accumulated Other Comprehensive (Loss) Income
 6 Months Ended
Jun. 30, 2016
Equity [Abstract]  
Accumulated Other Comprehensive (Loss) Income
Accumulated Other Comprehensive (Loss) Income
A summary of the Company's changes in accumulated other comprehensive (loss) income by component is shown below:
 
Foreign Currency Translation Adjustment
 
Unrealized Holding Gains (Losses) on Marketable Securities
 
Unrealized Gains on Foreign Currency Forward Contracts, net of tax
 
Total
 
(in thousands)
Balance at December 31, 2015
$
(2,080
)
 
$
126

 
$
3,778

 
$
1,824

Other comprehensive (loss) income before reclassifications
(5,201
)
 
200

 
1,847

 
(3,154
)
Amounts reclassified from accumulated other comprehensive loss
—

 
—

 
(2,060
)
 
(2,060
)
Net current period other comprehensive (loss) income
$
(5,201
)
 
$
200

 
$
(213
)
 
$
(5,214
)
Balance at June 30, 2016
$
(7,281
)
 
$
326

 
$
3,565

 
$
(3,390
)

 
Foreign Currency Translation Adjustment
 
Unrealized Holding (Losses) Gains on Marketable Securities
 
Unrealized Gains (Losses) on Foreign Currency Forward Contracts
 
Total
 
(in thousands)
Balance at December 31, 2014
$
(971
)
 
$
(123
)
 
$
2,011

 
$
917

Other comprehensive (loss) income before reclassifications
1,220

 
130

 
(1,370
)
 
(20
)
Amounts reclassified from accumulated other comprehensive loss
—

 
—

 
(2,604
)
 
(2,604
)
Net current period other comprehensive (loss) income
$
1,220

 
$
130

 
$
(3,974
)
 
$
(2,624
)
Balance at June 30, 2015
$
249

 
$
7

 
$
(1,963
)
 
$
(1,707
)
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.5.0.2
Hedging
 6 Months Ended
Jun. 30, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Hedging
Hedging
The Company maintains a hedging program intended to mitigate the effect of changes in foreign exchange rates for a portion of the Company’s forecasted product revenues denominated in certain foreign currencies. The program includes foreign currency forward contracts that are designated as cash flow hedges under GAAP having contractual durations from one to eighteen months.
The Company formally documents the relationship between foreign currency forward contracts (hedging instruments) and forecasted product revenues (hedged items), as well as the Company's risk management objective and strategy for undertaking various hedging activities, which includes matching all foreign currency forward contracts that are designated as cash flow hedges to forecasted transactions. The Company also formally assesses, both at the hedge’s inception and on an ongoing basis, whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If the Company determines that a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, the Company would discontinue hedge accounting treatment prospectively. The Company measures effectiveness based on the change in fair value of the forward contracts and the fair value of the hypothetical foreign currency forward contracts with terms that match the critical terms of the risk being hedged. As of June 30, 2016, all hedges were determined to be highly effective and the Company had not recorded any ineffectiveness related to the hedging program.
The following table summarizes the notional amount of the Company’s outstanding foreign currency forward contracts designated as cash flow hedges:
 
As of June 30, 2016
 
As of December 31, 2015
Foreign Currency
(in thousands)
Euro
$
193,542

 
$
103,362

British pound sterling
79,845

 
78,756

Australian dollar
28,318

 
27,167

Total foreign currency forward contracts
$
301,705

 
$
209,285


The following table summarizes the fair value of the Company's outstanding foreign currency forward contracts designated as cash flow hedges under GAAP included on the Company's condensed consolidated balance sheets:
As of June 30, 2016
Assets
 
Liabilities
Classification
 
Fair Value
 
Classification
 
Fair Value
(in thousands)
Prepaid and other current assets
 
$
9,966

 
Other liabilities, current portion
 
$
(7,317
)
Other assets
 
1,604

 
Other liabilities, excluding current portion
 
(88
)
Total assets
 
$
11,570

 
Total liabilities
 
$
(7,405
)
As of December 31, 2015
Assets
 
Liabilities
Classification
 
Fair Value
 
Classification
 
Fair Value
(in thousands)
Prepaid and other current assets
 
$
5,161

 
Other liabilities, current portion
 
$
(769
)
Other assets
 
605

 
Other liabilities, excluding current portion
 
(132
)
Total assets
 
$
5,766

 
Total liabilities
 
$
(901
)
The following table summarizes the potential effect of offsetting derivatives by type of financial instrument on the Company's condensed consolidated balance sheets:
 
As of June 30, 2016
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amounts Presented
 
Gross Amounts Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
11,570

 
$
—

 
$
11,570

 
$
(7,405
)
 
$
4,165

Total liabilities
$
(7,405
)
 
$
—

 
$
(7,405
)
 
$
7,405

 
$
—

 
As of December 31, 2015
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amounts Presented
 
Gross Amounts Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
5,766

 
$
—

 
$
5,766

 
$
(901
)
 
$
4,865

Total liabilities
$
(901
)
 
$
—

 
$
(901
)
 
$
901

 
$
—
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.5.0.2
Inventories
 6 Months Ended
Jun. 30, 2016
Inventory Disclosure [Abstract]  
Inventories
Inventories
Inventories consisted of the following:
 
As of June 30, 2016
 
As of December 31, 2015
 
(in thousands)
Raw materials
$
5,408

 
$
8,696

Work-in-process
45,807

 
40,695

Finished goods
15,374

 
7,816

Total
$
66,589

 
$
57,207
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.5.0.2
Intangible Assets and Goodwill
 6 Months Ended
Jun. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets and Goodwill
Intangible Assets and Goodwill
Intangible Assets
As of June 30, 2016 and December 31, 2015, in-process research and development intangible assets of $284.3 million were recorded on the Company's condensed consolidated balance sheet.
In June 2015, in connection with entering into the Parion Agreement, the Company recorded an in-process research and development intangible asset of $255.3 million based on the Company’s estimate of the fair value of Parion’s lead investigational ENaC inhibitors, including VX-371 and VX-551, that were licensed by the Company from Parion. The Company aggregated the fair value of the ENaC inhibitors into a single intangible asset because the phase, nature and risks of development as well as the amount and timing of benefits associated with the assets were similar. In October 2014, the Company recorded an in-process research and development intangible asset of $29.0 million based on the Company’s estimate of the fair value of VX-210, a drug candidate for patients with spinal cord injuries that was licensed by the Company from BioAxone. The Company used discount rates of 7.1% and 7.5% in the present-value models to estimate the fair values of the ENaC inhibitors and VX-210 intangible assets, respectively.
Goodwill
As of June 30, 2016 and December 31, 2015, goodwill of $50.4 million was recorded on the Company's condensed consolidated balance sheet.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.5.0.2
Long-term Obligations
 6 Months Ended
Jun. 30, 2016
Long-term Debt and Capital Lease Obligations [Abstract]  
Long-term Obligations
Long-term Obligations
Fan Pier Leases
In 2011, the Company entered into two lease agreements, pursuant to which the Company leases approximately 1.1 million square feet of office and laboratory space in two buildings (the “Buildings”) at Fan Pier in Boston, Massachusetts (the “Fan Pier Leases”). The Company commenced lease payments in December 2013, and will make lease payments pursuant to the Fan Pier Leases through December 2028. The Company has an option to extend the term of the Fan Pier Leases for an additional ten years.
Because the Company was involved in the construction project, the Company was deemed for accounting purposes to be the owner of the Buildings during the construction period and recorded project construction costs incurred by the landlord. Upon completion of the Buildings, the Company evaluated the Fan Pier Leases and determined that the Fan Pier Leases did not meet the criteria for “sale-leaseback” treatment. Accordingly, the Company began depreciating the asset and incurring interest expense related to the financing obligation in 2013. The Company bifurcates its lease payments pursuant to the Fan Pier Leases into (i) a portion that is allocated to the Buildings and (ii) a portion that is allocated to the land on which the Buildings were constructed. The portion of the lease obligations allocated to the land is treated as an operating lease that commenced in 2011.
Property and equipment, net, included $495.7 million and $502.3 million as of June 30, 2016 and December 31, 2015, respectively, related to construction costs for the Buildings. The carrying value of the Company's lease agreement liability for the Buildings was $472.8 million and $473.0 million as of June 30, 2016 and December 31, 2015, respectively.
San Diego Lease
On December 2, 2015, the Company entered into a lease agreement for 3215 Merryfield Row, San Diego, California with ARE-SD Region No. 23, LLC. Pursuant to this agreement, the Company agreed to lease approximately 170,000 square feet of office and laboratory space in a building to be built in San Diego, California. The lease will commence upon completion of the building, scheduled for the second half of 2017, and will extend for 16 years from the commencement date. Pursuant to the lease agreement, during the initial 16-year term, the Company will pay an average of approximately $10.2 million per year in aggregate rent, exclusive of operating expenses. The Company has the option to extend the lease term for up to two additional five-year terms.

Term Loan
In July 2014, the Company entered into a credit agreement with the lenders party thereto, and Macquarie US Trading LLC ("Macquarie"), as administrative agent. The credit agreement provides for a $300.0 million senior secured term loan ("Term Loan"). The credit agreement also provides that, subject to satisfaction of certain conditions, the Company may request that the lenders establish an incremental senior secured term loan facility in an aggregate amount not to exceed $200.0 million.
The Term Loan initially bore interest at a rate of 7.2% per annum, which was reduced to 6.2% per annum based on the FDA's approval of ORKAMBI. The Term Loan bears interest at a rate of LIBOR plus 5.0% per annum during the third year of the term.
The maturity date of all loans under the facilities is July 9, 2017. Interest is payable quarterly and on the maturity date. In October 2015, the Company amended the terms of the credit agreement to provide for, among other things, a modification to the repayment schedule of the loan. As amended, the Company is required to repay principal on the Term Loan in quarterly installments of $75 million from October 1, 2016 through the maturity date.
The Company may prepay the Term Loan, in whole or in part, at any time; provided that prepayments prior to the July 9, 2016 are subject to a make-whole premium to ensure Macquarie receives approximately the present value of two years of interest payments over the life of the loan. The Company accounted for the amendment as a debt modification, as opposed to an extinguishment of debt, based on an insignificant change to the present value of the future cash flows relating to the credit agreement.
The Company's obligations under the Term Loan are unconditionally guaranteed by certain of its domestic subsidiaries. All obligations under the Term Loan, and the guarantees of those obligations, are secured, subject to certain exceptions, by substantially all of the Company's assets and the assets of all guarantors, including the pledge of all or a portion of the equity interests of certain of its subsidiaries.
The credit agreement requires that the Company maintain, on a quarterly basis, a minimum level of KALYDECO net revenues. Further, the credit agreement includes negative covenants, subject to exceptions, restricting or limiting the Company's ability and the ability of its subsidiaries to, among other things, incur additional indebtedness, grant liens, engage in certain investment, acquisition and disposition transactions, pay dividends, repurchase capital stock and enter into transactions with affiliates. The credit agreement also contains customary representations and warranties, affirmative covenants and events of default, including payment defaults, breach of representations and warranties, covenant defaults and cross defaults. If an event of default occurs, the administrative agent would be entitled to take various actions, including the acceleration of amounts due under outstanding loans. There have been no events of default as of or during the period ended June 30, 2016.
Based on the Company's evaluation of the Term Loan, the Company determined that the Term Loan contains several embedded derivatives. These embedded derivatives are clearly and closely related to the host instrument because they relate to the Company's credit risk; therefore, they do not require bifurcation from the host instrument, the Term Loan.
The Company incurred $5.3 million in fees paid to Macquarie that were recorded as a discount on the Term Loan and are being recorded as interest expense using the effective interest method over the term of the loan in the Company’s condensed consolidated statements of operations. As of June 30, 2016 and December 31, 2015, the unamortized discount associated with the Term Loan that was included in the senior secured term loan caption on the Company’s condensed consolidated balance sheet was $3.4 million and $4.6 million, respectively.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stock-based Compensation Expense
 6 Months Ended
Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-based Compensation Expense
Stock-based Compensation Expense
During the three and six months ended June 30, 2016 and 2015, the Company recognized the following stock-based compensation expense:
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2016
 
2015
 
2016
 
2015
 
(in thousands)
Stock-based compensation expense by type of award:
 
 
 
 
 
 
 
Stock options
$
31,826

 
$
37,687

 
$
58,086

 
$
66,646

Restricted stock and restricted stock units
29,608

 
24,902

 
57,141

 
52,071

ESPP share issuances
1,436

 
1,825

 
3,960

 
3,965

Less stock-based compensation expense capitalized to inventories
(928
)
 
(1,153
)
 
(1,773
)
 
(2,037
)
Total stock-based compensation included in costs and expenses
$
61,942

 
$
63,261

 
$
117,414

 
$
120,645

 
 
 
 
 
 
 


Stock-based compensation expense by line item:
 
 
 
 
 
 
 
Research and development expenses
$
40,640

 
$
41,632

 
$
75,088

 
$
79,849

Sales, general and administrative expenses
21,302

 
21,629

 
42,326

 
40,796

Total stock-based compensation included in costs and expenses
$
61,942

 
$
63,261

 
$
117,414

 
$
120,645


The following table sets forth the Company's unrecognized stock-based compensation expense, net of estimated forfeitures, by type of award and the weighted-average period over which that expense is expected to be recognized:
 
As of June 30, 2016
 
Unrecognized Expense,
Net of
Estimated Forfeitures
 
Weighted-average
Recognition
Period
 
(in thousands)
 
(in years)
Type of award:
 
 
 
Stock options
$
176,251

 
2.66
Restricted stock and restricted stock units
$
201,858

 
2.57
ESPP share issuances
$
5,546

 
0.64

The following table summarizes information about stock options outstanding and exercisable at June 30, 2016:
 
 
Options Outstanding
 
Options Exercisable
Range of Exercise Prices
 
Number
Outstanding
 
Weighted-average
Remaining
Contractual Life
 
Weighted-average
Exercise Price
 
Number
Exercisable
 
Weighted-average
Exercise Price
 
 
(in thousands)
 
(in years)
 
(per share)
 
(in thousands)
 
(per share)
$18.93–$20.00
 
137

 
1.61
 
$
18.93

 
137

 
$
18.93

$20.01–$40.00
 
1,964

 
3.45
 
$
34.24

 
1,962

 
$
34.23

$40.01–$60.00
 
2,066

 
6.07
 
$
48.14

 
1,657

 
$
48.66

$60.01–$80.00
 
1,368

 
7.62
 
$
75.90

 
734

 
$
75.39

$80.01–$100.00
 
3,555

 
8.60
 
$
90.68

 
1,080

 
$
88.91

$100.01–$120.00
 
1,644

 
8.57
 
$
109.32

 
500

 
$
109.27

$120.01–$134.69
 
1,497

 
9.05
 
$
130.61

 
420

 
$
129.84

Total
 
12,231

 
7.21
 
$
79.37

 
6,490

 
$
63.32
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.5.0.2
Other Arrangements
 6 Months Ended
Jun. 30, 2016
Other Income and Expenses [Abstract]  
Other Arrangements
Other Arrangements
Sale of HIV Protease Inhibitor Royalty Stream
In 2008, the Company sold to a third party its rights to receive royalty payments from GlaxoSmithKline plc, net of royalty amounts to be earned by and due to a third party, for a one-time cash payment of $160.0 million. These royalty payments relate to net sales of HIV protease inhibitors, which had been developed pursuant to a collaboration agreement between the Company and GlaxoSmithKline plc. As of June 30, 2016, the Company had $18.9 million in deferred revenues related to the one-time cash payment, which it is recognizing over the life of the collaboration agreement with GlaxoSmithKline plc based on the units-of-revenue method. In addition, the Company continues to recognize royalty revenues equal to the amount of the third-party subroyalty and an offsetting royalty expense for the third-party subroyalty payment.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.5.0.2
Income Taxes
 6 Months Ended
Jun. 30, 2016
Income Tax Disclosure [Abstract]  
Income Taxes
Income Taxes
The Company is subject to United States federal, state, and foreign income taxes. For the three and six months ended June 30, 2016, the Company recorded a provision for income taxes of $18.1 million and $23.6 million, respectively. The provision for income taxes recorded in the three and six months ended June 30, 2016 included $17.5 million and $20.6 million, respectively, related to the Company's VIEs' income tax provision. The Company has no liability for taxes payable by the Company's VIEs and the income tax provision and related liability have been allocated to noncontrolling interest (VIE). For the three and six months ended June 30, 2015, the Company recorded a provision for income taxes of $30.1 million and $30.4 million, respectively, primarily related to the Company's VIEs' income tax provision.
As of June 30, 2016 and December 31, 2015, the Company had unrecognized tax benefits of $0.4 million. The Company recognizes interest and penalties related to income taxes as a component of income tax expense. As of June 30, 2016, no interest and penalties have been accrued. The Company does not expect that its unrecognized tax benefits will materially increase within the next twelve months. The Company did not recognize any material interest or penalties related to uncertain tax positions as of June 30, 2016 and December 31, 2015. In 2016, it is reasonably possible that the Company will reduce the balance of its unrecognized tax benefits by approximately $0.4 million due to the application of statute of limitations and settlements with taxing authorities, all of which would reduce the Company’s effective tax rate.
The Company continues to maintain a valuation allowance against certain deferred tax assets where it is more likely than not that the deferred tax asset will not be realized because of its extended history of annual losses.
The Company files United States federal income tax returns and income tax returns in various state, local and foreign jurisdictions. The Company is no longer subject to any tax assessment from an income tax examination in the United States before 2011 or any other major taxing jurisdiction for years before 2009, except where the Company has net operating losses or tax credit carryforwards that originated before 2009. The Company currently is under examination by the Internal Revenue Service for the year ended December 31, 2011 and in Delaware, Canada and Quebec for varying periods including the years ended December 31, 2011 through 2014. No adjustments have been reported. The Company is not under examination by any other jurisdictions for any tax year. The Company concluded audits with Pennsylvania and Texas during 2016 and Massachusetts and New York during 2015 with no material adjustments.
The Company currently intends to reinvest the total amount of its unremitted earnings. At June 30, 2016, foreign earnings, which were not significant, have been retained indefinitely by foreign subsidiary companies for reinvestment; therefore, no provision has been made for income taxes that would be payable upon the distribution of such earnings, and it would not be practicable to determine the amount of the related unrecognized deferred income tax liability. Upon repatriation of those earnings, in the form of dividends or otherwise, the Company would be subject to United States federal income taxes (subject to an adjustment for foreign tax credits) and withholding taxes payable to the various foreign countries.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.5.0.2
Restructuring Liabilities
 6 Months Ended
Jun. 30, 2016
Restructuring and Related Activities [Abstract]  
Restructuring Liabilities
Restructuring Liabilities
2003 Kendall Restructuring
In 2003, the Company adopted a plan to restructure its operations to coincide with its increasing internal emphasis on advancing drug candidates through clinical development to commercialization. The restructuring liability relates to specialized laboratory and office space that is leased to the Company pursuant to a 15-year lease that terminates in 2018. The Company has not used more than 50% of this space since it adopted the plan to restructure its operations in 2003. This unused laboratory and office space currently is subleased to third parties.
The activities related to the restructuring liability for the three and six months ended June 30, 2016 and 2015 were as follows:
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2016
 
2015
 
2016
 
2015
 
(in thousands)
 
 
 
 
Liability, beginning of the period
$
7,224

 
$
9,506

 
$
7,944

 
$
11,596

Cash payments
(3,833
)
 
(2,584
)
 
(7,764
)
 
(6,569
)
Cash received from subleases
3,008

 
2,799

 
6,016

 
5,275

Restructuring expense (income)
(11
)
 
203

 
192

 
(378
)
Liability, end of the period
$
6,388

 
$
9,924

 
$
6,388

 
$
9,924



Fan Pier Move Restructuring
In connection with the relocation of its Massachusetts operations to Fan Pier in Boston, Massachusetts, which commenced in 2013, the Company is incurring restructuring charges related to its remaining lease obligations at its facilities in Cambridge, Massachusetts. The majority of these restructuring charges were recorded in the third quarter of 2014 upon decommissioning three facilities in Cambridge. During the first quarter of 2015, the Company terminated two of these lease agreements resulting in a credit to restructuring expense equal to the difference between the Company’s estimated future cash flows related to its lease obligations for these facilities and the termination payment paid to the Company’s landlord on the effective date of the termination. The third major facility included in this restructuring activity is 120,000 square feet of the Kendall Square Facility that the Company continued to use for its operations following its 2003 Kendall Restructuring. The rentable square footage in this portion of the Kendall Square Facility was subleased to a third party in February 2015. The Company will continue to incur charges through April 2018 related to the difference between the Company’s estimated future cash flows related to this portion of the Kendall Square Facility, which include an estimate for sublease income to be received from the Company's sublessee and its actual cash flows. The Company discounted the estimated cash flows related to this restructuring activity at a discount rate of 9%.
The activities related to the restructuring liability for the three and six months ended June 30, 2016 and 2015 were as follows:
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2016
 
2015
 
2016
 
2015
 
(in thousands)
 
 
 
 
Liability, beginning of the period
$
5,449

 
$
11,137

 
$
5,964

 
$
33,390

Cash payments
(3,096
)
 
(3,095
)
 
(6,252
)
 
(22,351
)
Cash received from subleases
2,361

 
—

 
4,769

 
—

Restructuring expense (income)
149

 
975

 
382

 
(2,022
)
Liability, end of the period
$
4,863

 
$
9,017

 
$
4,863

 
$
9,017


Other Restructuring Activities
The Company has engaged in several other restructuring activities that are unrelated to its 2003 Kendall Restructuring and the Fan Pier Move Restructuring. The most significant activity commenced in October 2013 when the Company adopted a restructuring plan that included (i) a workforce reduction primarily related to the commercial support of INCIVEK following the continued and rapid decline in the number of patients being treated with INCIVEK as new medicines for the treatment of HCV infection neared approval and (ii) the write-off of certain assets. This action resulted from the Company's decision to focus its investment on future opportunities in CF and other research and development programs.
The activities related to the Company's other restructuring liabilities for the three and six months ended June 30, 2016 and 2015 were as follows:
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2016
 
2015
 
2016
 
2015
 
(in thousands)
 
 
 
 
Liability, beginning of the period
$
1,262

 
$
845

 
$
1,450

 
$
869

Cash payments
(234
)
 
(893
)
 
(673
)
 
(1,223
)
Restructuring expense
205

 
950

 
456

 
1,256

Liability, end of the period
$
1,233

 
$
902

 
$
1,233

 
$
902
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.5.0.2
Commitments and Contingencies
 6 Months Ended
Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
Commitments and Contingencies
Financing Arrangements
As of June 30, 2016, the Company had irrevocable stand-by letters of credit outstanding that were issued in connection with property leases and other similar agreements totaling $21.9 million that are cash collateralized. The cash used to support these letters of credit is included in restricted cash, as of June 30, 2016, on the Company's condensed consolidated balance sheet.
Litigation
On May 28, 2014, a purported shareholder class action Local No. 8 IBEW Retirement Plan & Trust v. Vertex Pharmaceuticals Incorporated, et al. was filed in the United States District Court for the District of Massachusetts, naming the Company and certain of the Company's current and former officers and directors as defendants. The lawsuit alleged that the Company made material misrepresentations and/or omissions of material fact in the Company's disclosures during the period from May 7, 2012 through May 29, 2012, all in violation of Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. The purported class consists of all persons (excluding defendants) who purchased the Company’s common stock between May 7, 2012 and May 29, 2012. The plaintiffs seek unspecified monetary damages, costs and attorneys’ fees as well as disgorgement of the proceeds from certain individual defendants’ sales of the Company’s stock. On October 8, 2014, the Court approved Local No. 8 IBEW Retirement Fund as lead plaintiff, and Scott and Scott LLP as lead counsel for the plaintiff and the putative class. On February 23, 2015, the Company filed a reply to the plaintiffs’ opposition to its motion to dismiss.  The court heard oral argument on the motion to dismiss on March 6, 2015 and took the motion under advisement. On September 30, 2015, the court granted the Company's motion to dismiss. On October 15, 2015, the plaintiff filed a notice of appeal. The First Circuit Court of Appeals issued a scheduling order on December 24, 2015. On February 2, 2016, the Plaintiff filed their opening brief and the Company filed its opposition brief on March 7, 2016. On March 24, 2016, the plaintiff filed their reply brief. Oral argument on the appeal took place on July 26, 2016. The Company believes the claims to be without merit and intend to vigorously defend the litigation. As of June 30, 2016, the Company has not recorded any reserves for this purported class action.
Guaranties and Indemnifications
As permitted under Massachusetts law, the Company’s Articles of Organization and By-laws provide that the Company will indemnify certain of its officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that the Company could be required to make under these indemnification provisions is unlimited. However, the Company has purchased directors’ and officers’ liability insurance policies that could reduce its monetary exposure and enable it to recover a portion of any future amounts paid. No indemnification claims currently are outstanding, and the Company believes the estimated fair value of these indemnification arrangements is minimal.
The Company customarily agrees in the ordinary course of its business to indemnification provisions in agreements with clinical trial investigators and sites in its drug development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for the Company and its real estate leases. The Company also customarily agrees to certain indemnification provisions in its drug discovery, development and commercialization collaboration agreements. With respect to the Company’s clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator’s institution relating to personal injury or property damage, violations of law or certain breaches of the Company’s contractual obligations arising out of the research or clinical testing of the Company’s compounds or drug candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by the Company, to violations of law by the Company or to certain breaches of the Company’s contractual obligations. The indemnification provisions appearing in the Company’s collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for its collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although the Company believes the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that the Company could be required to make under these provisions is generally unlimited. The Company has purchased insurance policies covering personal injury, property damage and general liability that reduce its exposure for indemnification and would enable it in many cases to recover all or a portion of any future amounts paid. The Company has never paid any material amounts to defend lawsuits or settle claims related to these indemnification provisions. Accordingly, the Company believes the estimated fair value of these indemnification arrangements is minimal.
Other Contingencies
The Company has certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a reserve for contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. There were no material contingent liabilities accrued as of June 30, 2016 or December 31, 2015.
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.5.0.2
Basis of Presentation and Accounting Policies (Policies)
 6 Months Ended
Jun. 30, 2016
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company") in accordance with accounting principles generally accepted in the United States of America ("GAAP").
The condensed consolidated financial statements reflect the operations of (i) the Company, (ii) its wholly-owned subsidiaries and (iii) consolidated variable interest entities (VIEs). All material intercompany balances and transactions have been eliminated. The Company operates in one segment, pharmaceuticals.

Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended June 30, 2016 and 2015.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2015, which are contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2015 that was filed with the Securities and Exchange Commission (the “SEC”) on February 16, 2016 (the "2015 Annual Report on Form 10-K").
Use of Estimates and Summary of Significant Accounting Policies
Use of Estimates and Summary of Significant Accounting Policies
The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. Significant estimates in these condensed consolidated financial statements have been made in connection with the calculation of revenues, inventories, research and development expenses, stock-based compensation expense, restructuring expense, the fair value of intangible assets, goodwill, contingent consideration, noncontrolling interest, the consolidation of VIEs, leases, the fair value of cash flow hedges and the provision for or benefit from income taxes. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
In 2016, the Financial Accounting Standards Board (“FASB”) issued amended guidance applicable to leases that will be effective for the year ending December 31, 2019. Early adoption is permitted. This update requires an entity to recognize assets and liabilities for leases with lease terms of more than 12 months on the balance sheet. The Company is in the process of evaluating the new guidance and determining the expected effect on its consolidated financial statements.

In 2016, the FASB issued amended guidance applicable to share-based compensation to employees that will be effective for the year ending December 31, 2017. Early adoption is permitted. This update simplifies the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The Company is in the process of evaluating the new guidance and determining the expected effect on its consolidated financial statements.

For a discussion of other recent accounting pronouncements please refer to Note A, “Nature of Business and Accounting Policies—Recent Accounting Pronouncements,” in the 2015 Annual Report on Form 10-K. The Company did not adopt any new accounting pronouncements during the six months ended June 30, 2016 that had a material effect on its condensed consolidated financial statements.
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.5.0.2
Product Revenues, Net (Tables)
 6 Months Ended
Jun. 30, 2016
Product Revenues [Abstract]  
Schedule of product revenue allowances and reserve categories
The following table summarizes activity in each of the product revenue allowance and reserve categories for the six months ended June 30, 2016:
 
Trade
Allowances
 
Rebates,
Chargebacks
and Discounts
 
Product
Returns
 
Other
Incentives
 
Total
 
(in thousands)
Balance at December 31, 2015
$
2,089

 
$
44,669

 
$
1,228

 
$
1,310

 
$
49,296

Provision related to current period sales
9,935

 
65,066

 
1,288

 
4,220

 
80,509

Adjustments related to prior period sales
(77
)
 
(1,712
)
 
(205
)
 
5

 
(1,989
)
Credits/payments made
(9,762
)
 
(44,113
)
 
(260
)
 
(4,638
)
 
(58,773
)
Balance at June 30, 2016
$
2,185

 
$
63,910

 
$
2,051

 
$
897

 
$
69,043
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.5.0.2
Collaborative Arrangements (Tables)
 6 Months Ended
Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Collaborative Arrangement Activity Net Loss Attributable to Noncontrolling Interest
An aggregate summary of net loss attributable to noncontrolling interest related to the Company's VIEs for the three and six months ended June 30, 2016 and 2015 is as follows:
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2016
 
2015
 
2016
 
2015
 
(in thousands)
Loss attributable to noncontrolling interest before provision for income taxes
$
2,835

 
$
1,293

 
$
3,674

 
$
1,579

Provision for income taxes
17,511

 
29,653

 
20,573

 
29,590

(Increase) decrease in fair value of contingent milestone and royalty payments
(48,720
)
 
1,198

 
(58,150
)
 
1,073

Net (income) loss attributable to noncontrolling interest
$
(28,374
)
 
$
32,144

 
$
(33,903
)
 
$
32,242
Changes In Fair Value Of Contingent Consideration [Table Text Block]
During the three and six months ended June 30, 2016 and 2015, the increase (decrease) in the fair value of the contingent milestone and royalty payments related to the Company's VIEs was as follows:
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2016
 
2015
 
2016
 
2015
 
(in thousands)
Parion
$
48,400

 
$
(1,621
)
 
$
57,400

 
$
(1,621
)
BioAxone
320

 
423

 
750

 
548
Schedule Of Collaborative Arrangement Summary Of Items Related To Variable Interest Entities
The following table summarizes items related to the Company's VIEs included in the Company's condensed consolidated balance sheets as of the dates set forth in the table:
 
June 30, 2016
 
December 31, 2015
 
(in thousands)
Restricted cash and cash equivalents (VIE)
$
70,513

 
$
78,910

Prepaid expenses and other current assets
3,001

 
3,138

Intangible assets
284,340

 
284,340

Goodwill
19,391

 
19,391

Other assets
383

 
455

Accounts payable
1,129

 
676

Taxes payable
11,723

 
24,554

Other current liabilities
7,059

 
7,100

Deferred tax liability, net
132,810

 
110,438

Other liabilities
310

 
300

Noncontrolling interest
187,491

 
153,661
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.5.0.2
Earnings Per Share (Tables)
 6 Months Ended
Jun. 30, 2016
Earnings Per Share [Abstract]  
Potential gross common equivalent shares
The Company did not include the securities in the following table in the computation of the net loss per share attributable to Vertex common shareholders calculations because the effect would have been anti-dilutive during each period:
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2016
 
2015
 
2016
 
2015
 
(in thousands)
Stock options
12,231

 
11,933

 
12,231

 
11,933

Unvested restricted stock and restricted stock units
3,506

 
3,355

 
3,506

 
3,355
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.5.0.2
Fair Value Measurements (Tables)
 6 Months Ended
Jun. 30, 2016
Fair Value Disclosures [Abstract]  
Financial assets subject to fair value measurements (excluding restricted cash and cash equivalents (Alios))
The following table sets forth the Company’s financial assets (excluding VIE cash and cash equivalents) and liabilities subject to fair value measurements:
 
Fair Value Measurements as
of June 30, 2016
 
 
 
Fair Value Hierarchy
 
Total
 
Level 1
 
Level 2
 
Level 3
 
(in thousands)
Financial assets carried at fair value:
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
110,696

 
$
110,696

 
$
—

 
$
—

Marketable securities:
 
 
 
 
 
 
 
U.S. Treasury securities
33,142

 
33,142

 
—

 
—

Government-sponsored enterprise securities
131,900

 
131,900

 
—

 
—

Corporate debt securities
135,675

 
—

 
135,675

 
—

Commercial paper
164,853

 
—

 
164,853

 
—

Prepaid and other current assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
9,966

 
—

 
9,966

 
—

Other assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
1,604

 
—

 
1,604

 
—

Total financial assets
$
587,836


$
275,738

 
$
312,098

 
$
—

Financial liabilities carried at fair value:
 
 
 
 
 
 
 
Other liabilities, current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
$
(7,317
)
 
$
—

 
$
(7,317
)
 
$
—

Other liabilities, excluding current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
(88
)
 
—

 
(88
)
 
—

Total financial liabilities
$
(7,405
)
 
$
—

 
$
(7,405
)
 
$
—


 
Fair Value Measurements as
of December 31, 2015
 
 
 
Fair Value Hierarchy
 
Total
 
Level 1
 
Level 2
 
Level 3
 
(in thousands)
Financial instruments carried at fair value (asset position):
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
199,507

 
$
199,507

 
$
—

 
$
—

Government-sponsored enterprise securities
85,994

 
85,994

 
—

 
—

Commercial paper
34,889

 
—

 
34,889

 
—

Corporate debt securities
11,533

 
—

 
11,533

 
—

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities
87,162

 
87,162

 
—

 
—

Commercial paper
99,123

 
—

 
99,123

 
—

Corporate debt securities
141,409

 
—

 
141,409

 
—

Prepaid and other current assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
5,161

 
—

 
5,161

 
—

Other assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
605

 
$
—

 
605

 
$
—

Total financial assets
$
665,383

 
$
372,663

 
$
292,720

 
$
—

Financial instruments carried at fair value (liability position):
 
 
 
 
 
 
 
Other liabilities, current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
$
(769
)
 
$
—

 
$
(769
)
 
$
—

Other liabilities, excluding current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
(132
)
 
—

 
(132
)
 
—

Total financial liabilities
$
(901
)
 
$
—

 
$
(901
)
 
$
—
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.5.0.2
Marketable Securities (Tables)
 6 Months Ended
Jun. 30, 2016
Cash and Cash Equivalents [Abstract]  
Summary of cash, cash equivalents and marketable securities
A summary of the Company’s cash, cash equivalents and marketable securities is shown below:
 
Amortized Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Fair Value
 
(in thousands)
As of June 30, 2016
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
Cash and money market funds
$
605,866

 
$
—

 
$
—

 
$
605,866

Total cash and cash equivalents
$
605,866

 
$
—

 
$
—

 
$
605,866

Marketable securities:
 
 
 
 
 
 
 
U.S. Treasury securities (due within 1 year)
$
33,138

 
$
4

 
$
—

 
$
33,142

Government-sponsored enterprise securities (due within 1 year)
131,868

 
35

 
(3
)
 
131,900

Commercial paper (due within 1 year)
164,575

 
278

 
—

 
164,853

Corporate debt securities (due within 1 year)
135,663

 
34

 
(22
)
 
135,675

Total marketable securities
$
465,244

 
$
351

 
$
(25
)
 
$
465,570

Total cash, cash equivalents and marketable securities
$
1,071,110

 
$
351

 
$
(25
)
 
$
1,071,436

 
 
 
 
 
 
 
 
As of December 31, 2015
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
Cash and money market funds
$
582,352

 
$
—

 
$
—

 
$
582,352

Government-sponsored enterprise securities
85,994

 
—

 
—

 
85,994

Commercial paper
34,889

 
—

 
—

 
34,889

Corporate debt securities
11,533

 
—

 
—

 
11,533

Total cash and cash equivalents
$
714,768

 
$
—

 
$
—

 
$
714,768

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities (due within 1 year)
$
87,176

 
$
—

 
$
(14
)
 
$
87,162

Commercial paper (due within 1 year)
98,877

 
246

 
—

 
99,123

Corporate debt securities (due within 1 year)
141,515

 
—

 
(106
)
 
141,409

Total marketable securities
$
327,568

 
$
246

 
$
(120
)
 
$
327,694

Total cash, cash equivalents and marketable securities
$
1,042,336

 
$
246

 
$
(120
)
 
$
1,042,462
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.5.0.2
Accumulated Other Comprehensive (Loss) Income (Tables)
 6 Months Ended
Jun. 30, 2016
Equity [Abstract]  
Accumulated Other Comprehensive (Loss) Income
A summary of the Company's changes in accumulated other comprehensive (loss) income by component is shown below:
 
Foreign Currency Translation Adjustment
 
Unrealized Holding Gains (Losses) on Marketable Securities
 
Unrealized Gains on Foreign Currency Forward Contracts, net of tax
 
Total
 
(in thousands)
Balance at December 31, 2015
$
(2,080
)
 
$
126

 
$
3,778

 
$
1,824

Other comprehensive (loss) income before reclassifications
(5,201
)
 
200

 
1,847

 
(3,154
)
Amounts reclassified from accumulated other comprehensive loss
—

 
—

 
(2,060
)
 
(2,060
)
Net current period other comprehensive (loss) income
$
(5,201
)
 
$
200

 
$
(213
)
 
$
(5,214
)
Balance at June 30, 2016
$
(7,281
)
 
$
326

 
$
3,565

 
$
(3,390
)

 
Foreign Currency Translation Adjustment
 
Unrealized Holding (Losses) Gains on Marketable Securities
 
Unrealized Gains (Losses) on Foreign Currency Forward Contracts
 
Total
 
(in thousands)
Balance at December 31, 2014
$
(971
)
 
$
(123
)
 
$
2,011

 
$
917

Other comprehensive (loss) income before reclassifications
1,220

 
130

 
(1,370
)
 
(20
)
Amounts reclassified from accumulated other comprehensive loss
—

 
—

 
(2,604
)
 
(2,604
)
Net current period other comprehensive (loss) income
$
1,220

 
$
130

 
$
(3,974
)
 
$
(2,624
)
Balance at June 30, 2015
$
249

 
$
7

 
$
(1,963
)
 
$
(1,707
)
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.5.0.2
Hedging (Tables)
 6 Months Ended
Jun. 30, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Cash Flow Hedging Instruments
The following table summarizes the notional amount of the Company’s outstanding foreign currency forward contracts designated as cash flow hedges:
 
As of June 30, 2016
 
As of December 31, 2015
Foreign Currency
(in thousands)
Euro
$
193,542

 
$
103,362

British pound sterling
79,845

 
78,756

Australian dollar
28,318

 
27,167

Total foreign currency forward contracts
$
301,705

 
$
209,285
Schedule of Foreign Exchange Contracts
The following table summarizes the fair value of the Company's outstanding foreign currency forward contracts designated as cash flow hedges under GAAP included on the Company's condensed consolidated balance sheets:
As of June 30, 2016
Assets
 
Liabilities
Classification
 
Fair Value
 
Classification
 
Fair Value
(in thousands)
Prepaid and other current assets
 
$
9,966

 
Other liabilities, current portion
 
$
(7,317
)
Other assets
 
1,604

 
Other liabilities, excluding current portion
 
(88
)
Total assets
 
$
11,570

 
Total liabilities
 
$
(7,405
)
As of December 31, 2015
Assets
 
Liabilities
Classification
 
Fair Value
 
Classification
 
Fair Value
(in thousands)
Prepaid and other current assets
 
$
5,161

 
Other liabilities, current portion
 
$
(769
)
Other assets
 
605

 
Other liabilities, excluding current portion
 
(132
)
Total assets
 
$
5,766

 
Total liabilities
 
$
(901
)
Derivatives Offsetting
The following table summarizes the potential effect of offsetting derivatives by type of financial instrument on the Company's condensed consolidated balance sheets:
 
As of June 30, 2016
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amounts Presented
 
Gross Amounts Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
11,570

 
$
—

 
$
11,570

 
$
(7,405
)
 
$
4,165

Total liabilities
$
(7,405
)
 
$
—

 
$
(7,405
)
 
$
7,405

 
$
—

 
As of December 31, 2015
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amounts Presented
 
Gross Amounts Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
5,766

 
$
—

 
$
5,766

 
$
(901
)
 
$
4,865

Total liabilities
$
(901
)
 
$
—

 
$
(901
)
 
$
901

 
$
—
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.5.0.2
Inventories (Tables)
 6 Months Ended
Jun. 30, 2016
Inventory Disclosure [Abstract]  
Schedule of Inventories by Type
Inventories consisted of the following:
 
As of June 30, 2016
 
As of December 31, 2015
 
(in thousands)
Raw materials
$
5,408

 
$
8,696

Work-in-process
45,807

 
40,695

Finished goods
15,374

 
7,816

Total
$
66,589

 
$
57,207
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stock-based Compensation Expense (Tables)
 6 Months Ended
Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-based compensation expense by line item
During the three and six months ended June 30, 2016 and 2015, the Company recognized the following stock-based compensation expense:
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2016
 
2015
 
2016
 
2015
 
(in thousands)
Stock-based compensation expense by type of award:
 
 
 
 
 
 
 
Stock options
$
31,826

 
$
37,687

 
$
58,086

 
$
66,646

Restricted stock and restricted stock units
29,608

 
24,902

 
57,141

 
52,071

ESPP share issuances
1,436

 
1,825

 
3,960

 
3,965

Less stock-based compensation expense capitalized to inventories
(928
)
 
(1,153
)
 
(1,773
)
 
(2,037
)
Total stock-based compensation included in costs and expenses
$
61,942

 
$
63,261

 
$
117,414

 
$
120,645

 
 
 
 
 
 
 


Stock-based compensation expense by line item:
 
 
 
 
 
 
 
Research and development expenses
$
40,640

 
$
41,632

 
$
75,088

 
$
79,849

Sales, general and administrative expenses
21,302

 
21,629

 
42,326

 
40,796

Total stock-based compensation included in costs and expenses
$
61,942

 
$
63,261

 
$
117,414

 
$
120,645
Unrecognized stock-based compensation expense, net of estimated forfeitures
The following table sets forth the Company's unrecognized stock-based compensation expense, net of estimated forfeitures, by type of award and the weighted-average period over which that expense is expected to be recognized:
 
As of June 30, 2016
 
Unrecognized Expense,
Net of
Estimated Forfeitures
 
Weighted-average
Recognition
Period
 
(in thousands)
 
(in years)
Type of award:
 
 
 
Stock options
$
176,251

 
2.66
Restricted stock and restricted stock units
$
201,858

 
2.57
ESPP share issuances
$
5,546

 
0.64
Stock options outstanding and exercisable
The following table summarizes information about stock options outstanding and exercisable at June 30, 2016:
 
 
Options Outstanding
 
Options Exercisable
Range of Exercise Prices
 
Number
Outstanding
 
Weighted-average
Remaining
Contractual Life
 
Weighted-average
Exercise Price
 
Number
Exercisable
 
Weighted-average
Exercise Price
 
 
(in thousands)
 
(in years)
 
(per share)
 
(in thousands)
 
(per share)
$18.93–$20.00
 
137

 
1.61
 
$
18.93

 
137

 
$
18.93

$20.01–$40.00
 
1,964

 
3.45
 
$
34.24

 
1,962

 
$
34.23

$40.01–$60.00
 
2,066

 
6.07
 
$
48.14

 
1,657

 
$
48.66

$60.01–$80.00
 
1,368

 
7.62
 
$
75.90

 
734

 
$
75.39

$80.01–$100.00
 
3,555

 
8.60
 
$
90.68

 
1,080

 
$
88.91

$100.01–$120.00
 
1,644

 
8.57
 
$
109.32

 
500

 
$
109.27

$120.01–$134.69
 
1,497

 
9.05
 
$
130.61

 
420

 
$
129.84

Total
 
12,231

 
7.21
 
$
79.37

 
6,490

 
$
63.32
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.5.0.2
Restructuring Liabilities (Tables)
 6 Months Ended
Jun. 30, 2016
Kendall Restructuring  
Restructuring Cost and Reserve [Line Items]  
Activity related to restructuring liability
The activities related to the restructuring liability for the three and six months ended June 30, 2016 and 2015 were as follows:
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2016
 
2015
 
2016
 
2015
 
(in thousands)
 
 
 
 
Liability, beginning of the period
$
7,224

 
$
9,506

 
$
7,944

 
$
11,596

Cash payments
(3,833
)
 
(2,584
)
 
(7,764
)
 
(6,569
)
Cash received from subleases
3,008

 
2,799

 
6,016

 
5,275

Restructuring expense (income)
(11
)
 
203

 
192

 
(378
)
Liability, end of the period
$
6,388

 
$
9,924

 
$
6,388

 
$
9,924
Fan Pier Move Restructuring  
Restructuring Cost and Reserve [Line Items]  
Activity related to restructuring liability
The activities related to the restructuring liability for the three and six months ended June 30, 2016 and 2015 were as follows:
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2016
 
2015
 
2016
 
2015
 
(in thousands)
 
 
 
 
Liability, beginning of the period
$
5,449

 
$
11,137

 
$
5,964

 
$
33,390

Cash payments
(3,096
)
 
(3,095
)
 
(6,252
)
 
(22,351
)
Cash received from subleases
2,361

 
—

 
4,769

 
—

Restructuring expense (income)
149

 
975

 
382

 
(2,022
)
Liability, end of the period
$
4,863

 
$
9,017

 
$
4,863

 
$
9,017
Other Restructuring  
Restructuring Cost and Reserve [Line Items]  
Activity related to restructuring liability
The activities related to the Company's other restructuring liabilities for the three and six months ended June 30, 2016 and 2015 were as follows:
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2016
 
2015
 
2016
 
2015
 
(in thousands)
 
 
 
 
Liability, beginning of the period
$
1,262

 
$
845

 
$
1,450

 
$
869

Cash payments
(234
)
 
(893
)
 
(673
)
 
(1,223
)
Restructuring expense
205

 
950

 
456

 
1,256

Liability, end of the period
$
1,233

 
$
902

 
$
1,233

 
$
902
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.5.0.2
Basis of Presentation and Accounting Policies (Details)
 6 Months Ended
Jun. 30, 2016
segment
Accounting Policies [Abstract]  
Number of operating segments 1
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.5.0.2
Product Revenues, Net (Details)
$ in Thousands
 6 Months Ended
Jun. 30, 2016
USD ($)
Product Revenue Allowance and Reserve [Roll Forward]  
Balance at December 31, 2015 $ 49,296
Provision related to current period sales 80,509
Adjustments related to prior period sales (1,989)
Credits/payments made (58,773)
Balance at June 30, 2016 69,043
Trade Allowances  
Product Revenue Allowance and Reserve [Roll Forward]  
Balance at December 31, 2015 2,089
Provision related to current period sales 9,935
Adjustments related to prior period sales (77)
Credits/payments made (9,762)
Balance at June 30, 2016 2,185
Rebates, Chargebacks and Discounts  
Product Revenue Allowance and Reserve [Roll Forward]  
Balance at December 31, 2015 44,669
Provision related to current period sales 65,066
Adjustments related to prior period sales (1,712)
Credits/payments made (44,113)
Balance at June 30, 2016 63,910
Product Returns  
Product Revenue Allowance and Reserve [Roll Forward]  
Balance at December 31, 2015 1,228
Provision related to current period sales 1,288
Adjustments related to prior period sales (205)
Credits/payments made (260)
Balance at June 30, 2016 2,051
Other Incentives  
Product Revenue Allowance and Reserve [Roll Forward]  
Balance at December 31, 2015 1,310
Provision related to current period sales 4,220
Adjustments related to prior period sales 5
Credits/payments made (4,638)
Balance at June 30, 2016 $ 897
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.5.0.2
Collaborative Arrangement - Cystic Fibrosis Foundation Therapeutics Incorporated (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Apr. 30, 2011
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2015
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Dec. 31, 2013
Dec. 31, 2012
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Collaborative revenues   $ 675,000     $ 611,000 $ 749,000 $ 1,453,000    
Cystic Fibrosis Foundation Therapeutics Incorporated                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Collaborative funding $ 75,000,000                
Number of years over which funding will be made (in years) 5 years                
Collaborative revenues           $ 0 $ 0    
Milestone Revenues     $ 13,900,000 $ 13,900,000       $ 9,300,000 $ 9,300,000
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.5.0.2
Collaborative Arrangements - CRISPR Therapeutics AG (Details) - CRISPR Therapeutics
 3 Months Ended
Oct. 26, 2015
USD ($)
target
Jun. 30, 2016
USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Right to license, number of targets (up to) | target 6  
Up-front payment $ 75,000,000  
Investment in collaborative partner, pursuant to convertible loan agreement 30,000,000 $ 3,100,000
Collaborative funding 75,000,000  
Collaborative arrangement development and regulatory potential milestone payments maximum $ 420,000,000  
Prior to marketing approval, time period of notice required to terminate (in days) 90 days  
Subsequent to marketing approval, time period of notice required to terminate (in days) 270 days  
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.5.0.2
Collaborative Arrangements - Parion Sciences, Inc. (Details) - USD ($)
Jun. 04, 2015
Jun. 30, 2016
Dec. 31, 2015
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Intangible assets   $ 284,340,000 $ 284,340,000
Parion Sciences, Inc      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Up-front payment $ 80,000,000    
Prior to marketing approval, time period of notice required to terminate (in days) 90 days    
Subsequent to marketing approval, time period of notice required to terminate (in days) 180 days    
Change of control prior to clinical trial, time period of notice required to terminate (in days) 30 days    
Term of agreement following first commercial sale (in years) 10 years    
Intangible assets $ 255,300,000    
ENaC Inhibitors in CF | Parion Sciences, Inc      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Collaborative arrangement development and regulatory potential milestone payments maximum 490,000,000    
Collaborative arrangement regulatory potential milestone payments maximum, global filling and approval 360,000,000    
Enac Inhibitors in Non Cf | Parion Sciences, Inc      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Collaborative arrangement development and regulatory potential milestone payments maximum 370,000,000    
Additional Enac Inhibitors | Parion Sciences, Inc      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Collaborative arrangement development and regulatory potential milestone payments maximum $ 230,000,000    
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.5.0.2
Collaborative Arrangements Collaborative Arrangements - BioAxone Biosciences, Inc. (Details) - BioAxone Biosciences Inc - USD ($)
 1 Months Ended 3 Months Ended
Oct. 31, 2014
Dec. 31, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Up-front payment   $ 10,000,000
Maximum license fees and milestone payments $ 90,000,000.0  
In-process research and development intangible asset 29,000,000  
Deferred tax liability attributable to BioAxone $ 11,300,000  
Purchase option, term of extension of expiration date (in years) 1 year  
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.5.0.2
Collaborative Arrangements - Aggregate VIE Financial Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Dec. 31, 2015
Jun. 04, 2015
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]            
Provision for income taxes $ 18,130 $ 30,131 $ 23,615 $ 30,430    
Net (income) loss attributable to noncontrolling interest (28,374) 32,144 (33,903) 32,242    
Variable Interest Entity, Consolidated, Carrying Amount, Assets and Liabilities, Net:            
Restricted cash and cash equivalents (VIE) 70,513   70,513   $ 78,910  
Prepaid expenses and other current assets 56,256   56,256   50,935  
Intangible assets 284,340   284,340   284,340  
Goodwill 50,384   50,384   50,384  
Other assets 14,203   14,203   6,912  
Accounts payable 51,302   51,302   74,942  
Other current liabilities 275,165   275,165   305,820  
Deferred tax liability, net 132,810   132,810   110,439  
Other liabilities 30,648   30,648   31,778  
Noncontrolling interest 187,491   187,491   153,661  
BioAxone Biosciences Inc            
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]            
Contingent consideration, liability 28,700   28,700   28,000  
Parion Sciences, Inc            
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]            
Provision for income taxes 17,500   20,600      
Contingent consideration, liability 231,400   231,400   179,000  
Variable Interest Entity, Consolidated, Carrying Amount, Assets and Liabilities, Net:            
Intangible assets           $ 255,300
Variable Interest Entity, Primary Beneficiary            
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]            
Loss attributable to noncontrolling interest before provision for income taxes 2,835 1,293 3,674 1,579    
Provision for income taxes 17,511 29,653 20,573 29,590    
(Increase) decrease in fair value of contingent milestone and royalty payments 48,720 (1,198) 58,150 (1,073)    
Net (income) loss attributable to noncontrolling interest (28,374) 32,144 (33,903) 32,242    
Variable Interest Entity, Consolidated, Carrying Amount, Assets and Liabilities, Net:            
Restricted cash and cash equivalents (VIE) 70,513   70,513   78,910  
Prepaid expenses and other current assets 3,001   3,001   3,138  
Intangible assets 284,340   284,340   284,340  
Goodwill 19,391   19,391   19,391  
Other assets 383   383   455  
Accounts payable 1,129   1,129   676  
Taxes payable 11,723   11,723   24,554  
Other current liabilities 7,059   7,059   7,100  
Deferred tax liability, net 132,810   132,810   110,438  
Other liabilities 310   310   300  
Noncontrolling interest 187,491   187,491   $ 153,661  
Variable Interest Entity, Primary Beneficiary | BioAxone Biosciences Inc            
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]            
(Increase) decrease in fair value of contingent milestone and royalty payments 320 423 750 548    
Variable Interest Entity, Primary Beneficiary | Parion Sciences, Inc            
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]            
(Increase) decrease in fair value of contingent milestone and royalty payments $ 48,400 $ (1,621) $ 57,400 $ (1,621)    
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.5.0.2
Collaborative Arrangements Collaborative Arrangements - Janssen Pharmaceuticals, Inc. (Details) - Janssen - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Dec. 31, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Up-front payment         $ 35.0
Reimbursement for development and commercialization of compounds $ 4.3 $ 7.1 $ 7.8 $ 14.7  
Time period of notice required to terminate     6 months    
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.5.0.2
Collaborative Arrangements Collaborative Arrangements - Moderna Therapeutics, Inc. (Details) - Subsequent Event - Moderna Therapeutics, Inc.
$ in Millions
 1 Months Ended
Jul. 31, 2016
USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]  
Collaborative Arrangement Up-front License Fee $ 20.0
Collaborative Arrangement, Investment in Collaborative Partner, Amount 20.0
Collaborative arrangement development and regulatory potential milestone payments maximum 275.0
Collaborative Arrangement Approval and Reimbursement Milestones $ 220.0
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.5.0.2
Earnings Per Share (Details) - shares
shares in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Stock options        
Antidilutive Securities Excluded from Computation of Earnings Per Share        
Antidilutive securities excluded from computation of earnings per share (in shares) 12,231 11,933 12,231 11,933
Unvested restricted stock and restricted stock units        
Antidilutive Securities Excluded from Computation of Earnings Per Share        
Antidilutive securities excluded from computation of earnings per share (in shares) 3,506 3,355 3,506 3,355
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.5.0.2
Fair Value Measurements (Details) - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Level 3    
Financial instruments carried at fair value (liability position):    
Term loan fair value $ 296,500  
Recurring basis    
Financial assets carried at fair value:    
Total financial assets 587,836 $ 665,383
Financial instruments carried at fair value (liability position):    
Total financial liabilities (7,405) (901)
Recurring basis | Money market funds    
Financial assets carried at fair value:    
Cash equivalents 110,696 199,507
Recurring basis | Commercial paper    
Financial assets carried at fair value:    
Cash equivalents   34,889
Marketable securities 164,853 99,123
Recurring basis | U.S. Treasury securities    
Financial assets carried at fair value:    
Marketable securities 33,142  
Recurring basis | Government-sponsored enterprise securities    
Financial assets carried at fair value:    
Cash equivalents   85,994
Marketable securities 131,900 87,162
Recurring basis | Corporate debt securities    
Financial assets carried at fair value:    
Cash equivalents   11,533
Marketable securities 135,675 141,409
Recurring basis | Level 1    
Financial assets carried at fair value:    
Total financial assets 275,738 372,663
Financial instruments carried at fair value (liability position):    
Total financial liabilities 0 0
Recurring basis | Level 1 | Money market funds    
Financial assets carried at fair value:    
Cash equivalents 110,696 199,507
Recurring basis | Level 1 | Commercial paper    
Financial assets carried at fair value:    
Cash equivalents   0
Marketable securities 0 0
Recurring basis | Level 1 | U.S. Treasury securities    
Financial assets carried at fair value:    
Marketable securities 33,142  
Recurring basis | Level 1 | Government-sponsored enterprise securities    
Financial assets carried at fair value:    
Cash equivalents   85,994
Marketable securities 131,900 87,162
Recurring basis | Level 1 | Corporate debt securities    
Financial assets carried at fair value:    
Cash equivalents   0
Marketable securities 0 0
Recurring basis | Level 2    
Financial assets carried at fair value:    
Total financial assets 312,098 292,720
Financial instruments carried at fair value (liability position):    
Total financial liabilities (7,405) (901)
Recurring basis | Level 2 | Money market funds    
Financial assets carried at fair value:    
Cash equivalents 0 0
Recurring basis | Level 2 | Commercial paper    
Financial assets carried at fair value:    
Cash equivalents   34,889
Marketable securities 164,853 99,123
Recurring basis | Level 2 | U.S. Treasury securities    
Financial assets carried at fair value:    
Marketable securities 0  
Recurring basis | Level 2 | Government-sponsored enterprise securities    
Financial assets carried at fair value:    
Cash equivalents   0
Marketable securities 0 0
Recurring basis | Level 2 | Corporate debt securities    
Financial assets carried at fair value:    
Cash equivalents   11,533
Marketable securities 135,675 141,409
Recurring basis | Level 3    
Financial assets carried at fair value:    
Total financial assets 0 0
Financial instruments carried at fair value (liability position):    
Total financial liabilities 0 0
Recurring basis | Level 3 | Money market funds    
Financial assets carried at fair value:    
Cash equivalents 0 0
Recurring basis | Level 3 | Commercial paper    
Financial assets carried at fair value:    
Cash equivalents   0
Marketable securities 0 0
Recurring basis | Level 3 | U.S. Treasury securities    
Financial assets carried at fair value:    
Marketable securities 0  
Recurring basis | Level 3 | Government-sponsored enterprise securities    
Financial assets carried at fair value:    
Cash equivalents   0
Marketable securities 0 0
Recurring basis | Level 3 | Corporate debt securities    
Financial assets carried at fair value:    
Cash equivalents   0
Marketable securities 0 0
Prepaid and other current assets | Foreign currency forward contracts | Recurring basis    
Financial assets carried at fair value:    
Foreign currency forward contracts 9,966 5,161
Prepaid and other current assets | Foreign currency forward contracts | Recurring basis | Level 1    
Financial assets carried at fair value:    
Foreign currency forward contracts 0 0
Prepaid and other current assets | Foreign currency forward contracts | Recurring basis | Level 2    
Financial assets carried at fair value:    
Foreign currency forward contracts 9,966 5,161
Prepaid and other current assets | Foreign currency forward contracts | Recurring basis | Level 3    
Financial assets carried at fair value:    
Foreign currency forward contracts 0 0
Other Assets | Foreign currency forward contracts | Recurring basis    
Financial assets carried at fair value:    
Foreign currency forward contracts 1,604 605
Other Assets | Foreign currency forward contracts | Recurring basis | Level 1    
Financial assets carried at fair value:    
Foreign currency forward contracts 0 0
Other Assets | Foreign currency forward contracts | Recurring basis | Level 2    
Financial assets carried at fair value:    
Foreign currency forward contracts 1,604 605
Other Assets | Foreign currency forward contracts | Recurring basis | Level 3    
Financial assets carried at fair value:    
Foreign currency forward contracts 0 0
Other liabilities, current portion | Foreign currency forward contracts | Recurring basis    
Financial assets carried at fair value:    
Foreign currency forward contracts (7,317)  
Financial instruments carried at fair value (liability position):    
Derivative liability current   (769)
Other liabilities, current portion | Foreign currency forward contracts | Recurring basis | Level 1    
Financial assets carried at fair value:    
Foreign currency forward contracts 0  
Financial instruments carried at fair value (liability position):    
Derivative liability current   0
Other liabilities, current portion | Foreign currency forward contracts | Recurring basis | Level 2    
Financial assets carried at fair value:    
Foreign currency forward contracts (7,317)  
Financial instruments carried at fair value (liability position):    
Derivative liability current   (769)
Other liabilities, current portion | Foreign currency forward contracts | Recurring basis | Level 3    
Financial assets carried at fair value:    
Foreign currency forward contracts 0  
Financial instruments carried at fair value (liability position):    
Derivative liability current   0
Other liabilities, excluding current portion | Foreign currency forward contracts | Recurring basis    
Financial assets carried at fair value:    
Foreign currency forward contracts (88)  
Financial instruments carried at fair value (liability position):    
Derivative liability noncurrent   (132)
Other liabilities, excluding current portion | Foreign currency forward contracts | Recurring basis | Level 1    
Financial assets carried at fair value:    
Foreign currency forward contracts 0  
Financial instruments carried at fair value (liability position):    
Derivative liability noncurrent   0
Other liabilities, excluding current portion | Foreign currency forward contracts | Recurring basis | Level 2    
Financial assets carried at fair value:    
Foreign currency forward contracts (88)  
Financial instruments carried at fair value (liability position):    
Derivative liability noncurrent   (132)
Other liabilities, excluding current portion | Foreign currency forward contracts | Recurring basis | Level 3    
Financial assets carried at fair value:    
Foreign currency forward contracts 0  
Financial instruments carried at fair value (liability position):    
Derivative liability noncurrent   $ 0
Variable Interest Entity, Primary Beneficiary | BioAxone Biosciences Inc | Level 1    
Financial instruments carried at fair value (liability position):    
Cash and cash equivalents $ 70,200  
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.5.0.2
Marketable Securities (Details) - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Summary of cash, cash equivalents and marketable securities    
Amortized Cost $ 1,071,110 $ 1,042,336
Gross Unrealized Gains 351 246
Gross Unrealized Losses (25) (120)
Fair Value 1,071,436 1,042,462
Total cash and cash equivalents    
Summary of cash, cash equivalents and marketable securities    
Amortized Cost 605,866 714,768
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 0
Fair Value 605,866 714,768
Cash and money market funds    
Summary of cash, cash equivalents and marketable securities    
Amortized Cost 605,866 582,352
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 0
Fair Value 605,866 582,352
Government-sponsored enterprise securities    
Summary of cash, cash equivalents and marketable securities    
Amortized Cost   85,994
Gross Unrealized Gains   0
Gross Unrealized Losses   0
Fair Value   85,994
Commercial paper    
Summary of cash, cash equivalents and marketable securities    
Amortized Cost   34,889
Gross Unrealized Gains   0
Gross Unrealized Losses   0
Fair Value   34,889
Corporate debt securities    
Summary of cash, cash equivalents and marketable securities    
Amortized Cost   11,533
Gross Unrealized Gains   0
Gross Unrealized Losses   0
Fair Value   11,533
Total marketable securities    
Summary of cash, cash equivalents and marketable securities    
Amortized Cost 465,244 327,568
Gross Unrealized Gains 351 246
Gross Unrealized Losses (25) (120)
Fair Value 465,570 327,694
U.S. Treasury securities (due within 1 year)    
Summary of cash, cash equivalents and marketable securities    
Amortized Cost 33,138  
Gross Unrealized Gains 4  
Gross Unrealized Losses 0  
Fair Value 33,142  
Government-sponsored enterprise securities (due within 1 year)    
Summary of cash, cash equivalents and marketable securities    
Amortized Cost 131,868 87,176
Gross Unrealized Gains 35 0
Gross Unrealized Losses (3) (14)
Fair Value 131,900 87,162
Commercial paper (due within 1 year)    
Summary of cash, cash equivalents and marketable securities    
Amortized Cost 164,575 98,877
Gross Unrealized Gains 278 246
Gross Unrealized Losses 0 0
Fair Value 164,853 99,123
Corporate debt securities (due within 1 year)    
Summary of cash, cash equivalents and marketable securities    
Amortized Cost 135,663 141,515
Gross Unrealized Gains 34 0
Gross Unrealized Losses (22) (106)
Fair Value $ 135,675 $ 141,409
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.5.0.2
Accumulated Other Comprehensive (Loss) Income Accumulated Other Comprehensive (Loss) Income (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
AOCI Attributable to Parent, Net of Tax [Roll Forward]        
Balance at balance sheet date     $ 1,824 $ 917
Other comprehensive (loss) income before reclassifications     (3,154) (20)
Amounts reclassified from accumulated other comprehensive loss     (2,060) (2,604)
Total changes in other comprehensive loss $ 1,509 $ (2,498) (5,214) (2,624)
Balance at balance sheet date (3,390) (1,707) (3,390) (1,707)
Foreign Currency Translation Adjustment        
AOCI Attributable to Parent, Net of Tax [Roll Forward]        
Balance at balance sheet date     (2,080) (971)
Other comprehensive (loss) income before reclassifications     (5,201) 1,220
Amounts reclassified from accumulated other comprehensive loss     0 0
Total changes in other comprehensive loss     (5,201) 1,220
Balance at balance sheet date (7,281) 249 (7,281) 249
Unrealized Holding Gains (Losses) on Marketable Securities        
AOCI Attributable to Parent, Net of Tax [Roll Forward]        
Balance at balance sheet date     126 (123)
Other comprehensive (loss) income before reclassifications     200 130
Amounts reclassified from accumulated other comprehensive loss     0 0
Total changes in other comprehensive loss     200 130
Balance at balance sheet date 326 7 326 7
Unrealized Gains on Foreign Currency Forward Contracts, net of tax        
AOCI Attributable to Parent, Net of Tax [Roll Forward]        
Balance at balance sheet date     3,778 2,011
Other comprehensive (loss) income before reclassifications     1,847 (1,370)
Amounts reclassified from accumulated other comprehensive loss     (2,060) (2,604)
Total changes in other comprehensive loss     (213) (3,974)
Balance at balance sheet date $ 3,565 $ (1,963) $ 3,565 $ (1,963)
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.5.0.2
Hedging (Details) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2016
Dec. 31, 2015
Offsetting Derivative Assets [Abstract]    
Gross Amounts Recognized $ 11,570 $ 5,766
Gross Amounts Offset 0 0
Gross Amounts Presented 11,570 5,766
Gross Amounts Not Offset (7,405) (901)
Legal Offset 4,165 4,865
Offsetting Derivative Liabilities [Abstract]    
Gross Amounts Recognized (7,405) (901)
Gross Amounts Offset 0 0
Gross Amounts Presented (7,405) (901)
Gross Amounts Not Offset 7,405 901
Legal Offset 0 0
Prepaid and other current assets    
Foreign Currency Cash Flow Hedge Derivative at Fair Value [Abstract]    
Fair Value - assets 9,966 5,161
Other liabilities, current portion    
Foreign Currency Cash Flow Hedge Derivative at Fair Value [Abstract]    
Fair Value - liabilities (7,317) (769)
Other assets    
Foreign Currency Cash Flow Hedge Derivative at Fair Value [Abstract]    
Fair Value - assets 1,604 605
Other liabilities, excluding current portion    
Foreign Currency Cash Flow Hedge Derivative at Fair Value [Abstract]    
Fair Value - liabilities (88) (132)
Designated as hedging instrument | Foreign Currency Forward Contract | Cash Flow Hedging    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 301,705 209,285
Designated as hedging instrument | Euro | Foreign Currency Forward Contract | Cash Flow Hedging    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 193,542 103,362
Designated as hedging instrument | British pound sterling | Foreign Currency Forward Contract | Cash Flow Hedging    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 79,845 78,756
Designated as hedging instrument | Australian dollar | Foreign Currency Forward Contract | Cash Flow Hedging    
Derivative [Line Items]    
Notional amount of foreign currency forward contract $ 28,318 $ 27,167
Minimum | Foreign Currency Forward Contract | Cash Flow Hedging    
Derivative [Line Items]    
Derivative term 1 month  
Maximum | Foreign Currency Forward Contract | Cash Flow Hedging    
Derivative [Line Items]    
Derivative term 18 months  
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.5.0.2
Inventories - Schedule of Inventories (Details) - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Inventory Disclosure [Abstract]    
Raw materials $ 5,408 $ 8,696
Work-in-process 45,807 40,695
Finished goods 15,374 7,816
Total $ 66,589 $ 57,207
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.5.0.2
Intangible Assets and Goodwill (Details) - USD ($)
$ in Thousands
 1 Months Ended
Oct. 31, 2014
Jun. 30, 2016
Dec. 31, 2015
Jun. 04, 2015
Indefinite-Lived Intangible Assets [Line Items]        
Intangible assets   $ 284,340 $ 284,340  
Goodwill   50,384 50,384  
Parion Sciences, Inc        
Indefinite-Lived Intangible Assets [Line Items]        
Intangible assets       $ 255,300
BioAxone Biosciences Inc        
Indefinite-Lived Intangible Assets [Line Items]        
In-process research and development intangible asset $ 29,000      
Variable Interest Entity, Primary Beneficiary        
Indefinite-Lived Intangible Assets [Line Items]        
Intangible assets   284,340 284,340  
Goodwill   $ 19,391 $ 19,391  
Variable Interest Entity, Primary Beneficiary | BioAxone Biosciences Inc        
Indefinite-Lived Intangible Assets [Line Items]        
In-process research and development intangible asset $ 29,000      
Indefinite-lived Intangible Assets | Variable Interest Entity, Primary Beneficiary | Parion Sciences, Inc        
Indefinite-Lived Intangible Assets [Line Items]        
Fair value inputs, discount rate (percent) 7.10%      
Indefinite-lived Intangible Assets | Variable Interest Entity, Primary Beneficiary | BioAxone Biosciences Inc        
Indefinite-Lived Intangible Assets [Line Items]        
Fair value inputs, discount rate (percent) 7.50%      
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.5.0.2
Long-term Obligations - Fan Pier Leases (Details)
$ in Thousands, ft² in Millions
 12 Months Ended
Dec. 31, 2011
ft²
lease
building
Jun. 30, 2016
USD ($)
Dec. 31, 2015
USD ($)
Property, Plant and Equipment [Line Items]      
Property and equipment, net   $ 690,607 $ 697,715
Fan Pier Leases      
Property, Plant and Equipment [Line Items]      
Number of leases | lease 2    
Area of real estate property (in square feet) | ft² 1.1    
Number of buildings under lease agreement | building 2    
Optional term of lease agreement (in years) 10 years    
Fan Pier Leases | Buildings      
Property, Plant and Equipment [Line Items]      
Construction financing lease obligation, current and noncurrent   472,800 473,000
Fan Pier Leases | Construction in progress      
Property, Plant and Equipment [Line Items]      
Property and equipment, net   $ 495,700 $ 502,300
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.5.0.2
Long-term Obligations - San Diego Lease (Details) - San Diego Lease
ft² in Thousands, $ in Millions
Dec. 02, 2015
USD ($)
ft²
term_extension
Property, Plant and Equipment [Line Items]  
Area of real estate property (in square feet) | ft² 170
Length of lease 16 years
Average yearly aggregate rent | $ $ 10.2
Amount of optional renewal terms | term_extension 2
Optional renewal term length 5 years
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.5.0.2
Long-term Obligations - Term Loan (Details) - USD ($)
 1 Months Ended
Oct. 31, 2015
Jul. 31, 2014
Jun. 30, 2016
Dec. 31, 2015
Senior Secured Term Loan        
Debt Instrument [Line Items]        
Face amount of term loan   $ 300,000,000    
Interest rate, stated percentage   7.20%    
Contingent interest rate (percent)   6.20%    
Amount of principal repayment on quarterly installment payments from October 1, 2016 through maturity $ 75,000,000      
Debt instrument, repayment provision, period over which present value of interest payments is determined (in years) 2 years      
Unamortized discount on term loan   $ 5,300,000 $ 3,400,000 $ 4,600,000
Senior Secured Term Loan Facility        
Debt Instrument [Line Items]        
Maximum borrowing capacity   $ 200,000,000    
Minimum | Senior Secured Term Loan | LIBOR        
Debt Instrument [Line Items]        
Basis spread on variable rate (percent)   5.00%    
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stock-based Compensation Expense - Stock-based Compensation Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Stock-based compensation expense:        
Less stock-based compensation expense capitalized to inventories $ (928) $ (1,153) $ (1,773) $ (2,037)
Total stock-based compensation included in costs and expenses 61,942 63,261 117,414 120,645
Stock options        
Stock-based compensation expense:        
Stock-based compensation expense by type of award: 31,826 37,687 58,086 66,646
Type of award:        
Unrecognized Expense, Net of Estimated Forfeitures 176,251   $ 176,251  
Weighted-average recognition period (in years)     2 years 7 months 28 days  
Restricted stock and restricted stock units        
Stock-based compensation expense:        
Stock-based compensation expense by type of award: 29,608 24,902 $ 57,141 52,071
Type of award:        
Unrecognized Expense, Net of Estimated Forfeitures 201,858   $ 201,858  
Weighted-average recognition period (in years)     2 years 6 months 26 days  
ESPP share issuances        
Stock-based compensation expense:        
Stock-based compensation expense by type of award: 1,436 1,825 $ 3,960 3,965
Type of award:        
Unrecognized Expense, Net of Estimated Forfeitures 5,546   $ 5,546  
Weighted-average recognition period (in years)     7 months 21 days  
Research and development expenses        
Stock-based compensation expense:        
Total stock-based compensation included in costs and expenses 40,640 41,632 $ 75,088 79,849
Sales, general and administrative expenses        
Stock-based compensation expense:        
Total stock-based compensation included in costs and expenses $ 21,302 $ 21,629 $ 42,326 $ 40,796
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stock-based Compensation Expense - Stock Options Outstanding and Exercisable (Details)
shares in Thousands
 6 Months Ended
Jun. 30, 2016
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award  
Exercise price range, options outstanding (in shares) | shares 12,231
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 7 years 2 months 16 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 79.37
Exercise price range, options exercisable (in shares) | shares 6,490
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 63.32
$18.93–$20.00  
Share-based Compensation Arrangement by Share-based Payment Award  
Exercise price, low end of range (usd per share) 18.93
Exercise price, high end of range (usd per share) $ 20.00
Exercise price range, options outstanding (in shares) | shares 137
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 1 year 7 months 10 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 18.93
Exercise price range, options exercisable (in shares) | shares 137
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 18.93
$20.01–$40.00  
Share-based Compensation Arrangement by Share-based Payment Award  
Exercise price, low end of range (usd per share) 20.01
Exercise price, high end of range (usd per share) $ 40
Exercise price range, options outstanding (in shares) | shares 1,964
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 3 years 5 months 12 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 34.24
Exercise price range, options exercisable (in shares) | shares 1,962
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 34.23
$40.01–$60.00  
Share-based Compensation Arrangement by Share-based Payment Award  
Exercise price, low end of range (usd per share) 40.01
Exercise price, high end of range (usd per share) $ 60
Exercise price range, options outstanding (in shares) | shares 2,066
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 6 years 26 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 48.14
Exercise price range, options exercisable (in shares) | shares 1,657
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 48.66
$60.01–$80.00  
Share-based Compensation Arrangement by Share-based Payment Award  
Exercise price, low end of range (usd per share) 60.01
Exercise price, high end of range (usd per share) $ 80
Exercise price range, options outstanding (in shares) | shares 1,368
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 7 years 7 months 13 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 75.90
Exercise price range, options exercisable (in shares) | shares 734
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 75.39
$80.01–$100.00  
Share-based Compensation Arrangement by Share-based Payment Award  
Exercise price, low end of range (usd per share) 80.01
Exercise price, high end of range (usd per share) $ 100
Exercise price range, options outstanding (in shares) | shares 3,555
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 8 years 7 months 6 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 90.68
Exercise price range, options exercisable (in shares) | shares 1,080
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 88.91
$100.01–$120.00  
Share-based Compensation Arrangement by Share-based Payment Award  
Exercise price, low end of range (usd per share) 100.01
Exercise price, high end of range (usd per share) $ 120
Exercise price range, options outstanding (in shares) | shares 1,644
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 8 years 6 months 26 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 109.32
Exercise price range, options exercisable (in shares) | shares 500
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 109.27
$120.01–$134.69  
Share-based Compensation Arrangement by Share-based Payment Award  
Exercise price, low end of range (usd per share) 120.01
Exercise price, high end of range (usd per share) $ 134.69
Exercise price range, options outstanding (in shares) | shares 1,497
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 9 years 18 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 130.61
Exercise price range, options exercisable (in shares) | shares 420
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 129.84
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.5.0.2
Other Arrangements (Details) - USD ($)
 12 Months Ended
Dec. 31, 2008
Jun. 30, 2016
Sale of HIV Protease Inhibitor Royalty Stream    
Gross proceeds from sale of royalty rights receivable from GlaxoSmithKline $ 160,000,000.0  
Deferred revenue royalty purchase agreement   $ 18,900,000
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.5.0.2
Income Taxes (Details) - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Dec. 31, 2015
Schedule of Collaborative Arrangement Agreements [Line Items]          
Provision for income taxes $ 18,130,000 $ 30,131,000 $ 23,615,000 $ 30,430,000  
Unrecognized tax benefits 400,000   400,000   $ 400,000
Income taxes, interest and penalties accrued 0   0    
Income taxes, material interest or penalties related to uncertain tax positions     0   $ 0
Estimated reduction in unrecognized tax benefits in next fiscal year 400,000   400,000    
Parion Sciences, Inc          
Schedule of Collaborative Arrangement Agreements [Line Items]          
Provision for income taxes $ 17,500,000   $ 20,600,000    
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.5.0.2
Restructuring Liabilities - Narrative (Details)
ft² in Thousands
 3 Months Ended 12 Months Ended
Jun. 30, 2015
ft²
lease
Sep. 30, 2014
facility
Dec. 31, 2003
Kendall Restructuring      
Restructuring Cost and Reserve [Line Items]      
Lease term (in years)     15 years
Restructuring and related activities, leased office space, maximum percentage used - not more than     50.00%
Fan Pier Move Restructuring      
Restructuring Cost and Reserve [Line Items]      
Number of facilities decommissioned | facility   3  
Number of leases terminated | lease 2    
Area of real estate property (in square feet) | ft² 120    
Discount rate related to leases (percent) 9.00%    
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.5.0.2
Restructuring Liabilities - Activity Related to Restructuring Liability (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Restructuring activities        
Restructuring expense (income) $ 343 $ 2,128 $ 1,030 $ (1,144)
Kendall Restructuring        
Restructuring activities        
Liability, beginning of the period 7,224 9,506 7,944 11,596
Cash payments (3,833) (2,584) (7,764) (6,569)
Cash received from subleases 3,008 2,799 6,016 5,275
Restructuring expense (income) (11) 203 192 (378)
Liability, end of the period 6,388 9,924 6,388 9,924
Fan Pier Move Restructuring        
Restructuring activities        
Liability, beginning of the period 5,449 11,137 5,964 33,390
Cash payments (3,096) (3,095) (6,252) (22,351)
Cash received from subleases 2,361 0 4,769 0
Restructuring expense (income) 149 975 382 (2,022)
Liability, end of the period 4,863 9,017 4,863 9,017
Other Restructuring        
Restructuring activities        
Liability, beginning of the period 1,262 845 1,450 869
Cash payments (234) (893) (673) (1,223)
Restructuring expense (income) 205 950 456 1,256
Liability, end of the period $ 1,233 $ 902 $ 1,233 $ 902
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.5.0.2
Commitments and Contingencies (Details)
$ in Millions
Jun. 30, 2016
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
Restricted cash and cash equivalents $ 21.9
EXCEL 72 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 73 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 74 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 76 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 328 265 1 false 80 0 false 11 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.vrtx.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Condensed Consolidated Statements of Operations (unaudited) Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited Condensed Consolidated Statements of Operations (unaudited) Statements 2 false false R3.htm 1002000 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited) Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited Condensed Consolidated Statements of Comprehensive Loss (unaudited) Statements 3 false false R4.htm 1003000 - Statement - Condensed Consolidated Balance Sheets (unaudited) Sheet http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (unaudited) Statements 4 false false R5.htm 1003501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 5 false false R6.htm 1004000 - Statement - Condensed Consolidated Statements of Shareholders' Equity and Noncontrolling Interest (unaudited) Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndNoncontrollingInterestUnaudited Condensed Consolidated Statements of Shareholders' Equity and Noncontrolling Interest (unaudited) Statements 6 false false R7.htm 1006000 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (unaudited) Statements 7 false false R8.htm 2101100 - Disclosure - Basis of Presentation and Accounting Policies Sheet http://www.vrtx.com/role/BasisOfPresentationAndAccountingPolicies Basis of Presentation and Accounting Policies Notes 8 false false R9.htm 2102100 - Disclosure - Product Revenues, Net Sheet http://www.vrtx.com/role/ProductRevenuesNet Product Revenues, Net Notes 9 false false R10.htm 2104100 - Disclosure - Collaborative Arrangements Sheet http://www.vrtx.com/role/CollaborativeArrangements Collaborative Arrangements Notes 10 false false R11.htm 2105100 - Disclosure - Earnings Per Share Sheet http://www.vrtx.com/role/EarningsPerShare Earnings Per Share Notes 11 false false R12.htm 2106100 - Disclosure - Fair Value Measurements Sheet http://www.vrtx.com/role/FairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 2107100 - Disclosure - Marketable Securities Sheet http://www.vrtx.com/role/MarketableSecurities Marketable Securities Notes 13 false false R14.htm 2108100 - Disclosure - Accumulated Other Comprehensive (Loss) Income Sheet http://www.vrtx.com/role/AccumulatedOtherComprehensiveLossIncome Accumulated Other Comprehensive (Loss) Income Notes 14 false false R15.htm 2110100 - Disclosure - Hedging Sheet http://www.vrtx.com/role/Hedging Hedging Notes 15 false false R16.htm 2112100 - Disclosure - Inventories Sheet http://www.vrtx.com/role/Inventories Inventories Notes 16 false false R17.htm 2113100 - Disclosure - Intangible Assets and Goodwill Sheet http://www.vrtx.com/role/IntangibleAssetsAndGoodwill Intangible Assets and Goodwill Notes 17 false false R18.htm 2115100 - Disclosure - Long-term Obligations Sheet http://www.vrtx.com/role/LongTermObligations Long-term Obligations Notes 18 false false R19.htm 2116100 - Disclosure - Stock-based Compensation Expense Sheet http://www.vrtx.com/role/StockBasedCompensationExpense Stock-based Compensation Expense Notes 19 false false R20.htm 2118100 - Disclosure - Other Arrangements Sheet http://www.vrtx.com/role/OtherArrangements Other Arrangements Notes 20 false false R21.htm 2119100 - Disclosure - Income Taxes Sheet http://www.vrtx.com/role/IncomeTaxes Income Taxes Notes 21 false false R22.htm 2120100 - Disclosure - Restructuring Liabilities Sheet http://www.vrtx.com/role/RestructuringLiabilities Restructuring Liabilities Notes 22 false false R23.htm 2122100 - Disclosure - Commitments and Contingencies Sheet http://www.vrtx.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 23 false false R24.htm 2201201 - Disclosure - Basis of Presentation and Accounting Policies (Policies) Sheet http://www.vrtx.com/role/BasisOfPresentationAndAccountingPoliciesPolicies Basis of Presentation and Accounting Policies (Policies) Policies http://www.vrtx.com/role/BasisOfPresentationAndAccountingPolicies 24 false false R25.htm 2302301 - Disclosure - Product Revenues, Net (Tables) Sheet http://www.vrtx.com/role/ProductRevenuesNetTables Product Revenues, Net (Tables) Tables http://www.vrtx.com/role/ProductRevenuesNet 25 false false R26.htm 2304301 - Disclosure - Collaborative Arrangements (Tables) Sheet http://www.vrtx.com/role/CollaborativeArrangementsTables Collaborative Arrangements (Tables) Tables http://www.vrtx.com/role/CollaborativeArrangements 26 false false R27.htm 2305301 - Disclosure - Earnings Per Share (Tables) Sheet http://www.vrtx.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://www.vrtx.com/role/EarningsPerShare 27 false false R28.htm 2306301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.vrtx.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.vrtx.com/role/FairValueMeasurements 28 false false R29.htm 2307301 - Disclosure - Marketable Securities (Tables) Sheet http://www.vrtx.com/role/MarketableSecuritiesTables Marketable Securities (Tables) Tables http://www.vrtx.com/role/MarketableSecurities 29 false false R30.htm 2308301 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Tables) Sheet http://www.vrtx.com/role/AccumulatedOtherComprehensiveLossIncomeTables Accumulated Other Comprehensive (Loss) Income (Tables) Tables http://www.vrtx.com/role/AccumulatedOtherComprehensiveLossIncome 30 false false R31.htm 2310301 - Disclosure - Hedging (Tables) Sheet http://www.vrtx.com/role/HedgingTables Hedging (Tables) Tables http://www.vrtx.com/role/Hedging 31 false false R32.htm 2312301 - Disclosure - Inventories (Tables) Sheet http://www.vrtx.com/role/InventoriesTables Inventories (Tables) Tables http://www.vrtx.com/role/Inventories 32 false false R33.htm 2316301 - Disclosure - Stock-based Compensation Expense (Tables) Sheet http://www.vrtx.com/role/StockBasedCompensationExpenseTables Stock-based Compensation Expense (Tables) Tables http://www.vrtx.com/role/StockBasedCompensationExpense 33 false false R34.htm 2320301 - Disclosure - Restructuring Liabilities (Tables) Sheet http://www.vrtx.com/role/RestructuringLiabilitiesTables Restructuring Liabilities (Tables) Tables http://www.vrtx.com/role/RestructuringLiabilities 34 false false R35.htm 2401402 - Disclosure - Basis of Presentation and Accounting Policies (Details) Sheet http://www.vrtx.com/role/BasisOfPresentationAndAccountingPoliciesDetails Basis of Presentation and Accounting Policies (Details) Details http://www.vrtx.com/role/BasisOfPresentationAndAccountingPoliciesPolicies 35 false false R36.htm 2402402 - Disclosure - Product Revenues, Net (Details) Sheet http://www.vrtx.com/role/ProductRevenuesNetDetails Product Revenues, Net (Details) Details http://www.vrtx.com/role/ProductRevenuesNetTables 36 false false R37.htm 2404402 - Disclosure - Collaborative Arrangement - Cystic Fibrosis Foundation Therapeutics Incorporated (Details) Sheet http://www.vrtx.com/role/CollaborativeArrangementCysticFibrosisFoundationTherapeuticsIncorporatedDetails Collaborative Arrangement - Cystic Fibrosis Foundation Therapeutics Incorporated (Details) Details 37 false false R38.htm 2404403 - Disclosure - Collaborative Arrangements - CRISPR Therapeutics AG (Details) Sheet http://www.vrtx.com/role/CollaborativeArrangementsCrisprTherapeuticsAgDetails Collaborative Arrangements - CRISPR Therapeutics AG (Details) Details 38 false false R39.htm 2404404 - Disclosure - Collaborative Arrangements - Parion Sciences, Inc. (Details) Sheet http://www.vrtx.com/role/CollaborativeArrangementsParionSciencesIncDetails Collaborative Arrangements - Parion Sciences, Inc. (Details) Details 39 false false R40.htm 2404405 - Disclosure - Collaborative Arrangements Collaborative Arrangements - BioAxone Biosciences, Inc. (Details) Sheet http://www.vrtx.com/role/CollaborativeArrangementsCollaborativeArrangementsBioaxoneBiosciencesIncDetails Collaborative Arrangements Collaborative Arrangements - BioAxone Biosciences, Inc. (Details) Details 40 false false R41.htm 2404406 - Disclosure - Collaborative Arrangements - Aggregate VIE Financial Information (Details) Sheet http://www.vrtx.com/role/CollaborativeArrangementsAggregateVieFinancialInformationDetails Collaborative Arrangements - Aggregate VIE Financial Information (Details) Details 41 false false R42.htm 2404407 - Disclosure - Collaborative Arrangements Collaborative Arrangements - Janssen Pharmaceuticals, Inc. (Details) Sheet http://www.vrtx.com/role/CollaborativeArrangementsCollaborativeArrangementsJanssenPharmaceuticalsIncDetails Collaborative Arrangements Collaborative Arrangements - Janssen Pharmaceuticals, Inc. (Details) Details 42 false false R43.htm 2404408 - Disclosure - Collaborative Arrangements Collaborative Arrangements - Moderna Therapeutics, Inc. (Details) Sheet http://www.vrtx.com/role/CollaborativeArrangementsCollaborativeArrangementsModernaTherapeuticsIncDetails Collaborative Arrangements Collaborative Arrangements - Moderna Therapeutics, Inc. (Details) Details 43 false false R44.htm 2405402 - Disclosure - Earnings Per Share (Details) Sheet http://www.vrtx.com/role/EarningsPerShareDetails Earnings Per Share (Details) Details http://www.vrtx.com/role/EarningsPerShareTables 44 false false R45.htm 2406402 - Disclosure - Fair Value Measurements (Details) Sheet http://www.vrtx.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) Details http://www.vrtx.com/role/FairValueMeasurementsTables 45 false false R46.htm 2407402 - Disclosure - Marketable Securities (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesDetails Marketable Securities (Details) Details http://www.vrtx.com/role/MarketableSecuritiesTables 46 false false R47.htm 2408402 - Disclosure - Accumulated Other Comprehensive (Loss) Income Accumulated Other Comprehensive (Loss) Income (Details) Sheet http://www.vrtx.com/role/AccumulatedOtherComprehensiveLossIncomeAccumulatedOtherComprehensiveLossIncomeDetails Accumulated Other Comprehensive (Loss) Income Accumulated Other Comprehensive (Loss) Income (Details) Details http://www.vrtx.com/role/AccumulatedOtherComprehensiveLossIncomeTables 47 false false R48.htm 2410402 - Disclosure - Hedging (Details) Sheet http://www.vrtx.com/role/HedgingDetails Hedging (Details) Details http://www.vrtx.com/role/HedgingTables 48 false false R49.htm 2412402 - Disclosure - Inventories - Schedule of Inventories (Details) Sheet http://www.vrtx.com/role/InventoriesScheduleOfInventoriesDetails Inventories - Schedule of Inventories (Details) Details 49 false false R50.htm 2413401 - Disclosure - Intangible Assets and Goodwill (Details) Sheet http://www.vrtx.com/role/IntangibleAssetsAndGoodwillDetails Intangible Assets and Goodwill (Details) Details http://www.vrtx.com/role/IntangibleAssetsAndGoodwill 50 false false R51.htm 2415401 - Disclosure - Long-term Obligations - Fan Pier Leases (Details) Sheet http://www.vrtx.com/role/LongTermObligationsFanPierLeasesDetails Long-term Obligations - Fan Pier Leases (Details) Details 51 false false R52.htm 2415402 - Disclosure - Long-term Obligations - San Diego Lease (Details) Sheet http://www.vrtx.com/role/LongTermObligationsSanDiegoLeaseDetails Long-term Obligations - San Diego Lease (Details) Details 52 false false R53.htm 2415403 - Disclosure - Long-term Obligations - Term Loan (Details) Sheet http://www.vrtx.com/role/LongTermObligationsTermLoanDetails Long-term Obligations - Term Loan (Details) Details 53 false false R54.htm 2416402 - Disclosure - Stock-based Compensation Expense - Stock-based Compensation Expense (Details) Sheet http://www.vrtx.com/role/StockBasedCompensationExpenseStockBasedCompensationExpenseDetails Stock-based Compensation Expense - Stock-based Compensation Expense (Details) Details 54 false false R55.htm 2416403 - Disclosure - Stock-based Compensation Expense - Stock Options Outstanding and Exercisable (Details) Sheet http://www.vrtx.com/role/StockBasedCompensationExpenseStockOptionsOutstandingAndExercisableDetails Stock-based Compensation Expense - Stock Options Outstanding and Exercisable (Details) Details 55 false false R56.htm 2418401 - Disclosure - Other Arrangements (Details) Sheet http://www.vrtx.com/role/OtherArrangementsDetails Other Arrangements (Details) Details http://www.vrtx.com/role/OtherArrangements 56 false false R57.htm 2419401 - Disclosure - Income Taxes (Details) Sheet http://www.vrtx.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.vrtx.com/role/IncomeTaxes 57 false false R58.htm 2420402 - Disclosure - Restructuring Liabilities - Narrative (Details) Sheet http://www.vrtx.com/role/RestructuringLiabilitiesNarrativeDetails Restructuring Liabilities - Narrative (Details) Details 58 false false R59.htm 2420403 - Disclosure - Restructuring Liabilities - Activity Related to Restructuring Liability (Details) Sheet http://www.vrtx.com/role/RestructuringLiabilitiesActivityRelatedToRestructuringLiabilityDetails Restructuring Liabilities - Activity Related to Restructuring Liability (Details) Details 59 false false R60.htm 2422401 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.vrtx.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.vrtx.com/role/CommitmentsAndContingencies 60 false false All Reports Book All Reports vrtx-20160630.xml vrtx-20160630.xsd vrtx-20160630_cal.xml vrtx-20160630_def.xml vrtx-20160630_lab.xml vrtx-20160630_pre.xml true true ZIP 78 0000875320-16-000091-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000875320-16-000091-xbrl.zip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�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